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Abstract 
              Since the Gram positive anaerobe Clostridium difficile was first isolated and 
described, it has emerged as an increasingly important nosocomial pathogen  in 
Europe, North America and elsewhere, and the prime causative agent of antibiotic 
associated dirrhoea and pseudomembranous colitis in humans.  
              The two large toxins, A and B, are the main virulence factors, proteins that 
are expressed in the gastrointestinal tract after colonisation by C. difficile. The 
pathological symptoms mediated by these toxins include disruption of the integrity 
of the the epithelium, fluid loss, intestinal inflammation and tissue destruction. 
               Important as the toxins are to C. difficile pathogenesis, several other 
proteins are known to contribute to colonisation and other aspects of the disease 
process remain poorly understood. Immunological studies using antisera from the 
patients revealed a number of candidates and amongst these, proteins present, or 
thought to be present, at the bacterial surface contribute to adhesion, motility and 
other interactions with the human host.  
         The aims of this study were to produce a number of surface proteins from C. 
difficile as recombinant products and to isolate antibodies against these targets via 
phage display. The goal was to assess if these antibodies could inhibit the normal 
function of these targets and to confirm their location in C. difficile. Of 11 
clostridial proteins, expression and purification of 3 proved impossible (Cwp84, 
FbpA and Acd) but 8 others (CspA, GroEL, FliC, FliD, a putative sortase, Cwp66, and 
its amino and carboxy terminal regions) were used for antibody isolation along 
with recombinant and native forms of SlpA. Phage display yielded a large panel of 
specific single chain variable fragments (scFv) antibodies that were expressed, 
purified and characterised. 
Reaction between the scFvs and their targets took place in ELISA and 
Western blotting suggesting the recognition of linear rather than conformational 
epitopes. The binding of scFvs to SlpA and its components showed strain specificity 
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with good recognition of protein from C. difficile 630 but no reaction towards SlpA 
from R20291, and 027 ribotype. Binding of scFvs of a range of specificities to 
extracts from C. difficile M120 indicated that a component of the S layer from this 
strain might possess immunoglobulin binding activities in the manner of a 
superantigen. 
The scFvs against flagellar proteins FliC and FliD were able to inhibit 
bacterial motility and therefore there would be potential in testing whether other 
scFvs generated in this study were able to inhibit the biological activity of their 
targets. 
Some scFvs were tested in immunofluorescence microscopy. The positive 
results from these experiments showed that the reagents and the strategy 
pursued could be used to establish surface exposure of the targets and other 
components of the bacterial surface. Given the high specificity of the reagents, and 
in the case of Cwp66, the ability to isolate scFvs against defined regions of the 
protein, the strategy has the capacity to define the orientation of proteins in the 
bacterial surface.  In contrast, the use of scFvs to locate their targets in electron 
microscopy using immunogold reagents was unsuccessful. As this approach has 
been successful in other studies, it deserves further investment of effort. 
Overall, expression of proteins from C. difficile in an E.coli host was 
generally successful and phage display provided a rapid, highly efficient method 
for the isolation of specific immunological reagents. These have the potential to 
explore the location, orientation and activity of proteins from the pathogen. 
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1 Introduction 
1.1 Overview 
 
Clostridium difficile is a  bacteria of the genus Clostridium,  first described in 1935 
and named Bacillus difficilis (Hall I, 1935). Since then and based on its emerging 
importance in the field of human health, much research has been devoted to 
understanding the pathogenesis of this organism. Despite this effort, the incidence 
of C.difficile infection continues to rise across Europe and America with new 
outbreaks occurring frequently(Freeman et al.). Clostridium difficile is an anaerobic 
gram positive, spore forming bacteria, 3-5 µm in length and motile like other 
members of the genus. Typically, colonies are irregular in shape and show 
optimum growth on blood agar at 37˚ C after 24-48 h to form colonies 3-5 mm in 
diameter, grey and opaque in appearance and without obvious haemolytic activity 
(Figure 1.1).  
 
 
figure1. 1.  C. difficile colonies on a blood agar plate. 
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The bacteria have two forms, vegetative cells and spores, related to the 
environment around them. Conditions that create stress – the presence of oxygen 
poor nutrition, aggressive chemicals – trigger the vegetative cells to undergo 
sporulation so that the organisms can resist hostile situations. C. difficile has a 
wide spread distribution in humans and animals but there is no evidence so far of 
direct transmission from animals to humans. C. difficile is also present in the 
environment; one study of 2580 samples in the Cardiff area showed these bacteria 
to be present in rivers (87.5%), beaches (44%), lake water (46.7%), soil (21%), 
hospitals (20%), and swimming pools (50%). Samples from animal faeces were also 
positive: assorted  farm animals (1%), dogs (10%) and cats (2%) (al Saif and Brazier, 
1996).  
       In a separate study of animal carriage, C. difficile was found in the faeces of 
boiler chickens at market, revealing 29% of birds were positive and of these 
isolates, 89.7% were toxigenic, although most were also susceptible to antibiotics 
such as metronidazole and vancomycin (Simango and Mwakurudza, 2008). In 
another study in Canada, testing of calves revealed that 40% of  these animals 
were positive with 8 different ribotypes recovered , 7 of which are capable of  
causing infections in humans (Rodriguez-Palacios et al., 2006). These finding are 
not unusual – similar results have emerged from studies in the United Kingdom 
(Keel et al., 2007) and  the Netherlands (Debast et al., 2009a, Debast et al., 2009b) 
– and while early  isolation of C. difficile from different animal sources suggested 
no relationship with human infection (Oneill et al., 1993), more recently,  
investigators have questioned this conclusion (Keel et al., 2007, Arroyo et al., 
2005). While direct transmission from animals to humans has yet to be 
demonstrated, spores of C. difficile have been isolated from various meat products 
(Songer et al., 2009, Weese et al., 2009) and vegetables (Bakri et al., 2009).  
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1.2 Epidemiology 
 
          Among the human population, C. difficile carriage and infection has been 
observed at different rates and with different strains since the medical importance 
of this pathogen first became clear. One of the earliest studies reported the 
isolation of  bacteria from the urinary tract of both males and females (Hafiz et al., 
1975).  Following shortly after, Larson and colleagues isolated the bacteria from 
patients with pseudomembranous colitis (PMC) and showed the ability of the 
organisms to produce toxin in vitro (Larson et al., 1978). Early indications of a link 
with antibiotic usage emerged from a study of patients in postnatal wards which 
showed a wide range of carriage (2% to 52%) and also a reasonable  relationship 
between antibiotics and  the development of PMC (Larson et al., 1982).  
        Asymptomatic carriage appears to be common. In a study of neonates, a 
carriage rate of 64% in children aged 1-8 months was revealed (Holst et al., 1981), 
while this rate was 15.4% in healthy young  adults and 7% in healthy elderly adults 
(Nakamura et al., 1981). Other reports support the finding that neonates typically 
carry  C. difficile with high frequency and that very many isolates (71-100%) are 
toxigenic. To explain these findings, it has been proposed that the toxin receptor is 
masked  in some way in healthy newborn babies (Donta and Myers, 1982, Bolton 
et al., 1984). Given the increasing numbers of reports of C. difficile infection over 
the years, different countries have devised strategies for managing this infection 
and following its epidemiology using a range of typing methods. 
 
1.2.1 Europe 
        Although European countries have adopted different methods for the 
detection of C. difficile, assays for toxin detection and culture based methods 
remained in common use when Barbut and colleagues carried out an extensive 
survey 9 years ago (Barbut et al., 2003). Although other methods have picked up in 
popularity in the intervening period, their benefits over time-consuming reference 
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methods are not always clear-cut and problems can arise with sensitivity and 
specificity (Crobach et al., 2009) . Using these and other tools, the mean incidence 
of hospital-acquired C. difficile infection (CDI) was estimated to be 1.1 for 1000 
patient admissions. However, it is clear that the pattern of infection is also 
changing. This is illustrated by an outbreak of CDI in the southeast of England in 
2003 – 2004 in which 59% of isolates were typed as PCR ribotype 027, a strain that 
was unusual for the UK at that time and a strain with similarity to outbreak strains 
first identified in Canada and USA. 
          Ribotype 027 strains are hypertoxigenic and pose a particular threat to 
elderly patients (Smith, 2005). This is further illustrated by a recent Finnish study 
that determined that the rate of deaths between 1994 and 2004 that were 
attributable to CDI increased two-fold for patients over 64 years of age 
(Lyytikainen et al., 2009). Strain variation also emerged from a prospective study of 
411 suspected isolates that was carried out across 38 hospitals in 14 European 
countries. In total, 86.1% of all isolates were toxigenic, 322 were positive for the 
large glucosyltransferase toxins A and B and the majority of them were toxinotype 
0. Other toxinotypes such as V, VIII and III were also reported. Toxinotyping is tool 
for assessing genetic variation at a 19 kb pathogenicity locus (PaLoc) that carries 
tcdA and tcdB, the genes for toxin A and toxin B, along with regulatory factors.  
MIC (minimum inhibitory concentration) determination for 6 antibiotics showed a 
full susceptibility to metronidazole for all toxigenic isolates. Ribotyping – another 
molecular tool for strain characterisation that derives data from variation in the 
16S – 23S rRNA intergenic region – revealed 6.2% of isolates belonged to the 027 
epidemic strain. This strain is characterised by an 18 base pair deletion in the tcdC 
gene that confers hypertoxigenic properties, and the ability to produce a binary 
toxin that possesses ADP-ribosyltransferase activity. Mean incidence of C. difficile 
infection was 2.45 per 10000 patients, although this was highly variable between 
hospitals (Barbut et al., 2007).  
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The appearance of the 027 ribotype is cause for concern. In a hospital in the 
Netherlands, an 027 outbreak increased  the rate of CDI from 4 cases per 10000 
patient to 83 cases in 10000 (Kuijper et al., 2006). Similar patterns   occurred in 
Belgium and Austria.  C. difficile ribotype 027, toxinotype 111, emerged in seven 
hospitals in Belgium between 2005-2006 and the incidence of infection increased 
3-fold (Kuijper et al., 2006, Indra et al., 2006). Appearance of  ribotype 027 has also 
been reported  in Finland, Switzerland, Norway, Hungary, Poland, and Denmark 
(Pituch et al., 2008, Lyytikainen et al., 2007, Fenner et al., 2008, Ingebretsen et al., 
2008, Terhes et al., 2009, Bacci et al., 2009, Indra et al., 2009). 
 
1.2.2 North America 
      There are many reports of the spread of CDI in America and Canada. In America 
incidence of C. difficile colitis showed a significant increase from a base of 0.68% 
during 1989 and following years to 1.2% in 2000 in hospitalised patients. This 
proportion of patients with C. difficile colitis that went on to develop life threating 
symptoms doubled over the same period from 1.6% (1989 through the the latter 
years of the century) to 3.2% in 2000. Mortality amongst patients that required 
colectomy also rose sharply (57% in 1989 to 69% in 2000)  (Dallal et al., 2002). The 
results from a large scale study for the period 1991-2003 in Quebec, Canada, 
revealed 5-fold growth in CDI infection rates from 35.6 per 100000 in 1991 to 
156.3 per 100000 in 2003 (Pepin et al., 2004). Data was collected by cytotoxicity 
assays of patient samples and reports of the causes of death.  
Another Canadian report from 12 hospitals documented C. difficile 
infections by the detection of toxins,  culture of C. difficile, pulse-field gel 
electrophoresis (PFGE) for strain characterisation, other genetic analysis (binary 
toxin gene and tcdC) and the link with prescription of antibiotics. The investigation 
found that incidence of infection increased in patients after the age of 50 and that 
mortality rose after age 60. PFGE results revealed that most strains of C. difficile 
Chapter 1 Introduction 20 
had  the same characteristics as the epidemic 027 strain from the United States 
(Warny et al., 2005a). The mean of incidence of CDAD in the study was 22.5 per 
1000 hospital admissions.  Resistance to fluoroquinolones was noted, and the 
existence of genes for the binary toxin genes and a deletion in the tcdC gene, 
leading to hypertoxigenic properties, illustrated the new challenges emerging in  
CDI (Loo, 2006). Spread of the B1/NAP1/027 strain has been reported from across 
Canada and the USA.  
           Epidemiologic studies have examined C. difficile infection in other parts of 
the world. A shift of strains was detected in Japan over a 5 year period and in 
2007, the 027 strain was isolated from a 30 year old woman after treatment with 
antibiotics (Sawabe et al., 2007, Kato et al., 2007). Other reports from Korea (Shin 
et al., 2008, Tae et al., 2009), China (Sundram et al., 2009), and Hong Kong (Cheng 
et al., 2009) noted  the  appearance of the 027 ribotype. Although toxigenic strains 
(078 - 097) have been isolated in Kuwait (Rotimi et al., 2003), there are no 
documented reports of the 027 ribotype from the Middle East or South American 
countries. More study and the isolation of greater numbers of samples may be 
required, following procedures that are now applied in European countries for 
detection and characterisation of CDI.    
 
1.3 Clinical characteristics 
       Clinical symptoms of CDI are highly variable from mild to severe diarrhoea and 
they depend on patient factors such as history of antibiotic treatment or previous 
exposure to the infection. Treatment with antibiotics and the consequent growth 
C. difficile – either pre-existing in the patient or newly acquired from the 
environment – that has the capacity to produce toxin (Bartlett, 2002) leads to CDI 
which can range between mild diarrhoea to pseudomembranous colitis, lower 
abdominal cramping or pain, fever, nausea and dehydration. Faecal leukocytes and 
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leukocytosis are two common signs. In fulminant cases, patients may develop toxic 
megacolon (Kelly et al., 1994). 
        Renal failure, malignancy, immunosuppression, or the administration of  
clindamycin are some of the more significant factors that can make patients 
susceptible to developing severe colitis and symptoms like peritonitis, 
hyperalbuminemia and alteration in peripheral leukocyte numbers (Rubin et al., 
1995). Molecular analysis of bacteria from patients with recurrent disease has 
revealed that half arise from acquisition of a new strain of C. difficile (Oneill et al., 
1991). Physical examination such as endoscopy can be used to confirm the 
existence of white or yellow plaques on the intestinal surface, these features being 
made up of ruptured cells and mucin, and indicative of the typical  signs of 
pseudomembranous colitis (Mylonakis et al., 2001).  
1.4 Diagnosis of C. difficile 
       Since the emergence of CDI, different methods have been proposed for 
diagnosis of this infection. Most are applied to samples of the patient stool but 
tests vary widely and include  assays for the presence of cytotoxin or glutamate 
dehyrogenase (GDH) from the bacteria, PCR in different formats, analysis of faecal 
leukocytes, blood tests, imaging and endoscopy methods (Figure 1.2). Of these, 
the most reliable include in vitro tests for cytotoxin production, toxin-specific 
immunoassays, assay for glutamate dehydrogenase and RT-PCR. Although 
diagnosing Glutamate dehydrogenase is not very specific but this assay is very 
sensitive to find out of the presence of Clostridium difficile in stool samples 
(Goldenberg et al.). Each of these tests requires different times and they also differ 
in their specificity and sensitivity creating advantages and disadvantages. Among 
these diagnostic tests, those that take the least time to perform yet report with 
the highest accuracy are preferred.  
      New features of C. difficile infection such as the production of the binary toxin 
may require a revision of assay methods, but at present, the cell culture 
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cytotoxicity neutralization assay (CCNA) is considered the best standard test. This 
detects the cytopathic activity of the glucosyltransferase toxins toxins A and B 
based upon their impact upon cultured fibroblast cells and can detect as little as 
1pg of toxin in a stool sample. This test is cheap to conduct but relatively time-
consuming and comparing results with outcomes from immunoassays for toxin A 
and B suggests that immunoassays may emerge as a good replacement (Aldeen et 
al., 2000). An analysis of reports on CDI from 1991 – 2008 revealed a mean 
sensitivity of 75%-80% and specificity of 97%-98% across a range of popular 
methods (Crobach et al., 2009).  
       A new screening test based upon immunoassay of glutamate dehydrogenase 
can generate results within 24 hours and positive samples can be followed up with 
the CCNA test (Reller et al., 2007). Of the molecular detection tests, the most 
sensitive is RT-PCR for detection of toxin B. This shows potential as a replacement 
for immunoassays (Peterson et al., 2007).  Although new commercially-available 
PCR detection kits are faster and more accurate than the CCNA test, they will need 
to be updated regularly to keep abreast of the changing nature of CDI as outlined 
earlier (Swindells et al.).  
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figure1. 2. Diagnostic tests for Clostridium difficile (taken from Nature Reviews Microbiology 7, 526-
536 [July 2009]) 
 
1.5 Risk factors 
        Many studies have shown that there are three main risk factors for the 
development of CDI: use of antibiotics, age of the patient and hospitalization. 
Although other factors such as consumption of acid anti-secretory agents, 
immunosuppressive treatment and polymorphism in the IL8 gene have been 
reported, antibiotic therapy consistently emerges as the most important 
predisposing factor for CDI with clindamycin and quinolones showing particularly 
strong linkage. One of the earliest studies on the development of C. difficile 
infection amongst patients taking clindamycin revealed 21% developed diarrhoea 
and 10% progressed to pseudomembranous colitis (Tedesco et al., 1974). Many 
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other reports have shown an association between clindamycin use and C. difficile 
outbreaks and mutations in erm gene(s) encoding a 23S ribosomal RNA methylase 
(Johnson et al., 1999).  
       Large studies have also shown that exposure to fluoroquinolones is also linked 
with CDI outbreaks and the reverse, that limiting use of these antibiotics is an 
effective way to decrease the frequency of outbreaks (Muto et al., 2005). An  in 
vitro study of an outbreak in Quebec used pulsed field gel electrophoresis (PFGE) 
to discriminate between C. difficile strains and revealed that all were susceptible to 
such antibiotics such as vancomycin but resistant to ceftriaxone, clarithromycin, 
gatifloxacin and moxifloxacin (Bourgault et al., 2006). Changing from use of 
gatifloxacin to levofloxacin decreased the rate of CDI (Gaynes et al., 2004). This 
study and others reinforce the idea that control of antibiotic choice and variation 
of the drugs that are used can be effective in decreasing rates of CDI.  
      Turning to the importance of anti-secretory drugs, a cohort study conducted in 
Montreal revealed that proton pump inhibitors and H2 blockers were potential risk 
factors and that they should be use with care for the patients at threat of CDI   
(Dial et al., 2004). This was supported by data from the United Kingdom (Dial et al., 
2005). Immunosupression and IL8 polymorphism are other risk factors which have 
been reported (Sanchez et al., 2005, Jiang et al., 2006). 
 
1.6 Prevention and treatment 
      There are two main ways to prevent CDI: careful use of antimicrobial agents 
and blocking transmission. To minimize the effect of antimicrobial agents, patients 
should be treated with drugs which have minimal effect on the intestinal 
microflora. Transmission can be blocked by having a managed system for the care 
of patients that have developed CDI, maintaining isolation and exercising 
meticulous hygiene. Although antibiotics remain mainstay of treatment for CDI, 
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other approaches are under development such as immunotherapy, probiotics, 
vaccination and polymers that can adsorb bacterial toxins and other virulence 
factors. 
        Vancomycin and metronidazole are the main drugs used to treat CDI (Gerding, 
2005). A study of 27 patients showed that metronidazole taken orally for 7-10 days 
was effective, but could fail if co-adminstered with  the antibiotic that originally 
triggered CDI (Modena et al., 2006). Analysis of relapse of CDI revealed 
vancomycin was better than metronidazole in removing C. difficile as assessed by 
culture or the presence of toxin in the patient stool. When vancomycin was 
delivered in pulsed doses, recurrence of infection was significantly decreased 
(McFarland et al., 2002). More recent studies have reported reduced efficacy with 
metronidazole treatment and in a study of 207 patients treated with 
metronidazole, C. difficile was cleared from 50% but 22% underwent relapse and 
symptoms of colitis returned. The emergence of resistance to metronidazole is an 
issue of concern (Musher et al., 2005).  
      In addition to antibiotics, prebiotics and probiotics are under investigation as 
treatments for a range of gastrointestinal disorders including C. difficile. Use of 
vancomycin has been explored, with or without Saccharomyces boulardii as a 
probiotic. Decreased relapse rates were reported in patients that received 
vancomycin and the probiotic, when compared to groups that were treated with 
the antibiotic alone (Surawicz et al., 2000). Using the antibiotic with oligofructose 
as a prebiotic, also showed benefits (Lewis et al., 2005). Tolevamer is a novel toxin 
binding polymer that can be used to treat C. difficile. In a hamster model,  the 
polymer reduced the severity and recurrence rate of CDI and in the same study, 
the enterotoxic effects of toxin A were reduced by administration of tolevamer to 
rats (Barker et al., 2006).   
       Oral immunotherapy or passive intravenous immunoglobulin (IVIG) have also 
been considered as strategies against C. difficile infection and there are many 
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reports showing the effect of passive immunity in treatment of CDI. Immunized 
female hamsters can transfer protection to their offspring  (Kim et al., 1987) and in 
other work with this animal model, concentrated hyperimmune bovine IgG, 
prepared from cattle vaccinated with toxin A and B, was able to protect against 
CDI providing treatment commenced before the onset of diarrhoea (Lyerly et al., 
1991). In a study with human patients, oral delivery of whey protein concentrates 
from cattle  immunised with inactivated toxins and whole cell killed C. difficile 
proved effective (van Dissel et al., 2005). These whey protein concentrates are 
particularly rich in bovine secretory IgA and appear safe to use with CDI patients 
(Young et al., 2007). Passive intravenous therapy with human immunoglobulin also 
shows potential in the limited number of reports in the literature (Abougergi and 
Kwon).  
Vaccination with inactivated toxins from C. difficile is also another field of 
immunology relavant to the control of this infection. Reports of the use of 
parenteral vaccines containing toxoid A and B or separately purified proteins 
showed a strong response to toxin A and protection against CDI. The results from 
some studies show no recurrence of CDI after vaccination, strongly supporting the 
view that this method has potential against CDAD and colitis (Sougioultzis et al., 
2004, Aboudola et al., 2003, Giannasca and Warny, 2004b).  
 
1.7 Typing of Clostridium difficile 
       There are different typing methods for C. difficile can be divided into two 
groups, phenotypic and genotypic methods. In phenotypic methods the 
characteristics of the surface components of bacteria are used in typing schemes. 
Typing via this method can use different technical approaches such as SDS-PAGE or 
the immunochemical fingerprinting of cell extracts. Combination of these methods 
showed some value in documenting the differences between isolates in an 
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outbreak but methods based on the genotype would be useful for cosmopolitan 
typing of C. difficile (van den Berg et al., 2007).  
      The earliest methods of serotyping used antisera which were prepared against 
formol treated strains. Serogrouping of isolates through slide agglutination 
revealed 6 groups which differed in toxin production and association with 
antibiotic-associated diarrhoea, serogroups A, C and D being identified in cases of 
antibiotic-associated diarrhoea  (Delmee et al., 1985). Another study reported the 
development of 15 serogroup antisera which were used to identify 6  cytotoxigenic   
serogroups isolated from midly to severe cases of CDI (Toma et al., 1988).  
         While different studies used these methods to interpret the behaviour of new 
isolates, molecular methods based on bacterial genotyping have been developed. 
In summary, PCR ribotyping (analysis of the spacer regions between 16S and 23S 
ribosomal RNA genes), pulsed field gel electrophoresis (PFGE), multilocus variable 
number tandem repeat analysis (MLVA), restriction endonuclease analysis (REA) 
and toxinotyping are the most frequently reported. They have all their advantages 
and disadvantages. Activity since the 1980s has aimed to improve typing methods 
and to select the best, and from this, molecular methods have emerged because of 
the stability of the clostridial genome and the reproducibility of the methods 
(Brazier, 2001).  
       For quick recognition of strains, REA, arbitary primer PCR and PCR ribotyping 
are preferred over MLST or MLVA which are better suited to long term 
epidemiology studies (Kuijper et al., 2009). The new outbreak strain of C. difficile 
has been variously termed B1/NAP1/027 based on different typing methods: by 
REA, it belongs to the B1 group; by PFGE, it belongs to North American PFGE type 1 
(NAP1); by ribotyping it belongs to ribotype 027. The toxinotyping method places 
the strain in toxinotype III, a group that in addition to toxin A and B, shows the 
existence of the binary toxin CDT and deletion of 18 base pair in tcdC, the gene for 
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a negative regulator of toxin A and B. These properties help explain the virulence 
of the strain.  
        Although this strain is relatively new and different from the strains first 
reported in 1984, differences have been noted in its incidence and  resistance to 
fluoroquinolones (McFarland et al., 2007). In a study that analysed C. difficile from 
124 patients, isolates were characterised by different typing method that 
examined the deletion in tcdC, production of toxins A and B, and the presence of 
the binary toxin. Results showed B1/NAP1/027 produced 16 times more toxin A, 
and 23 times more toxin B than was typical(Vohra and Poxton, Vohra and Poxton, 
Warny et al., 2005b).  
      
1.8 Life cycle of C.difficile 
       The ability of C. difficile to form spores poses a particular challenge in control 
of the pathogen, particularly in the hospital environment where rigorus cleaning 
methods are required to contain spread (Figure 1.3). Spores can be transmitted by 
inhalation or ingestion. Gastric pH provides effective protection against the 
vegetative cells of many pathogens but the ability of spores to germinate can also 
be effected to some extent (Fordtran, 2006). In the lower part of the 
gastrointestinal tract, germination is triggered by factors such as heat, pH, bile 
acids, and glycine  (Wheeldon et al., 2008). Proton pump inhibitors increase the 
rate of germination, enhancing the patient’s risk of contracting C. difficile infection 
(Nachnani et al., 2008, Dalton et al., 2009) (Figure 1.3). Germination can be rapid – 
78% of spores can germinate in the small intestine one hour after reaching this 
destination (Wilson et al., 1985).  
        Following germination of spores in the intestine, C. difficile does not appear to 
pose a significant typo as the normal microflora inhibits its colonization. Under 
some conditions (broad-spectrum antibiotic therapy, long term hospitalization, 
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surgery or other cirumstances that disrupt the normal flora) the vegetative cells of 
C. difficile can colonize and under these circumstances, the characteristic 
symptoms of infection can emerge (Figure 1.3). The development of new 
diagnostic methods and awareness of the potential consequences of antibiotic 
therapy has done little to curb the rise of C. difficile-associated diarrhoea (Elliott et 
al., 2007).    
 
figure1. 3. The typical Clostridium difficile life cycle. 
 Taken from Southend University Hospital web site 
 
1.9 Pathogenesis 
       Pathogenesis of C. difficile infection is a multi-step process. The first step is the 
creation of the appropriate microenvironment for germination of spores in the 
gastrointestinal tract. Spores, which can be acquired from the external 
environment or from existing clostridial cells in the intestine, germinate and new 
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vegetative cells then establish through active colonisation. Penetration of the 
mucus layer and attachment of clostridial cells to the epithelium takes place 
through the activity of surface factors such as surface layer proteins and flagella 
but current understanding of these processes is incomplete. The production of 
toxin A and B, the main virulence factors, then ensues.  
      The pathogenicity locus (PaLoc) on the C. difficile genome carries the genes for 
toxin A and B. This 19.6 kb locus compromises five genes for the regulated 
production of the toxins (tcdABCRE). TcdA and tcdB genes are the toxin structural 
genes. There are two regulator genes: tcdD is a positive regulator; tcdC is a 
negative regulator. tcdE encodes a protein which may play a role in releasing the 
large toxin molecules from the bacterial cell.  The first strain to be sequenced, 
strain 630, can produce both toxin A and B. Several other strains possess a third 
toxin known as the binary toxin which is encoded near to the PaLoc  (Sebaihia et 
al., 2006) 
      Both toxins A and B are members of a family of large clostridial toxins. Based on 
variations in the genes for these toxins and elsewhere in the PaLoc, there are more 
than 20 toxinotypes . Toxin A (308 kDa) and B (270 kDa) comprise three domains. 
At the amino-terminus, they have an enzyme domain and the carboxy-terminus is 
a region responsible for receptor binding , while the central part with hydrophobic 
amino acids is believed to be involved in translocation of the toxin into the cytosol 
of host cells (Jank et al., 2007). Sequence and crystalographic analysis of the 
carboxy-terminus showed there are  repeated sequence in this domain and 
through these repeats toxins, the toxins can bind to cell surface carbohydrates (Ho 
et al., 2005).  
      Following receptor binding, the toxins are internalised by endocytosis and after 
that, two steps are required for the toxins to exert their effects. First is the 
translocation of the toxins into cytosol. This is thought to be induced by the 
progressive acidification of the endocytic vesicle which induces translocation of 
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toxins from the endosome interior into the cytosol (Barth et al., 2001). Once in this 
compartment, the enzyme activity of the toxins drives glucosylation of Rho 
GTPases. The resulting inhibition of the activity of Rho proteins causes down 
regulation or inactivation of a wide range of vital cell activities such as actin 
cytoskeleton regulation, epithelial barrier function, cell deaths, wound repair and 
phagocytosis, reflecting the involvement of Rho GTPases in many aspects of cell 
biology (Jank et al., 2007).  
     There are many reports showing the multiple effects of toxins A and B can lead 
to disruption of intestinal function, proceeding to pseudomembranous colitis (Voth 
and Ballard, 2005) (Figure 1.4). The advent of gene knockout systems for C. difficile 
(Heap et al., 2007) has allowed the relative contributions of toxins A and B to 
pathogenesis to be assessed in animal models. This has revealed that toxin B is 
more important in virulence than toxin A (Lyras et al., 2009) and that its damaging 
effect may be 10 times greater than that of toxin A (Riegler et al., 1995). 
Production of the toxins is influenced by different environmental signals. 
Depending on the strain, nutrient levels, temperature and sub-inhibitory levels of 
antibiotics can all contribute (Freeman et al., 2005) and a modest depletion of 
biotin (0.05 nM) results in higher production of toxin A (64 fold increase) and toxin 
B (35 fold increase) (Yamakawa et al., 1996).      
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figure1. 4. Action of toxins from C. difficile in the intestine. 
C. difficile  cells are shown free and attached to the intestinal epithelium as red shapes. TcdA and TcdB are 
shown as coloured circles. Binding of TcdA to apical surfaces causes shape change, disruption of tight 
junctions and loosening of the epithelial barrier. This in turn allows TcdB to bind basolateral cell surfaces. 
Inflammatory mediators are induced by toxin action and attract neutrophils leading for formation of the 
pseudomembrane. Taken from Nature Reviews in Microbiology 7, 526-536 (July 2009). 
 
1.10 Other virulence factors 
      Adherence to the intestinal wall is likely to be a necessary step in the infection 
process before toxin production. C. difficile has been shown to possess an ability to 
attach to different cells in vitro (eg Caco-2 and Vero cells) and in vivo, adherence to 
the caecal mucus of mice has been reported. In this animal study model, germ free 
mice were used and reproducible adherence to the caecum was observed, a 
process that was compared to adherence ex vivo. Data was reproducible for most 
strains, adherence to mucus being better for toxigenic strains than non toxigenic 
strains (GomezTrevino et al., 1996).  
      Analysis of bacterial adherence to Caco-2 cell monolayers revealed that with all 
C. difficile strains tested, binding mainly took place at the outer edge of cell 
clusters. Use of chelating agents increased bacterial adherence and binding was 
noted at the basolateral surface of cells and directly to protein fibres of the extra 
cellular matrix. This study suggested two processes for adherence, the first being 
direct attachment to a receptor on the lateral part of Caco-2 cells and the second 
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via binding to the extracellular matrix (Cerquetti et al., 2002). One can imagine a 
scenario in vivo in which adherence of bacteria to the apical surface of the human 
intestinal epithelium, followed by toxin production, would disrupt the integrity of 
the wall and allow further rounds of adherence to take place at the basolateral 
surface of cells and to components of the extracellular matrix.  
More detailed studies of virulence factors and other proteins present at the 
surface of C. difficile, proteins such as SlpA, Cwp66, Cwp84, FliC, FliD, GroEL,  and 
the fibronectin binding protein, has the potential to help clarify the substantial 
uncertainties of the process of colonisation and other aspects of the pathogenesis 
of this pathogen. 
 
1.10.1  Surface layer proteins 
     Surface layer proteins are found in a number of different bacteria. These 
proteins are involved in various activities such as the formation of a protective 
layer, cell adherence to surfaces, the creation of molecular sieves, as a scaffold for 
attachement of other virulence factors. They have a variety of molecular weights 
(40-170 kDa) with the capacity to interact with specific glycan chains and ions. 
Their location and their diverse functions makes a case for exploitation in vaccine 
development, and their ability to spontaneously self-associate into layers has been 
used in nanobiotechnology (Debabov, 2004). 
     Analysis of serum IgG from patients with the symptoms of CDI showed a 
positive reaction with a protein of around 36 kDa present in EDTA extracts of 
clostridial cells, showing that surface proteins are the target of immune responses 
in patients (Pantosti et al., 1989a). The 36 kDa protein was extracted from C. 
difficile C253 and purified. Results showed it could adopt a dimeric structure under 
native conditions but that it lacked glycan content. Immunofluoresence analysis 
made clear that this antigen is exposed on the surface of bacterial cells and has 
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similarity with S layer proteins from other bacteria. It lacked toxic or protease 
activity (Cerquetti et al., 1992a).  
       Electron microscopy of the cell wall of C. difficile GAI0714 showed a two layer 
structure with a 20 nm inner layer and a 10 nm outer layer. Removal of the outer 
layer completely changed the normal regular array present at the bacterial surface. 
Although the study showed a square array of components, determination of the 
true structure was difficult because of fixation conditions and autolysis. SDS-PAGE 
analysis of cell wall preparations showed a range of proteins of 45-47  kDa and 32 
kDa were extracted from some strains of C. difficile while the others showed 
proteins of 42 and 38 kDa (Kawata et al., 1984).  
       Result from reassembly experiments using the main two proteins extracted 
from bacteria showed the native array pattern could be reconstructed when the 
proteins were dialysed against CaCl2. The authors concluded that the outer cell 
wall layer of this pathogen comprised two proteins that required the presence of 
Ca2+ for formation of an array (Masuda et al., 1989). 
      Further investigations suggested that both components of the S layer – in C. 
difficile GAI0714, proteins of 32 and 45 kDa – can as dimers. Analysis showed that 
the two proteins were different in amino acid composition, but both were 
composed mostly of acidic amino acids, without cysteine and with low amounts of 
histidine and methionine. On account of their composition, pI values of 3.7-3.9 
were determined for the low molecular weight protein and 3.3 for the high 
molecular component of the S layer (Takeoka et al., 1991).  
      Another report showed that the major surface proteins are variable in 
molecular weight when extracted by urea and also that they are strain specific 
with the exception for 73 kDa antigen present in more modest quantities in the 
urea extracts (Sharp and Poxton, 1988). In related work (Cerquetti et al., 2000b), 
SlpA from six clinical isolates was characterised by a range of different methods. 
Electron microscopy data confirmed the presence of a regular crystalline array on 
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the surface of isolates. Although a lattice pattern could be recovered in vitro using 
urea extracts from cells, this was not possible when attempted with purified 
proteins either as single components or mixtures of the two dominant proteins 
present in urea extracts. These two proteins possessed molecular weights in the 
range 36-56 kDa and from all strains tested, they appeared to be glycoproteins. 
Rabbit antisera were raised against the 36 and 47 kDa proteins of strain C253 and 
used to understand better their antigenic relationship with components from the 
other six strains. Western blots showed antisera against the 47 kDa protein from 
C253 could react with high molecular weight SlpA proteins from the other six 
strains. In contrast, antisera to the 36kDa protein of C253 failed to recognise the 
low molecular proteins from other strains. Amino terminal sequencing revealed 
some similarity between low and high molecular parts of SlpA (Cerquetti et al., 
2000b).  
     A further study was done to characterise and compare the slpA genes and their 
proteins between different strains and ribotypes. Low pH extraction of SlpA from 
ribotypes 1 and 17 and also from strains Y and 630 showed a high molecular 
weight component of 41-45 kDa and 33-38 kDa for the smaller protein. While 
native electrophoresis of extracts from ribotypes 1 and 17 produced bands in 
excess of 140 kDa, other methods confirmed earlier reports of the formation of 
dimers or tetramers of SlpA components. Sequence analysis revealed that high and 
low molecular weight proteins are derived by post-translational cleavage events, 
the first removing the signal peptide from the amino terminus of the protein, the 
second taking place at an internal site. 
        Following removal of the signal sequence, the low molecular weight protein of 
SlpA derives from the amino terminal region and the carboxy terminal region 
constitutes the high molecular protein. Alignment of protein sequences for SlpA 
from ribotypes 1, 17 and strain 630 showed a conserved signal peptide and high 
similarity between mature forms of the high molecular weight proteins. In 
contrast, low molecular weight proteins were non identical (Calabi et al., 2001).  
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Analysis of genomic data from strain 630 showed that C. difficile possesses a 
number of open reading frames (ORF) with homology to the high molecular weight 
form (HMW) of SlpA and also similarity between the HMW and an autolysin from 
B. subtilis. Immunological analysis showed that the HMW is immunologically 
conserved between C. difficile strains in contrast to the diversity of LMW (Calabi et 
al., 2001). Working with the genome of C. difficile 630, the slpA gene (2160 bp) was 
predicted to encode a 73.4 kDa protein, the precursor for HMW and LMW. 
        Further sequence analysis of PCR products showed the gene to be similar 
between strains, C253 and 630. It was revealed that SlpA has 78 amino acids at its 
amino terminus with homology to an SLH domain, a feature detected in many S-
layer proteins and thought to be be responsible for anchoring to the bacterial 
surface. In the carboxy terminal part of SlpA, homology was noted with a domain 
with potential of amidase activity. More analysis determined a 37 kb region of the 
clostridial genome with 17 ORFs of which 11 ORF carried domains with homology 
to the cell wall anchoring domain of cwlB autolysin B. subtilis.   
      In almost all cases, these conserved domains lie on ORFs with a signal peptide 
and another variable domain with a range of functions (eg protease activity, 
Cwp84) (Karjalainen et al., 2001). Although deeper analysis of the S-layer proteins 
showed again a huge variation in the LMW between strains, conservation of a site 
for cleavage of LMW from HMW was observed consistently. The high rate variation 
in LMW sequences suggested that this might serve as means to evade the immune 
response of the host (Calabi and Fairweather, 2002).  
       Analysing of the variable part of the slpA gene by PCR-RFLP and nucleotide 
sequencing showed this region is similar within a serogroup but few similarities 
exist between different serogroups. Although this analysis showed that the slpA 
gene can be a target for discrimination of C. difficile isolates, sequencing of more 
strains is required (Karjalainen et al., 2002). In Japan, PCR of the slpA gene of 
strains of the smz ribotype (Kato et al., 2001) has been used along with other 
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methods (tests for toxin A and B, PCR ribotyping and PCR for tcdA) as part of a 
typing scheme. Analysis of 10 smz strains revealed that three subtypes were 
detectable (smz-1, smz-2 and smz-3 ) on the basis of slpA sequencing (Kato et al., 
2005). This typing method has been applied in different wards of a hospital using 
the stool specimens from patients with diarrhoea. Two smz-1 and smz-2 subtypes 
were found amongst major cases (Kato et al., 2009). Analysis of endemic isolates in 
Japan revealed this typing method can be used in conjunction with testing for 
toxin A, B and binary toxin and also ribotyping with good reproducibility. Based on 
slpA sequencing, 87 isolates were divided into 14 main types and 18 subtypes, an 
outcome that was compatible with PCR ribotyping of isolates (Kato et al., Kato et 
al.).  
      Despite sequence differences, expression slpA and processing of its translation 
products seems to follow a consistent pattern.  Signal sequences comprise the 
amino terminal 24 residues and cleavage has been show to occur at the last amino 
acid of a conserved sequence, SAAPVFA. The second predicted cleavage site was 
found to have an absolute requirement for a conserved GKR motif close to the 
cleavage site and often takes place amino terminal to a serine residue, resulting in 
a TKS or TYX motif at the carboxy terminus of the LMW product. The TAA stop 
codon was found in slpA in most ribotypes except ribotype 078 which was 
terminated with TAG. 
      
     Downstream of the stop codon, sequence typical of Rho-independent 
transcriptional termination was found. The slpA gene was found to lie close to secA 
with the two genes separated by 202 to 268 bp depending on ribotype (Eidhin et 
al., 2006). Analysis of  slpA genes from two C. difficile strains of ribotype 027 
(CD196 and R20291) showed that both have cleavage sites after amino acids 24 
and 342, to generate HMW and LMW proteins of 44 and 34 kDa respectively. 
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Comparison of the amino acid sequences of slpA indicated high similarity between 
ribotype 027 and the epidemic ribotype 001  (Spigaglia et al.).  
     Although it is very likely that binding of C. difficile to the intestinal epithelium is 
multifactorial, the amino acid composition and high representation on the 
bacterial surface suggests that SlpA may have a contributory role and it has been 
shown that both native and recombinant SlpA can bind to HEp-2 cells in vitro. 
Acidic extraction of SlpA from three strains (1, 17 and 630) showed this property 
and that it was independent of the bacterial strain. Analysis of recombinant HMW 
and LMW showed binding of HMW to host cells was the more effective and this 
was confirmed by using fluorochrome-labelled C. difficile and specific antisera in a 
blocking assay with human epithelial cells. 
        In a further step, the investigators tested for binding of native and 
recombinant S layer proteins using gastrointestinal tissue sections. They noted that 
HMW could both bind strongly to the epithelium and the lamina propria of mucosa 
in all level of gastro tract, while LMW gave a much weaker signals and this was 
limited to the epithelium. Blot analysis also described the binding of recombinant 
HMW and acidic extracts from strain 630 to collagen I, thrombospondin and 
vitronectin which are some of the components of the extracellular matrix (Calabi 
et al., 2002).  
     While different studies have described the presence of a glycan chain on S-layer 
proteins of C. difficile (Calabi et al., 2001, Cerquetti et al., 2000a, Mauri et al., 
1999), recent research has demonstrated that this protein is not glycosylated. This 
conclusion was reached from analysis of different S-layer proteins from different 
strains using mass spectrometry. The authors propose that a lack of reliability in 
commercial glycan-labelling kits and contamination have generated misleading 
results (Qazi et al., 2009). Other improvements to understanding of the S-layer 
protein have come from structural analysis of the interaction between HMW and 
LMW. Construction of different derivates of both these proteins has shown the 
Chapter 1 Introduction 39 
importance of residues 260-312 of LMW and the first 156 residues of HMW to the 
ability of these two proteins to interact. Crystalographic analysis of a truncated 
LMW (residues 1-262; native length 321 residues) has revealed a novel protein 
with two domains: domain 1 comprises residues 1-88 and 239-249, while domain 2 
is formed from residues 82-238. The investigators have proposed an end-to-end 
complex between HMW and LMW with HMW facing the bacterial cell wall and 
LMW facing the external environment  (Fagan et al., 2009). 
     S-layer proteins are targeted by the host immune response and potentially, 
LMW could be more immunogenic (Cerquetti et al., 1992a). A study or the human 
antibody response to surface layer protein failed to find substantial differences 
between serum IgM, IgG and IgA levels at times post-exposure among CDI 
patients, asymptomatic carriers and controls. However, it has been noted that high 
levels of IgM against surface layer proteins was accompanied with decreasing 
recurrence of CDAD which may reflect the contribution of this protein to the 
process of colonisation (Drudy et al., 2004). Linking with this, passive immunisation 
of hamsters with antiserum raised against purified S-layer proteins showed 
extended survival time after challenge with C. difficile compared to controls. This 
was the basis for a suggestion that SLPs might form components of a vaccine 
(O'Brien et al., 2005).  
     Amongst other activities, SLP can also alter the function of monocytes and 
dendritic cells (DC) which are important in innate and immune defence. 
Monocytes treated with purified SLP from C.difficile C253 showed increases in the 
production the pro-inflammatory cytokines IL-6 and IL-1beta that were 
comparable to those stimulated by  LPS from E. coli. The maturation of monocyte 
derived dendritic cells can be followed by markers such as CD83 and MHC Class II. 
Treatment with SLP from C253 provoked expression of these markers and the 
production of the pro-inflammatory cytokine IL-12 p70 and the anti-inflammatory 
cytokine IL-10, activities that can induce orientation of the immune response to 
Th1 and Th2 respectively (Ausiello et al., 2006). In further work, the 
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immunomodulatory properties of SLP from different strains were considered. No 
differences were noted between hypervirulent epidemic strains and non-epidemic 
strains in the capacities of SLP to stimulate production of IL-1beta and IL-6 or cell 
markers. Some differences were noted in the stimulation of IL-10 and IL-12p70 
(Manuela Bianco, 2011). It has also been noted that the LMW component of SlpA 
has some advuvant properties (Brun et al., 2008). 
     Based on analysis of the genome of C. difficile 630 (Sebaihia et al., 2006), it is 
predicted that  29 genes carry three copies of the cell wall binding Pfam 04122 
motif (Fagan et al.). Examples include Cwp66 and Cwp84, as described below. 
Proteomic analysis of surface extracts has shown the presence of many other 
proteins (Wright et al., 2005) but the abundance, sequence variation, and multiple 
activities of the HMW and LMW component of SlpA, along with the bias of patient 
responses towards these proteins (Wright et al., 2008) lends them a special 
importance in understanding the pathogenesis of CDI.  
 
1.10.2 Cwp66 
     Studies on the ability of C. difficile to bind to different cultured cell lines (eg  
Vero, Hela) discovered that  after a heat shock at 60˚C, bacterial binding was 
increased. Analysis identified a surface protein that appeared important in the  
adhesion process (Karjalainen et al., 1994). Iron limiting media, high solute 
concentrations (eg NaCl2, 550mM; CaCl2 ,25mM) and acidic shock were also shown 
to enhance adhesion. Three surface proteins of 70, 50 and 40 kDa were implicated 
in this adhesion process (Waligora et al., 1999).  
       These studies lead to the identification of cwp66, a gene lying downstream 
from slpA. Two open reading frames were located, orfA and orfB, that are 
separated by a 32 bp gap. They appeared to comprise a small operon with a rho-
independent termination sequence. The investigators noted that orfA (651 bp) was 
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responsible for production of a 24.9kDa protein while orfB (1830 bp) encoded 
Cwp66, the surface-located adhesin. Cwp66 is made up of 610 amino acids, 
forming a protein of 66 kDa with a pI of 5.3. Primary and secondary prediction 
showed Cwp66 to be a hydrophilic protein with two domains. Comparison 
between strains indicated variability in the carboxy terminal part and conservation 
in amino terminal region. As with SlpA, similarity was noted with the autolysin 
CwlB of B. subtilis   at the amino terminus, suggesting this region of Cwp66 has a 
role in attachment of the protein to the bacterial cell wall.  
      Examination of heat-shocked bacteria using immunogold and specific 
antibodies against recombinant amino and carboxy terminal parts of Cwp66 
revealed that the carboxyl terminal domain is a surface exposed. The antisera also 
showed some capacity to inhibit the  adherence of C. difficile to cultured cell lines 
(Waligora et al., 2001). PCR-RFLP with different strains showed heterogenicity in 
cwp66 in the 3’ region (Pechine et al., 2005b). 
1.10.3 Cwp84 
Located just down stream of cwp66, cwp84 encodes another protein that is 
located at the bacterial surface. cwp84 was determined to be monocistronic and to 
be expressed early in exponential phase of growth. A cell-anchoring domain 
appeared to be present at the carboxy terminus while the amino terminal part of 
the protein possessed the features of a cysteine protease (Savariau-Lacomme et 
al., 2003). Deletion mutagenesis confirmed the location of the enzymic domain of 
Cwp84 but purification of the recombinant protein was unsuccessful possibly 
because of putative autocatalytic activity which has been reported for other 
cysteine proteases. The sequence of the functional domain was found to be highly 
conserved with little or no variation among different serotypes of C. difficile, 
suggesting an important role for this protease, possibly in the assembly of proteins 
at the bacterial surface (Savariau-Lacomme et al., 2003).  
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Further study characterised the biochemistry of Cwp84 and its proteolytic 
effect on the host extracellular matrix (ECM). SDS-PAGE analysis of purified 
recombinant Cwp84 using a fused histidine tag protein confirmed autocatalytic 
activity under reducing conditions leading through step-wise changes, to a mature 
protein of 61 kDa.  ECM proteins such as fibronectin, laminia and fibronectin can 
were cleaved by Cwp84 under reducing conditions, and protease activity was 
inhibited E64 or anti-Cwp84 antibodies (Janoir et al., 2007). The protease could be 
detected in surface extracts and was expressed by different clinical strains.  
Antibody responses against Cwp84 could be detected in patient sera showing its 
expression and immunogenicity in vivo. It has been suggested that the protein 
might be a good vaccine candidate (Pechine et al., 2005b).  
More recent reports have shown a role for Cwp84 in the maturation of 
surface layer proteins in C. difficile. Bacteria carrying deletions of of cwp84 had 
different colony morphology and were slow growing in liquid culture with a 
tendancy to aggregation. In cwp84 mutants, SlpA processing was incomplete but 
results from an animal model of C. difficile infection showed no substantial 
differences in pathogensis compared with wild type (Kirby et al., 2009).  
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figure1. 5 Post-translational processing of SlpA. 
       The high- and low-molecular weight (HMW and LMW) surface layer proteins (SLPs) 
are synthesized in C. difficile as a ‘full-length’ precursor, SlpA. (A) During the process of 
translocation across the membrane the signal peptide (SP) is removed, presumably by a 
signal peptidase; (B) further processing by the papain class cysteine protease Cwp84 
generates the mature S-layer proteins; (C) LMW and HMW SLPs self-assemble to form 
the S-layer. Taken from Bioorganic & Medicinal Chemistry 20 (2012) 614–621. 
   
 
1.10.4 CwpV 
    This is another surface-exposed protein of C. difficile but one which has phase 
variable expression. Analysis has shown that it possesses three PF04122 cell wall 
binding domains and nine repeats of sequences each of 120 amino acids.  The 
number of these repeat sequences appeared to differ between C. difficile strains. 
Domain-specific antibodies revealed that post translational modification takes 
place to cleave the protein, that the carboxy terminal part of CwpV is exposed on 
the bacterial surface but that at any one time, only 5% of bacteria expressed the 
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protein. Inverted repeats flanking the cwpV promoter and the action of a 
recombinase appear to explain the phase variable expression of cwpV. The exact 
role of CwpV is not clear but investigators suggest that it might help escape the 
host immune system or cycles of binding and release from host cells (Emerson et 
al., 2009).   
1.10.5 Flagellum 
       In bacteria, the flagellum is made of three parts: the basal body, the hook and 
the filament. In C. difficile 630 the regions of the genome that are involved in 
flagellar synthesis are called loci F1 (CD0226-CD0240) and F3 (CD0245-CD0271 
which are separated by a locus (F2) unrelated to this aspect of the biology of the 
organism (Stabler et al., 2009). Two structural components of the flagellum are FliC 
(the flagellin) and FliD (the flagellar cap protein). Preliminary studies of C. difficile 
strains showed the presence of a 39 kDa flagellar protein in bacteria of serogroups 
A (A1-A12), D, G, H and K (Delmee et al., 1990). Analysis of a 1.6 kb fragment from 
a genomic library revealed two orfs, one of 870 nucleotides and a second lying 90 
bases downstream.  Sequencing of orf1 showed an amino acid sequence very 
similar to that of other flagellins – this was designated fliC of C. difficile.  
       The predicted molecular weight of FliC (30.9 kDa) was substantially less than 
that of the protein as determined by SDS-PAGE (39 kDa) suggesting post 
translational modification. Restriction analysis of fliC from six strains of C. difficile 
allowed separation into two groups. This can be explained by a region of high 
variability.  Using electron microscopy, it has been found that some strains of C. 
difficile possess numerous flagella (eg strains W1194 and Kohn) but others carry 
fewer. Inhibition assays using anti-FliC sera showed that the flagellum is not able 
to adhere to eukaryotic cells (Tasteyre et al., 2000a).  
        Further study (Tasteyre et al., 2001b ) confirmed the presence of a single copy 
of fliC with 46 strains possessing a gene of 870 bp. Organisms of serogroup X have 
a slightly shorter sequence (850 bp). fliC has also been found in 17 non-flagellated 
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strains and appears to be transcribed (RT-PCR) suggesting the absence of flagellae 
arises from mutation(s) in other genes. As found in previous work, amino acid 
alignment showed substantial variability in a central region with conservation and 
the amino and carboxy termini.  Based on RFLP analysis, 47 strains could be 
divided into nine groups with most strains belonging to groups I and VII. RFLP 
groups II, III, IV, V, VI and IX all belong to a single serogroup but the rest are 
serologically distinct (Tasteyre et al., 2000b).  
       The flagellum filament is capped by FliD. Using primers for amplification of fliD 
gene from strain 630, a product of consist size (1524 bp) was detected from 43 
strains of C. difficile. The experimental and predicted molecular mass of FliD are 
the same (56 kDa). Data from RT-PCR with non-flagellated strains demonstrated 
again that this gene is transcribed in all of these strains. Moreover, FliD is highly 
conserved between strains and its surface exposure may contribute to attachment 
of bacteria to host cells (Tasteyre et al., 2001b).  
        Recombinant FliC, FliD and crude flagella have all been used to assess their 
role in adherence and colonization in vitro and in vivo. Mucus preparation from 
germ free mice was used in a blotting assay and the results showed recombinant 
FliC, FliD and crude flagella could bind. Colonisation of the mouse caecum was 
found to be more efficient for flagellated over non-flagellated strains. It therefore 
seems possible that flagellar proteins, particiularly FliD, may contribute to 
adherence (Tasteyre et al., 2001a). In patients, both FliC and FliD have been shown 
to be immunogenic (Pechine et al., 2005b) and the vaccine potential of FliD has 
been tested in mice using different immunisation routes (intranasal, intragastric 
and rectal) and in combination with other surface proteins from C. difficile (Cwp84, 
Cwp66 and SlpA). 
      Although some effects on colonisation were apparent, it was concluded that 
more studies were required if an effective vaccine for C. difficile. was to be 
developed (Pechine et al., 2007). Glycosylation appears important in assembly of 
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the bacterial flagellum (Logan, 2006) and a glycosyltransferase (CD0240)  has been 
identified downsteam of fliC in the C. difficile 630 genome. The predicted 
molecular mass of FliC from different strains is consistently less than that observed 
experimentally as noted earlier. In FliC from strain 630, five sites have been 
detected at S141, S174, T183, S188 and S205 at which O-linked glycosylation takes 
place; this explains the 9 kDa difference between predicted and observed 
molecular weights. Inactivation of the glycosyltransferase gene (CD0240) 
generated mutants without motile behaviour (Twine et al., 2009). 
 
1.10.6 Fbp68 
      Fibronectin is one of the glycoproteins of the extracellular matrix with the 
ability to bind to integrin, collagen, fibrin and heparin sulphate proteoglycans. A 
gene was identified in C. difficile 79-685 for a 68 kDa fibronectin binding protein. 
Identification was made using the gene for a putative fibronectin binding protein 
from B. subtilis (GenBank accession number G69877). The gene is termed fbpA in 
strain 630. The gene (1773 bp) encodes a protein with 591 amino acids that are 
mostly hydrophilic in character that creates a two domain protein with different 
repeats within each domain, and a coiled coil structure in the middle of the 
protein. Fbp68 is highly conserved between strains 79-685 and 630.  
       Results of binding assays revealed that Fbp68 could bind both soluble and 
immobilised forms of fibronectin suggesting a mechanism for C. difficile to attach 
indirectly to cell surfaces (Hennequin et al., 2003). Although binding activity 
showed dependence on a number of  metal ions, manganese appeared the most 
important in different aspects of Fbp68 interactions (Lin et al.). Binding of five 
manganese atoms to Fbp68 was shown to induce conformational change mainly in 
the random coiled region and to influence resistance to heat and protease activity. 
Interaction between Fbp68 and fibronectin appeared to be mediated via the 
carboxy terminal region of Fbp68 (residues 397-591) and the amino terminal 
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domain of fibronectin. Fbp68 is exposed at the surface of C. difficile. The role of 
the protein in adherence to mammalian cells via fibronectin was explored in 
experiments with fbp68 mutants generated using Clostron technology. These 
experiments question the role of FbpA in colonisation (Barketi-Klai et al.). 
 
1.10.7 GroEL (Hsp60) 
      This protein belongs to a large family of chaperones which are responsible for 
maintaining correct folding in their substrates. In a study of the properties of 
heated-shocked C. difficile, the rate of binding of bacteria to cells such as Caco-2 
and HT29-MTX was increased (Eveillard et al., 1993). DNA analysis of strain 79-685 
showed a single copy of a gene of 1940 bp encoding for GroES and GroEL (10 kDa 
and 57.6 K Da respectively). Upstream of groES a CIRCE-like sequence (controlling 
inverted repeat of chaperone expression) was detected as a binding site for HcrA, 
a negative regulator of heat shock protein expression. PCR-RFLP analysis of groEL 
from 12 strains indicated conservation in C. difficile. 
       Analysis of different fractions from heat-treated (48˚C) C.difficile using antisera 
against recombinant GroEL showed this protein could be found in all fractions, but 
that it appeared mainly cytoplasmic and membrane fractions. Further localisation 
experiments showed that GroEL levels increased at the bacterial surface and 
appeared in the supernatant following heat shock. Expression was also enhanced 
by contact with eukaryotic cells and antisera decreased the binding of C. difficile to 
target cells in tissue culture (Hennequin et al., 2001b). Previous studies showed 
the importance of the local environment on the growth of C. difficile and the 
expression of different proteins (Waligora et al., 1999). With this in mind, the 
expression of GroEL was assessed under different stress conditions (heat shock, 
decreasing iron, acidic medium, high osmolarity and semi minimal inhibitory 
concentrations of antibiotic). It was found that stress has direct effect on GroEL 
expression (Hennequin et al., 2001a). 
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1.10.8 Peptidoglycan hydrolase 
       Peptidoglycan hydrolases or autolysins are found in different bacteria and have 
different physiological roles, for instance in cell division, growth or 
permeablisation of the cell wall to allow passage of large components and 
extracellular assembly (Vollmer et al., 2008). A gene for a putative peptidoglycan 
hydrolase was identified in C. difficile 630 upstream of the gene encoding DNA 
polymerase III. The gene (1824 bp) was named acd and encoded a protein of 65.8 
kDa protein with 607 amino acids and a pI of 9.52. Alignment showed the first 22 
amino acids comprised the signal peptide, four repeat sequences similar to the 
bacterial SH3 domain were identified at the amino terminus of the mature protein 
and a catalytic domain with similarity to glucosaminidase enzymes was located at 
the carboxy terminus. The acd gene was conserved in sequence among 12 strains 
of C. difficile and was transcribed largely during the vegetative phase of growth,  
suggesting a important physiological role (Dhalluin et al., 2005). 
1.10.9 Other surface proteins 
         Preceding sections only describe a selection of proteins thought to be present 
at the surface of C. difficile.  A comparative genomic study among some members 
of the genus Clostridium revealed several domains that may determine surface 
location. These include the following Pfams: PF04122, a cell wall binding domain 
present in many surface proteins; PF01473, as domain that can anchor proteins at 
the surface through recognition of choline; PF00037 that binds to iron-sulfur; 
LPxTG, a motif that often acts as a substrate for sortase enzymes; PF04203, the 
sortase family itself; PF01471, a putative  peptidoglycan binding domain; PF00232, 
an O-glycosyl hydrolase (Bruggemann and Gottschalk, 2008).  
      The sortases have been identified in gram positive bacteria as enzymes that can 
recognise exported proteins carrying appropriate motifs and couple them to 
peptidoglycan through a transpeptidation reaction (Paterson and Mitchell, 2004). 
Chapter 1 Introduction 49 
In C. difficile 630 only one putative sortase has been identified (CD2718) along with 
14 putative sortase substrates, four of which appear to lie upon conjugative 
transposons. Of the putative substrates, two are collagen binding surface proteins 
(CD3392 and CD0386) a further two (CD0420 and CD1858) have been identified as 
putative cell surface proteins (Sebaihia et al., 2006). In addition, analysis of the 
genome showed there to be proteases that may be membrane associated 
(CD0181, CD2129, CD1751 and CD0156) and a cell wall hydrolase (CD0183). These 
examples show the potential range of factors that may exist at the bacterial 
surface and may thereby contribute to the host-pathogen interaction. 
 
1.11  Surface proteins and the aims of this project 
        In this project, it is proposed that a panel of recombinant antibodies be 
generated against some of the candidate surface exposed proteins highlighted 
above. The specificity of these reagents, the ability to express and purify them 
quickly and conveniently and to detect their binding and location using antibodies 
against small tag sequences would allow better definition of the location of the 
clostridial proteins, and conditions under which they are expressed. In addition, a 
panel of small recombinant antibodies could be tested to assess whether they 
show the ability to inhibit the natural activity of their targets and hence their 
individual contributions to the behaviour of C. difficile and its pathogenesis. 
Targets to be used comprise HMW and LMW derivatives of SlpA, Cwp66, Cwp84, 
FliC, FliD, and the putative sortase, FbpA, GroEL and CspA.   
       These will be expressed and purified from E. coli. To select the recombinant 
antibodies, a humanised phage library will be used to select high affinity binders 
against the recombinant targets. The selected antibodies will then be tested for 
binding to the recombinant proteins. Recognition of the native targets from C. 
difficile will also be assessed. Strong binders will be used to check if these 
antibodies can locate their targets at the surface of C. difficile. As a generic 
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approach to the analysis of location and activity of target proteins, these methods 
could in future be applied to proteins that make contributions to the biology of the 
pathogen.      
 
 
1.12 Phage display 
1.12.1 Principles of phage display 
      Phage display is a powerful technology that can be applied in many area of 
biological research. Basically, bacteriophage is used to display candidate peptides 
or proteins that are fused to components of the phage particle. The coding 
sequence for the peptide or protein is carried within the phage either as an insert 
to the viral genome or in a phagemid. Phage are isolated from mixtures by the 
ability of the peptide or protein to bind to a target. Therefore there is a direct link 
between phenotype (ability to interact with target) and genotype (coding 
sequence) which allows large libraries to be screened in a selection procedure. The 
first developments in this field were reported in 1985 by George Smith who 
confirmed that bacteriophage M13 could be used to present a foreign protein at 
the phage surface. To do this, a fusion protein was prepared by insertion of a DNA 
fragment into gene III of phage M13. The displayed protein retained native 
conformation and the infectivity of the recombinant phage was preserved allowing 
infection into suitable strains of E. coli and replication. Hence small numbers of 
phage with the capacity to bind could be amplified (Smith, 1985b).  
      The development of display libraries was reported shortly after Smith’s initial 
paper. Amongst the first did an epitope library comprise millions of phage that 
displayed randomised peptides fused to pIII, the minor coat protein encoded by 
gene III. The library could used to separate those phage able to bind specifically to 
antibodies and hence map the epitopes recognised by these immunoglobulins 
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(Scott and Smith, 1990). Devlin reported a random 15-mer peptide library on M13 
phage. Again, the peptides were fused into protein pIII of phage creating a library 
with a theoretical capacity of 2 x1015 different phage. This library was used to 
identify peptides which could bind to protein targets (Devlin et al., 1990). Another 
early library was constructed by expressing random hexapeptide sequences at the 
amino terminus of adsorption protein of fd phage (Cwirla et al., 1990). 
       Filamentous phages (Ff) are amongst the most popular vehicles for phage 
display. They have a long cylindrical protein capsid which encloses a single 
stranded DNA genome. The genome was completely sequenced in the early 1980s 
(Hill and Petersen, 1982, Vanwezenbeek et al., 1980).  The designation Ff is derived 
from their shape and their requirement for the F pilus for infection into E. coli. 
Their life cycle comprises infection, gene expression and replication, an assembly 
reaction and release from host by extrusion rather than lysis. Filamentous phages 
that have been used for phage display inlcude M13, f1, Fd and ft. The dimensions 
of Fd phage particles are 7 nm diameter and 930 nm length. Their genomes are 
6400 nucleotides in length and code for 11 proteins that contribute to assembly 
(pI, IV and pXI), replication (pII and X) or of the structure of the virion (pIII, pVI, 
pVII, pVIII and pIX).  
       The capsid of M13 virus is made up of 2700 copies of protein pVIII, a protein of 
50 amino acids which can embed itself into membrane of the bacterial host prior 
to viral assembly through hydrophobic residues at positions 20-40. The amino 
terminus projects into the host periplasm while the carboxy terminus remains in 
the cytoplasm (Wickner, 1976, Ohkawa and Webster, 1981, McDonnell et al., 
1993).   These proteins coat the assembling virion as it is extruded through the 
bacterial membrane. Five copies of the pIII protein of M13 cap the particle on 
release from the bacterial host. Whilst there are reports of the use of pVIII for 
phage display, the low copy number of pIII has advantages for display technology 
(see below)  (Arap, 2005).  
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pIII (406 amino acids) carries an 18 residue amino terminal signal sequence 
for export via the bacterial Sec protein system (Rapoza and Webster, 1993). After 
cleavage of the signal peptide, folding of the protein to its mature form creates 
two amino terminal domains (N1 and N2) and the CT domain at the carboxy 
terminal end which all are linked to each other by glycine rich sequences. The CT 
domain (residues 256-406) of pIII is partially buried in the tip of phage particle. This 
holds pIII in place and the interaction ends the process of phage assembly and 
initiates releasing of the extruded virion.  
        Approach to a new bacterial host commences a new cycle of infection, a 
process to which pIII also contributes. Analysis of crystal structures has shown that 
the binding of the N2 domain (residues 87-217) to the bacterial F pilus induces the 
release of the N1 domain (residues 1-67) from a intramolecular interaction. This 
then allows N1 to bind TolA in the bacterial outer membrane; TolA thus acts as co 
receptor (Holliger et al., 1999, Russel et al., 1988, Rakonjac et al., 1999).  Further 
studies have suggested  three step model for attachment with initial interaction of 
N2 with the F pilus, binding of N1 to TolA and in a subsequent step, attachment of 
N2 to a central domain of TolA (Karlsson et al., 2003). These intricate interactions 
can be retained after attachment of peptides and proteins to pIII or through the 
use of helper phage, loss of function can be compensated. 
        Whilst peptides and proteins can be fused with gIII in the viral genome, 
phagemids provide a more convenient basis for phage display. In a bacterial host, 
phagemids behave like conventional plasmids but they possess the ability to be 
packed into filamentous phage particles as single stranded DNA if the necessary 
functions are supplied in trans. This is possible because these vactors carry ori 
sequences from M13 phage and for initiation of plasmid replication. Helper phage 
such as M13KO7 provide the genes required for viral assemble and packaging but 
with a less effective origin of replication than that carried on the phagemid, the 
helper phage genome is incorporated into particles with much lower frequency 
than the phagemid.   
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Helper phages have been adapted to enhance these general properties. For 
example, Ex-phage was prepared by site-directed mutagenesis to create an amber 
codon in gIII. This helper phage can be generate functional pIII only in suppressor 
strains of E. coli and has been used in antibody phage display applications (Baek et 
al., 2002). In another study, a helper phage known as CT-phage was produced in 
which domains N1 and N2 were deleted from pIII (Kramer et al., 2003). The helper 
phage used in the current study, KM10, was prepared with a protease cleavage 
site between the second and third domains of pIII and hence virus carrying copies 
of pIII encoded by KM10 (ie lacking additional sequence fused to pIII) are non-
infective  after protease treatment (Kristensen and Winter, 1998).   
 
        Different vector systems have been developed for expression of fused 
sequences to the capsid proteins of filamentous phage. As indicated earlier, pIII 
and pVIII have been most frequently exploited as structural studies of pVI, pVII and 
pIX proteins have failed to show promise (Makowski, 1993).  In the first type of 
vector systems, two genes (either gIII or gVIII) are carried on separate genomes, 
the wild type gene carried on the helper phage and the recombinant version 
carrying fused sequence on the phagemid. These vectors are known as 3+3 or 8+8 
systems.  When bacteria carrying the recombinant phagemid are infected with a 
helper phage, virus carrying the phagemid genome are produced but the capsid 
carries a mixture of wild type and fusion protein (pIII or pVIII). The alternative 
systems are vectors that carry two copies of gIII or gVIII (so-called 33 or 88 type 
vectors). In these systems, the genome of phage encodes both a wild type and a 
recombinant version of the same sequence.   
      In either vector system, it is possible to regulate to an approximate extent the 
balance of wild type and recombinant capsid proteins. For pIII, low representation 
or monovalent display of the fusion protein has advantages as avidity effects in 
attachment of the phage to the target can be minimised and hence high affinity 
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binders can be extracted from libraries. For pVIII, the high copy number of this 
protein on each particle provides opportunities to select for low affinity 
interactions with target (Smith and Petrenko, 1997).  
       For both pIII and pVIII, foreign sequences are inserted after the signal peptide 
to ensure surface exposure at the surface of the phage particle (Smith, 1985a). 
Where library construction and fusion of additional sequence destroys the normal 
function of pIII, infectivity can be restored by protein encoded by the helper phage 
and the recombinant phage carry a mix of non-functional recombinant protein and 
function wild type (Felici et al., 1991, Greenwood et al., 1991). Vector systems 
developed for library construction have incorporated restriction sites for the 
insertion of foreign sequence, selectable markers (Scott and Smith, 1990, 
McCafferty et al., 1990a, Hoogenboom et al., 1991, McConnell et al., 1994) and 
epitope tags for detection of the fused sequence.  One of the most frequently used 
tags has been the c-myc epitope (EQKLISEEDDLN). 
       This can be found in vectors such as m663, M13mp18Xa enabling 
discrimination of recombinant and wild phage particles. In the pHEN display 
vector, the c-myc tag is located at the carboxy terminal end of the insert, before 
the coding sequence for  pIII (Hoogenboom et al., 1991). Other modifications 
include the addition of a proteolytic cleavage site between  foreign  and capsid 
sequence (eg a site for factor Xa in M13mpXa vector  (Rodriguez and Carrasco, 
1995)) and  lacZ (eg in  vectors like m66) to enable the detection of inserted 
sequence by blue white screening with Xgal (Fowlkes et al., 1992). Stop codons 
between the displayed sequence and pIII enable the expression of a fusion with 
the capsid protein in suppressor strains of E. coli or expression of the foreign 
sequence in non-suppressors without modification of the vector (Hoogenboom et 
al., 1991, Lowman and Wells, 1993). 
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1.12.2 Type of libraries and application of phage display 
     Generally phage display libraries can be divided into those that carry 
randomised sequences (eg random peptide libraries) and those that display 
natural peptide or protein domains on the phage surface (eg cDNA libraries).  
       In this field,  random peptide libraries (RPL) have developed quickly to support 
the identification of epitopes or synthetic mimotopes, as used in the early 
identification of random peptides against ß-endrophin (Lam et al., 1993). The use 
of randomised synthetic oligonucleotides has enabled the convenient assembly of 
large libraries (eg  NNK or NNS codons. N representing an equal mixture of all 
nucleotides; K, equal mixtures of G and T; S, equal mixtures of G and C). For 
instance a 6-mer RPL can have 64 million peptide sequences  (Irving et al., 2001). 
Synthetic oligonucleotides generated in this way can be cloned in-frame at the 
amino terminal coding region of  gIII or gVIII of M13. Once assembled, the RPL can 
be screened for clones with affinity against different targets such as the 
identification of immunodominant antigenic peptides, peptide competitors in 
antigen-antibody reactions or mapping functional sites. In this context, RPL have 
been used in HIV research (Christian et al., 1992), to characterise the hepatitis B 
coat protein (Folgori et al., 1994, Felici et al., 1993) and in studies of Bordetella 
pertussis toxin (Felici et al., 1993). 
      In research of receptor-ligand interactions, RPLs have proved equally valuable.  
Peptides from RPLs may possess similar primary sequence to receptor ligands or 
mimic the characteristics of peptide or non peptide ligands. In one application, 
platelets were used to screen an RPL to select peptide sequences able to bind to 
the thrombin receptor. Selected phage were able to precipitate the thrombin 
receptor and peptides were identified that behaved like tethered ligands (Doorbar 
and Winter, 1994). Antagonists against urokinase were also selected from a 15-
mer RPL (Goodson et al., 1994), three peptides with high affinity for single 
stranded DNA were extracted from a phage library (Krook et al., 1994) and peptide 
mimics of a carbohydrate ligand were identified by phage display against 
Chapter 1 Introduction 56 
concanavalin A (Oldenburg et al., 1992). Other examples of the use of RPLs include 
studies to define substrate specificity. In this example, an RPL was prepared with 
an amino terminal sequence that mediated binding to a solid support. The RPL was 
bound to the affinity support and then treated with the proteases under 
investigation. Cleavage of sequences in the RPL then released the phage while 
virus carrying resistant sequences remained attached to the solid support. 
Sequencing of insert sequences carried by the phage revealed the substrate 
sequences (Matthews and Wells, 1993). 
       The other main use of phage display technology is to display libraries of 
proteins or their isolated domains and to select from these libraries, proteins with 
particular properties. Three areas of application are highlighted: the mutagenesis 
and directed evolution of protein domains; the screening of cDNA expression 
libraries; and in the next section, the isolation of high affinity antibodies.  
       Phage display can be used to direct the evolution of a protein or protein 
domain by creating multiple mutations, selecting for desirable properties, and 
repeating cycles of mutation and selection to create by increments particular 
properties within the protein. Different methods can be used for mutagenesis such 
as cassette mutagenesis, error prone PCR or DNA shuffling. By displaying the 
library of mutated protein sequences on phage, binders can be selected by 
attachment to a solid surface. This has been used in receptor studies (Lowman and 
Wells, 1993) and the development of novel enzyme inhibitors   (Dennis and 
Lazarus, 1994). cDNA expression screening is other powerful technique. Here, 
proteins encoded in a cDNA library are displayed at the phage surface.  This has 
been used to identify epitopes from antigens able to induce autoimmunity 
(Fierabracci et al., 1999).  Another study used this method to target drugs for 
treatment of prostate cancer (Arap et al., 2002).  
       Similar studies of targeting have used in vivo selection; here, phage libraries 
are injected intravenously into animals, specific organs are isolated, and phage are 
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isolated that specifically accumulate because they carry proteins with a particular 
tropism.  The first studies in this areas focused on the phage that could bind to the 
renal and cerebral vascular endothelium (Pasqualini and Ruoslahti, 1996) but the 
technique can be used to find antigens that are recognised by the antibodies 
circulating in patients with cancer (Mintz et al., 2003).  Isolation and identification 
of allergens is another application of phage display. Phage display cDNA libraries 
can be screened for binding to serum IgE from patients. Phage isolated in this way 
can then be sequenced to identify the DNA sequence of the potential allergen 
(Rhyner et al., 2004).  
       While these applications focus upon the isolation and characterisation of 
reactive protein sequences, phage display can be also used in gene delivery to 
improve the efficacy of delivery and decrease toxicity (Goldman et al., 1997, 
LAROCCA et al., 1999, Barry et al., 1996) and, related, in development of DNA 
vaccines  (Gao et al.) or conventional immunogens. In DNA vaccination, the phage 
can be used as a carrier of a DNA vaccine expression cassette in which the gene for 
the candidate antigen is under the control of an appropriate eukaryotic promoter  
(Clark and March, 2004a). Testing these ideas with the capsid antigen from 
hepatitis B virus showed that phage delivery could stimulate an effective and long 
lasting immune response in mice (Clark and March, 2004b).  With more 
conventional approaches to vaccination, it has been shown that the display of 
immunogenic sequences on phage particles has advantages over the use of 
traditional protein carriers like ovalbumin revealed (van Houten et al., 2006). An 
orally delivered food and mouth disease vaccine was reported to induce 100% 
protection in mice (Ren et al., 2008).   
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1.12.3 Antibody phage display 
1.12.3.1 A brief history and application 
         In the early 1890s, Emil Von Behring and Shibasaburo Kitasato revealed the 
sera of animals immune to diphtheria and tetanus contained an antitoxic activity 
which was much later attributed to the presence of circulating proteins that were 
termed antibodies. Antibodies are a group of protein molecules produced in 
response to foreign substances and thereby create an important defence against 
pathogens.  An antibody can bind to specific part of a foreign molecule via 
interaction of its paratope with the corresponding epitope carried by the antigen. 
This reaction can be used in diagnosis, neutralisation of the antigen, localisation of 
the interaction or therapy. The specificity of the interaction and its affinity is 
determined by amino acids present in the complementary determining regions 
(CDRs) of the antibody. Of their nature, these are highly variable; other parts of the 
antibody – regions of the so-called variable domain and the constant domains of 
the heavy and light chains – are conserved to a lesser or greater extent.  
      The variable domains of heavy and light chains are encoded by gene segments 
that undergo rearrangement as VDJ (variable, diversity and join segments; heavy 
chain) or VJ (light chain) units (Litman et al., 1993, Borghesi and Milcarek, 2006). 
The multiplicity of responses that are stimulated by an antigen give rise to 
polyclonal responses which can be used to neutralise or detect toxic materials 
(Harris, 1999),  for protection against pathogens (Casadevall, 2003), for research 
into disease states (Lambrianides and Giles), cancer therapy (Reichert and Valge-
Archer, 2007) and many other branches of biology. Work in this area has been 
transformed by two landmark developments that took place in 1975 and 1988. 
        In 1975, it was shown that fusion of myeloma cells with B lymphocytes could 
be used to produce monoclonal antibodies against an antigen, thereby 
deconstructing the nature of the polyclonal response (Kohler and Milstein, 1975). 
Humanization of monoclonal antibodies was reported in 1988, a process in which 
the antigen binding properties of a rat antibody were transferred to the  structure 
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of a human IgG (Riechmann et al., 1988). This helps overcome the immunogenicity 
of rodent antibodies in the human patient. This can be approached by the 
generation of chimeric antibodies that take the variable domains of a rodent 
antibody (and hence the capacity to recognise antigen with high specificity) and to 
fuse them with human constant domains. Antibodies of this type are 60-70% 
human in sequence and the limited response that they provoke in patients has 
lead to their promotion for therapeutic use (Brekke and Sandlie, 2003, 
Chintalacharuvu and Morrison, 1995, Lupo et al., 2008).  
      The alternative approach is CDR-grafting that was developed in the 1990s. 
Here,  CDRs from a specific rodent antibody are transplanted onto human 
frameworks creating a recombinant molecule that is 90-95% human antibody 
sequence (Jones et al., 1986, McCafferty and Glover, 2000). Literally applied, 
grafted antibodies failed to retain the affinity of the original immunoglobulin 
because the influence of residues from the framework was overlooked.  
Improvements can be achieved by choosing a recipient human sequence that 
shows high homology to that of the donor rodent molecule (Shearman et al., 
1991).  
      A completely different approach is through the engineering of the mouse 
immune system such that antibodies of human sequence are expressed by mice 
that have been experimentally modified or fully transgenic animals (“HuMab 
mice”). Immunization thereby leads directly to the production of human 
antibodies that can be immortalised via hybridoma techniques (Green, 1999, 
Neuberger, 1996). Mice with these properties can be generated by transplanting 
human cells from for a human donor into animals that carry severe combined 
immunodeficiency or animals that have been lethally irradiated and and then 
immunologically reconstituted (Reisner and Dagan, 1998). Mice that have been 
manipulated in this way can be also used as models for the study of different 
diseases such as hepatitis virus (Ilan et al., 1999). Transgenic approaches to the 
same challenge are also possible by creating mouse lines in which the endogenous 
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antibody responses is inactivated and replaced with a human mini chromosome 
containing the human heavy and kappa light chain loci (Tomizuka et al., 2000).           
The structural basis of the interaction between antigen and antibody is now 
understood in substantial detail. The variable domain of each antibody heavy or 
light chain comprises a structure with two antiparallel beta sheets and an 
intramolecular disulfide bond. Three loops from each chain project from this 
structure and the amino acids in these short sections form the CDRs that together 
create a unique interface for the interaction with antigen.  Four of the six loops – 
two in the light chain, two in the heavy chain – are initially encoded by germline 
segments, the others being created through the rearrangement process.  
      Substitutions can be incorporated at any position in the variable domains 
during somatic mutation as B cells respond to antigen, but substitution in the CDRs 
are particularly important for the nature of the interaction with antigen.  While the 
third heavy chain CDR (H3) loop was found  to be most variable in length and 
sequence, L3 loop (CDR3 in the light chain) was determined to form the central 
point area of the antigen binding site (Wu and Kabat, 1970). The antibody binding 
sites so created can be classified into 4 groups including concave and mild concave 
(these are found with particular frequency in the interaction with small antigen 
molecules), rigid (peptide antigens) and planar (protein binders)  (MacCallum et 
al., 1996). Based on comparative studies, a series of “canonical” conformations 
have been identified that make possible the formation of these surfaces (Chothia 
et al., 1989).  In addition, sequence analysis and comparative studies of different 
framework and CDR sequences have identified residues that are particularly 
critical. These include residue 71 which lies within a framework region but is 
particularly influential in the conformation of the second CDR in heavy chains (H2) 
(Tramontano et al., 1990). 
Since 1975, scientists have worked towards the use of monoclonal 
antibodies in the clinic (Reichert, 2001). In attempts to overcome the reliance on 
Chapter 1 Introduction 61 
production of monoclonal reagents in cell culture, work through the 1980s began 
to look at cloning and expressing antibody genes in bacteria (Winter and Milstein, 
1991). Amplification of the genes encoding monoclonal antibodies by PCR and 
expressing them in prokaryotic hosts like E. coli  offers a convenient and economic 
route to antibody production (Plückthun et al., 1989). Whilst inherently variable in 
sequence, the rearrangement of segments from modest numbers of gene families 
has made this possible  (Larrick et al., 1989) (Benhar and Pastan, 1994, Ruberti et 
al., 1994). 
       Expression of full-length antibodies in bacterial hosts is problematic but the 
proteins can be engineered into different formats such Fv fragments (VH and VL 
domains that spontaneously associate), scFv proteins (VH linked to VL by a peptide 
linker), Fab fragments (VH and VL domains with the first constant domains) and 
oligomeric units of two, three or four identical or distinct antibody fragments 
(“diabodies”, “triabodies” etc) (Figure 1.5).  Fortuitously, the robust fold evident in 
the variable domain is retained in proteins with these formats and hence the 
capacity to interact with antigen and the affinity of the interaction is retained. 
Amongst these engineered antibodies, the most commonly encountered 
formats are scFvs and Fabs.  In scFvs a short polypeptide linker can be fused to link 
VH and VL allowing the domains to fold independently and associate in the 
bacterial periplasm but retaining them in close proximity as a single protein chain 
(Winter et al., 1994). Fabs contain two polypeptide chains that are independently 
coded and translated. The two chains can interact through formation of a disulfide 
bond which increases the stability (Carter et al., 1992) (Figure 1.5).  
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figure1. 6. Formats of engineered antibodies (taken from Nature Biotechnology 29, 5–6, [2011]). 
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1.12.3.2 Formats of antibodies in phage display 
1.12.3.2.1 Preface  
     Antibody phage display is identical in its approach to the other formats of phage 
technology described earlier: antibody chains are expressed as fusion proteins 
with of one the components of the phage coat; the recombinant phage particles 
are presented with target that is coated to a solid surface and those that fail to 
interact are washed out; phage recovered from the selecting surface are infected 
into bacteria and replicated in preparation for a further round of selection. As a 
technology, antibody display benefited from the coming together of display 
methods (McCafferty et al., 1990b) and the appreciation that export of antibodies 
to the environment of the Gram negative periplasmic would allow  folding to take 
place, thus creating functional immunoglobulin-like proteins (Skerra and 
Pluckthun, 1988b).  
      Recombinant antibody sequences can be carried on phage vectors but the use 
of phagemids vectors dominates the field. In these systems, the antibody 
sequence (typically scFv) is cloned into gIII in frame with  the coding sequence for 
the minor capsid component described earlier (Clackson et al., 1991, Hoogenboom 
et al., 1991, Barbas et al., 1991). Helper phage such as KM13 or M13KO7 are used 
to catalyse the assembly and packaging of phagemid  into particles that display the 
antibody-pIII fusion (Kristensen and Winter, 1998, Vieira et al., 1987). The most 
efficient  antibody formats for display are scFv (Marks et al., 1991), Fabs (Chang et 
al., 1991), Fvs and diabodies (Brinkmann et al., 1995, McGuinness et al., 1996) 
(Figure 1.5). As regards the range of antigen-binding capacities contained in a 
library of antibodies, these are made available through four approaches. 
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1.12.3.2.2 Immune libraries      
 
      Basically this method samples the antibody repertoire of an individual that has 
been exposed to an antigen (eg a pathogen) or deliberately immunised, using 
specific primers to recover antibody sequences by PCR (Welschof et al., 1997). The 
composition of the library will thus be influenced by the antigen(s) used in 
immunisation of the human patient or experimental animal (Cai and Garen, 1995, 
Barbas et al., 1993) but libraries of this sort are likely to be enriched for specific 
antibodies with high binding affinities (Clackson et al., 1991). Immune libraries 
have been reported from different species including humans (Barbas et al., 1993), 
mice (Kettleborough et al., 1994), chickens (Davies et al., 1995), rabbits (Yamanaka 
et al., 1996), and camels (Arbabi Ghahroudi et al., 1997) amonst others. 
 
1.12.3.2.3 Naïve libraries 
 
 
          The term “naïve” has been applied to these resources as they are prepared 
from non-immune sources that have not been stimulated to respond towards a 
specific target. Providing the libraries are large (approximately 107 different clones 
or greater) antibodies with different binding affinities can be found against a great 
many antigens in libraries of this type. Using PCR, recovery of sequences can draw 
upon IgM antibodies present on the surface of non activated B cells.  
          During development of this area, investigators have sought to create very 
large libraries to increase the chances of isolating high affinity binders to the target 
of interest (Marks et al., 1991, Griffiths et al., 1993). Affinity ranges for a small 
library of around 3 x 107 clones  lie between 106-107 M-1 whereas creating much 
larger libraries (1010 clones) has been shown to yield antibodies with affinities in 
the range 108-1010 M-1 (de Wildt et al., 1996, Griffiths et al., 1993, Vaughan et al., 
1996). Two or three cloning steps are used to create libraries of this size. Firstly the 
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amplified sequences of light chains are cloned to the phage vector and in a second 
step, heavy chain amplicons are ligated (Welschof et al., 1997, Johansen et al., 
1995). Some authors have divided the second step such that the heavy chain 
repertoire is constructed in a holding vector before insertion into the light library 
(Welschof et al., 1997). The random pairing of light and heavy chain products 
enhances the diversity of the resource. 
 
1.12.3.2.4 Synthetic antibody libraries  
 
            In this type of antibody library, variable genes are assembled together and 
diversity is created in the CDRs and / or bordering framework using in vitro 
methods (Hoogenboom and Winter, 1992, Barbas et al., 1992). The range of 
diversification and its location is chosen from studies of the natural diversity of 
antibody from in vivo sources, often focussing on CDR3 of the heavy chain (Chothia 
et al., 1989). In construction of synthetic libraries, there are many reports that 
used a variety of sequences and approaches to libraries containing large numbers 
of antibodies with reasonable efficiency.  
           Some of the creators have used as scaffolds the frameworks of known 
antibodies and incorporated randomised CDR3 sequences to the heavy and light 
variable chains regions (Desiderio et al., 2001). Another technique for constructing 
synthetic libraries was to use the diversity created in vivo. In this approach, CDRs 
were isolated from in vivo sources and integrated into a single human framework 
(Jirholt et al., 1998). Fully synthetic library was also reported that used heavy and 
light frameworks and incorporated six synthetic CDR cassettes (Knappik et al., 
2000).  One of the largest  synthetic libraries was constructed by combining of 49 
heavy human heavy chain sequences with a collection of 47 human κ and λ light 
chains, each containing partially randomized CDR3 sequences. Antibodies against 
different antigens were selected from this library with nanomolar affinities 
towards their targets (Griffiths et al., 1994). 
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One advantage that has been exploited in the development of synthetic 
libraries is that  variable gene segments can be chosen that are well-expressed in 
the bacterial host, that fold successfully and that possess low toxicity in bacteria. 
These features enhance the functional size of the library. In contrast, one problem 
that arises from in vitro  diversification – particularly when sequences are 
randomised – is the creation of stop codons.  This can be addressed by assembling 
from trinucleotides instead of single bases (Virnekas et al., 1994). Further design 
considerations can include pre-selection of synthetic variable domains on 
immunoglobulin binding  proteins such as Protein A (for VH) and Protein L (for Vκ) 
(إkerstrmِ et al., 1994), ensuring that all components of the library are functional.      
 
1.12.3.3 Selection strategy 
Having created a phage display library of diversified antibody sequences in 
scFv, Fab or other formats, phage that are reactive with a target can be extracted 
by panning. In panning, the target is immobilised to a solid support (eg a plastic 
surface with the capacity to bind protein) and the phage library is added. During 
washing, phage that lack the capacity to interact with target are eliminated and 
those that are captured to the solid support are recovered, infected into a 
bacterial host to allow replication from initial small numbers to yields sufficient for 
the next round of selection. Repeated rounds of selection, recovery and replication 
progressively enrich for binders.           
    There many different selection methods, the simplest being biopanning on 
supports to which the  target “antigen” is immobilised (Clackson et al., 1991),  be 
that a tube, columns (Marks et al., 1991, McCafferty et al., 1990b), or BIAcore 
sensor chips (Malmborg et al., 1996). In some cases, purification of the intended 
target proteins may lead to loss of the biological activities required for selection. 
Under these circumstances panning is possible on  prokaryotic or eukaryotic cells 
(Bradbury et al., 1993, Cai and Garen, 1995) or  in living animals (Pasqualini and 
Ruoslahti, 1996); the principles are identical but libraries may need to be pre-
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absorbed with cells that lack the target to ensure selection is guided specifically 
towards the target and spurious features of the cell surface are avoided (Watkins 
and Ouwehand, 2000).  
Given that very large numbers of phage are added to the selecting surface, 
the frequency and stringency of washing is an important factor in ensuring that 
panning is efficient and specific. Limited numbers of washing cycles are used to 
isolate low affinity antibodies while high affinity antibodies can extracted from 
libraries if more stringent conditions are employed (Winter et al., 1994). Other 
interventions that can drive the isolation of high affinity binders include use of  low 
concentrations of target at the selecting surface. The number rounds of selection 
required for extraction of specific antibodies from the display library depends 
upon the enrichment rate at each stage but three rounds of selection are typically 
employed given that enrichment rate are in the range of 20 to 1000 fold at each 
selective step (Marks et al., 1991, McCafferty et al., 1990b). 
Recovery of those phage – often very small numbers of phage from the 
library – from the target-coated surface can be through the use of media of low pH 
such glycine buffers (Kang et al., 1991, Roberts et al., 1992) or high pH such as 
triethylamine (Marks et al., 1991). Chaotropic agents with dithiothreitol have been 
reported; these are usual when biotin is linked to the target molecule through by a 
disulfide bond (Griffiths et al., 1993). Enzymatic cleavage is also a possibility that 
can be usefully exploited when  cleavage sites have been engineered in place 
between the antibody and pIII (Ward et al., 1996). Competing concentrations of 
free target can also be used  (Clackson et al., 1991).  
1.12.3.4        Phage antibody screening  
     In the selection steps of phage display, combinations of binders with different 
properties are recovered from the initial library. To identify clones that are best-
suited to the intended end use, screening methods are used that are fast, robust, 
and able to work with unpurified phage or soluble antibodies that are derived from 
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the phage. Mixed (“polyclonal”) populations of phage or clonal lines 
(“monoclonal”) phage antibodies can be tested in ELISA to assess the specificity of 
their interaction with target (Marks et al., 1991). Immunoprecipitation (de Wildt et 
al., 1996) or immunocyto chemistry (VanEwijk et al., 1997) can also be used to 
confirm specificity.  Bioassay screens that test directly if phage antibodies can 
neutralise the biological activity of the target are also possible (Zaccolo et al., 
1997). 
      One value of modern phagemid vectors is that many include an amber codon 
between the antibody coding sequence and gIII, allowing the screening of 
antibodies at the phage surface and the convenient production of soluble 
antibodies as monovalent proteins by switching from suppressor to non-
suppressor strains of E. coli (Hoogenboom et al., 1991). The incorporation of 
epitope tags to these vectors allows phage or protein to be detected 
immunochemically with reagents against c-myc (Marks et al., 1991) or Flag 
sequences (Lah et al., 1994). The other tag of value that these vector often fuse to 
the antibody sequence is a His tag that enable convenient purification of soluble 
antibody via affinity chromatography (Hochuli et al., 1988). 
1.12.3.5 Antibody expression  
 
      As outlined earlier, antibody phage display is only possible because 
microorganisms such as E. coli can be used as hosts for expression of recombinant 
antibodies. Once clones emerge from phage display, selection and screening, their 
properties can be best characterised through large scale expression and 
purification.  
Antibody Fab proteins contain five disulfide bonds, and scFvs contain two; 
successful folding and the formation of these bonds takes place in the Gram 
negative periplasm. To attain this location phage display vectors provide bacterial 
leader peptides derived from pelB, phoA or ompA (Skerra, 1993, Skerra and 
Pluckthun, 1988a). Within the periplasmic environment, bacteria proteins like 
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DcbA, DsbB and DsbC assist folding and the formation of disulfide bonds.   Yields of 
proteins from the bacterial periplasm can be enhanced by the use of specialised 
expression vectors with strong promoters (Colcher et al., 1990, Gibbs et al., 1991). 
Protein misfolding and aggregation can be decreased by growing cells at 25˚C or 
applying tightly regulated promoters such as pBAD arabinose inducible promoter 
(Somerville et al., 1994, Clark et al., 1997). 
       Some investigators have reported the use of non-metabolised materials to 
create osmotic stress and thereby increase the yield  of correctly folded antibodies 
in the periplasm (Kipriyanov et al., 1997, Kipriyanov and Little, 1999). Codon usage 
also appears to have effects in some cases on the solubility and hence the yield of 
antibodies from prokaryotic expression hosts (Dueaٌs et al., 1995, Forsberg et al., 
1997) and as described earlier, grafting CDRs onto the framework of antibodies 
that are inherently well-expressed also improves stability and antibody production 
(Wأ¶rn and Plأ¼ckthun, 1999).    
1.13 Aims of the project 
Bringing together the themes described above, this project aimed to generate a 
panel of recombinant antibodies against proteins known or suspected to be 
present at the surface of C. difficile the goals being to assess surface exposure 
where this is uncertain, to test whether the function of these proteins can be 
blocked by specific recombinant antibodies, and thereby to generate reagents that 
may contribute to a better understanding of the role of surface proteins in the 
biology and virulence of this important nosocomial pathogen.  
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2 Material and methods 
 
2.1 Culture of Clostridium difficile 
       To prepare genomic DNA, flagella and extracts containing surface layer 
proteins, C. difficile was cultured in liquid and agar media. Three strains were used 
at points in the project: 630 (the first strain to be sequenced; GCC 107), R20291 
(hypertoxigenic outbreak strain, ribotype 027; GCC 154) and M120 (a non-motile 
strain of ribotype 078; GCC 165). These strains were obtained as spores from the 
Glasgow Culture Collection maintained by Dr G. Douce (University of Glasgow) and 
grown under anaerobic conditions at 37˚C. 
        Brazier’s CCEY agar and BHI (brain heart infusion) were used to culture the 
strains. For the former medium, 48 g of Brazier’s powder (Oxoid) was added to 1 l 
deionised water, mixed and autoclaved at 121˚C for 15 minutes. The autoclaved 
medium was allowed to cool to 47˚C and then 10 ml cycloserine/cefoxitin with 40 
ml egg yolk emulsion was added as a supplement (X093 and X073, LAB M). The 
supplemented medium was mixed well and poured into petri dishes. Plates were 
put on the bench to solidify and then kept at 4˚C until required. BHI (Oxoid) liquid 
medium was prepared by weighing 12 g of powder into 1 l deionised water which 
was then autoclaved at 121˚C for 15 minutes.  
      C. difficile was initially plated on Brazier’s CCEY media and incubated for 48 
hours under anaerobic conditions at 37°C. After 48 hours, the plates were checked 
for growth, the appearance of colonies with a ruffled morphology and the smell 
that is characteristic of C. difficile. Aliquots of BHI liquid medium were pre-
incubated under anaerobic conditions overnight with caps loosened to allow 
removal of oxygen. Cultures were inoculated with single colonies from agar plates 
and grown under anaerobic conditions at 37°C.  
 
Cwp3’ 
Chapter 2 Material and methods 71 
2.2 Selection of target proteins 
       Surface proteins of bacterial pathogens operate at the interface with the host 
and make important contributions such as chemotaxis towards host cells, 
attachment and pathological change to host tissues. Whilst detailed structures are 
limited in their availability, analysis of hydrophobicity plots also can be a useful 
tool in such features as transmembrane domains or regions of the protein that are 
likely to be exposed. Kyte-Doolittle plots are commonly used to analyse the 
hydrophobicity of a protein while the Hopp-Woods scale can predict hydrophilic 
domains. Use of these algorithms and a survey of literature was used to select the 
following for cloning and expression as target proteins: SlpA, Cwp84, Cwp66, Acd, 
GroEL, FliD, FliC, CspA, FbpA and a putative sortase, Sortase B. 
 
2.3 Genomic DNA extraction 
       Genomic DNA from strain 630 was used as template to amplify coding 
sequences for the selected targets. DNA was extracted using a genomic DNA 
purification kit from Promega. To do this, a 10 ml BHI liquid culture of the bacteria 
was set up by inoculating a single colony of strain and incubating in an anaerobic 
cabinet at 37˚C overnight. The overnight culture was dispensed in 1 ml aliquots to 
1.5 ml tubes and centrifuged at 12000 x g for 2 minutes in a bench top centrifuge 
(Thermo Scientific PICO17). After removing the supernatant, the pellet from each 
tube  was resuspended in 480 µl of 50 mM EDTA and 120 µl of 10 mg/ml lysozyme 
(Sigma) was added to to the resuspended cells.  
      This was mixed gently and incubated at 37˚C for 30-60 minutes before spinning 
again for 2 minutes at 12000 x g to remove the supernatant. The remaining 
extraction process was carried out according to the technical manual: in turn, this 
lysed the cells, degraded RNA by addition of RNase, precipitated the cellular 
protein, and finally recovered genomic DNA by precipitation in 70% (v/v). The 
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amount of DNA from each tube was measured using a Nanodrop instrument and 
samples with high yields were mixed and aliquoted in 50 µl samples for storage at -
20˚C. 
 
 
2.4 Primer design and PCR 
2.4.1 Primer design 
      The genome sequence of Clostridium difficile 630 (NC-009089.1) was used to 
design all primers for amplification of the selected coding sequences. For each 
target, sense (forward) and antisense (reverse) primers were designed with 
additional sequence at the 5' terminus to enable ligation independent cloning (LIC) 
into the pET32 EK/LIC vector (Novagen). According to the LIC system,  the 5’ 
terminus of the coding sequence requires a 5’ overhanging sequence of  5' GAC 
GAC GAC AAG ATN 3' followed by the insert-specific sequence.  N can be any base 
but this then forms a codon that determines the reading frame in which the 
expressed sequence is translated. The 3’ terminus of the coding sequence requires 
a 5’ overhanging sequence 5' GAG GAG AAG CCC GGT 3' followed by the intended 
insert sequence. Table 2.1 shows the sense and antisense primers that were 
designed for each target and used in PCR to amplify the chosen coding sequence.
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Table 2. 1. List of sense and antisense primers  
GENE SENSE PRIMER ANTISENSE PRIMER 
groEL 5΄ GAC GAC GAC AAG  ATT GGA GTA 
ACT ATA GCA AAA GAG 3΄ 
5΄ GA GGA GAA GCC CGG TCC GCC ACC CAT 
TCC TGG 3΄  
 
cwp84 5΄ GAC GAC GAC AAG ATA GAT GGA 
GTA GAA ACT GCA GAG 3΄  
5΄ GA GGA GAA GCC CGG TTC ATT TCC ATT 
TCC ACC AAC 3΄  
 
cspA 5΄ GAC GAC GAC AAG ATG AAA AAC 
GGA ATA GTA AAA TGG 3΄ 
5΄ GA GGA GAA GCC CGG TAC GTT TTC AGC 
TTG AGG TCC 3΄  
 
5́ cwp66 5΄ GAC GAC GAC AAG ATA ACG GGT 
TCT GGA AGA TGG 3΄ 
5΄ GA GGA GAA GCC CGG TTT AGC TGC TAA 
TAC ACC CAC 3΄  
 
3́ cwp66 5΄ GAC GAC GAC AAG ATA GTT ACT 
CAA ATT GGT GGC 3΄ 
5΄ GA GGA GAA GCC CGG TGT AGC GTT AGT 
TCT TCC 3΄  
 
fbpA 5΄ GAC GAC GAC AAG ATA CAT CAA 
CCT GAA GAT GAT GAG 3΄  
5΄ GA GGA GAA GCC CGG TTT  
AAC CTT AAG CTT GGC TAC 3΄ 
fliC 5΄ GAC GAC GAC AAG ATG GAG AAG 
TTA TCT TCT GGG 3΄  
5΄ GA GGA GAA GCC CGG TAA AAC TCC TTG 
TGG TTG TTG 3΄  
 
fliD 5΄ GAC GAC GAC AAG ATT CCA GTA 
AGA GTT ACA GGC 3΄  
5΄ GA GGA GAA GCC CGG TTG TGA GAA ATA 
GTT CAT TTG 3΄  
 
Acd 5΄ GAC GAC GAC AAG ATT GAA CCA 
ACT GCC GAA AGT AGC 3΄ 
5΄ GA GGA GAA GCC CGG TTC CAT AAT TCC 
AGA AAT TCC 3΄  
 
sortaseB 5΄ GAC GAC GAC AAG ATC AAT CAT 
GAT ACT AAA ATA TCC 3΄ 
5΄ GA GGA GAA GCC CGG TCT 
ACCATGAATCAC C 3΄  
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2.4.2   PCR reactions 
      For amplification of the candidate sequences, DNA amplification was 
performed in a reaction volume of 50μl consisting of 2μl genomic DNA (from 114 
ng/µl) from C. difficile strain 630 as template, 2.5μl of each primer (0.5μM in final 
concentration), 1μl deoxyribonucleoside triphosphates (200µM of each, final 
concentration ), 0.5 μl of Phusion polymerase (New England Biolabs) and 10µl of 5x 
Phusion buffer. Reactions were carried out for 35 cycles consisting of denaturation 
at 94°C (30 sec), annealing at 55°C (30 sec) and extension at 72°C (1 min) in a 
ThermoHybrid PX2 thermocycler. Table 2.2 shows a summary of the PCR reactions 
to show volumes and final concentrations. Amplified products were analyzed for 
size and yield via gel electrophoresis and those with the predicted size (see Table 
2.3) were purified by QIA quick PCR purification kit (QIAGEN) for processing and 
cloning. 
 
Table 2. 2. PCR reactions  
COMPONENT 50µL REACTION 20µL REACTION FINAL 
CONCENTRATION 
H2O add to 50 µl add to 20 µl  
5x Phusion HF 
or GC buffer 
10 µl 4 µl 1x 
10 mM dNTPs 1 µl 0.4 µl 200 µM each 
Sense primer 2.5 µl 1 µl 0.5 µM 
Antisense primer 2.5 µl 1 µl 0.5 µM 
Template DNA 2 µl 0.8 µl  
Phusion DNA polymerase 0.5 µl 0.2 µl 0.02 U/ µl 
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2.4.3  Agarose gel electrophoresis 
      One percent agarose (Invitrogen) was prepared by adding 1 g of agarose 
powder into 100 ml of TEA (Tris-Acetate-EDTA; Amresco) buffer. The mixture was 
heated in a microwave until dissolved and cooled to 50˚C. SYBR Safe (3µl; 
Invitrogen) was added to the cooled solution, it was mixed and poured into a gel 
casting tray prepared in advance with an appropriate comb for loading samples. 
After 15 minutes, the comb was removed and the tray was placed in the 
electrophoresis tank. TAE buffer was added. After mixing loading buffer (10X 
BlueJuice Gel Loading Buffer, Invitrogen) with the samples and a DNA ladder (100 
kb or 1kb DNA ladder, Promega), samples were loaded into the gel. 
Electrophoresis was run at 100 V for 1 hour. DNA bands were visualised and 
recorded using a UV Pro Gold gel documentation system.  
 
 
 
 
2.5 Cloning and expression of target proteins 
2.5.1 Overview: 
      The pET-32 EK/LIC vector (Novagen) was used as the cloning and expression 
system. In ligation independent cloning system (LIC), inserts can be cloned directly 
into the plasmid without digestion or ligation. The plasmid itself was supplied with 
two overhanging termini which were complementary to overhanging sequences 
that were created on the PCR product. These sequences were included in primers 
used for amplication. To generate overhangs on the PCR products, they were firstly 
treated with T4 DNA polymerase. The 3' to 5' exonuclase activity of the enzyme 
created overhangs but in the presence dATP, the reaction ceased at a point 
determined by the primer sequence. The PCR products were then ready to anneal 
with complementary sequences carried on the vector (Figure 2.1).  
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       The annealed DNA duplex was transformed into NovaBlue competent cells. 
These cells are not suitable for protein expression but can be used for DNA analysis 
to confirm the accuracy of the construct. Once accomplished (eg by colony PCR 
and sequencing), the plasmid can be transformed into E. coli strains such as  BL21 
(DE3) and BL21 (DE3)pLysS that are suited to expression of the recombinant 
protein. In pET-32 EK/LIC, recombinant proteins can be expressed with  Trx and S 
tags for immunochemical detection, His tags for purification, and the inclusion of 
thrombin and entrokinase sites enable removal of these fused sequences if that is 
deemed important (Figure 2.2).    
 
 
 
  
Figure 2. 1. LIC strategy showing the structure of the vector, generation and processing of a PCR product, 
and annealing of vector and insert. Adapted from data from Novagen. 
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Figure 2. 2.  Features of the pET-32 EK/LIC vector. The site for insertion of PCR products is located between 
SmaI and KpnI sites and offers the potential to fuse detection and purification tags to the expressed protein 
(lower panel). Adapted from data from Novagen. 
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2.5.2 Cloning protocol 
2.5.2.1 T4 DNA polymerase treatment of purified PCR products 
      Purified PCR products were treated by T4 DNA polymerase of a quality certified 
for LIC in order to create the overhangs required for cloning. To do this, DNA 
concentrations were measured (Table 2.3) and 0.2 pmol of purified PCR product 
was added with other reactants to create a reaction of 20µl (Table 2.4). Reactions 
were started by adding T4 DNA polymerase and slowly pipetting the reaction 
mixtures for 30 minutes at 22˚C. Reactions were then terminated by incubation at 
75˚C for 20 minutes. Prepared inserts were stored at -20˚C in preparation for 
annealing to the pET-32 EK/LIC vector. As controls,  a lacZ  PCR product of 1815 bp 
was provided in the kit (100ng / µl) as a positive control,  and negative control 
reactions were assembled that lacked a PCR product (nuclease free water). 
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Table 2. 3. Purified PCR products and their concentrations 
SAMPLE BASE PAIR 
PURIFUED PCR 
PRODUCT(NG/µL) 
0.2 PMOL PURIFIED PCR 
PRODUCT IN 
NANOGRAM 
VOLUME FROM 
PURIFIED PCR 
PRODUCT(µG) 
cwp84 2265 62.4 294.45 4.8 
cspA 192 85.05 24.96 0.3 
5'cwp66 742 100.83 96.46 0.96 
fbpA 1689 82.6 219.57 2.66 
groEL 1461 74.46 194.61 2.62 
fliD 1497 61.14 194.61 3.14 
acd 1712 61.98 222.56 3.6 
fliC 780 88.6 101 1.5 
3'cwp66 898 69.38 116.74 1.65 
sortaseB 584 70.73 75.92 1.07 
cwp66 1700 43.84 221 5.04 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. 4. Components of T4 DNA polymerase reaction 
VOLUME (µL) COMPONENT  
x 0.2 pmol purified PCR product in TE buffer (10 mM Tris HCl, 
0.1 mM EDTA, pH 8.0)  
2 10X T4 DNA Polymerase buffer 
2 25 mM dATP 
1 100 mM DTT 
y  Nuclease-free water to 20 μl final volume 
0.4 2.5 U/μl T4 DNA Polymerase LIC-certified 
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2.5.2.2 Annealing of treatment insert and pET-32 EK/LIC 
      The vector pET-32 EK/LIC was supplied by the manufacturer at 50 ng/ µl ready 
for the annealing reaction. Fifty ng of vector DNA was added to 2 µl of the T4 DNA 
polymerase reaction and incubated at 22˚ C for 5 minutes. Then, 1 µl of 25 mM 
EDTA was added to the mixture for a further 20 minutes at 22˚ C.  Samples were 
then used directly for transformation without further treatment.  
 
 
2.5.3 Transformation 
       NovaBlue competent cells (Novagen) were used for transformation. A pre-
prepared 50 µl aliquot of NovaBlue competent cells was placed on ice and left to 
thaw for 5 minutes. Thawed tubes were flicked gently to resuspend the cells and 
then 1 µl of annealed DNA duplex was added to each tube and stirred lightly. To 
check transformation efficiency an extra transformation was prepared containing 
closed circular plasmid DNA. Tubes were incubated on ice for another 5 minutes 
and heated for 30 seconds in a 40˚C water bath without shaking. They were all put 
back on ice for an extra 2 minutes. Before plating on selective medium, 250 µl of 
SOC medium was added to each tube and shaken (250 rpm) at 37˚C for 60 
minutes. Aliquots of 25 µl were taken from each sample and plated to selective 
agar (2xYT ampicillin. 2xYT: tryptone 16 g/l, yeast extract 10 g/l, NaCl  5g/l, agar 15 
g/l, mixed and autoclaved. Once cooled, ampicilin was added to 50 µg/ml final 
concentration) for  growth overnight at 37˚C. Next day, all plates were checked for 
colonies. 
2.5.4 Colony PCR and DNA sequencing  
2.5.4.1 Colony PCR 
     Ten colonies from each transformation plate were identified for analysis. All 10 
colonies were picked and inoculated to fresh 2x YT ampicillin for growth overnight 
at 37˚C and then stored at 4˚C for future use. Frozen stocks were also prepared for 
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each transformant by pelleting cells from 1 ml of overnight culture (liquid 2xYT 
ampicillin) and resuspending in 100µl of fresh liquid medium containing  glycerol at 
15% (v/v) final concentration. Colonies chosen from analysis were also picked and 
added to separate 50µl aliquots of sterile water for colony PCR. The tubes were 
placed in boiling water for 5 minutes to disrupt the cells and inactivate DNases. 
Then all tubes were centrifuged at 12000 x g for 1 min and 2 µl samples from the 
supernatants were used in PCR. PCR reactions were conducted as described earlier 
with primer sets required for each target sequence except that Taq DNA 
polymerase (GoTaq Flexi DNA polymerase, Promega) was used. Table 2.5 shows 
components of the colony PCR reactions. PCR products were analysed on 1% 
agarose gels as explained earlier to assess yield and the size of the products.  
 
 
 
 
 
Table 2. 5. Components of PCR reactions for colony PCR 
COMPONENT 25µL REACTION 
FINAL 
CONCENTRATION 
H2O add to 25 µl  
5X GoTaq Flexi Buffer 5 µl 1x 
MgCl2 25mM 2 µl 1mM 
dNTPs 10 mM each 0.5 µl 0.2mM each 
Sense primer 1.25 µl 0.5 µM 
Antisense primer 1.25 µl 0.5 µM 
Template 2 µl  
GoTaq DNA polymerase 0.25 µl 0.05 U/ µl 
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2.5.4.2 DNA sequencing 
     Based on the results of colony PCR, transformants from each cloning reaction 
were chosen and added to 2 ml liquid 2x YT-ampicillin medium and incubated 
overnight in a shaker (250 rpm) at 37˚C. Plasmid DNA was isolated from the cells in 
each culture using a QIA prep spin miniprep kit (QIAGEN). Plasmid DNA was then 
sent for sequencing with T7 terminator primer (Figure 2.2).  
 
  
 
2.6 Preparation of S-layer extracts using low pH 
glycine buffer 
      The method was provided by Professor N. Fairweather (Imperial College, 
London) and based on experience in his laboratory, it is estimated that a typical 50 
ml culture of C. difficile will provide 0.5 – 1 mg of total surface protein including 
the high and low molecular weight derivatives of SlpA, the major protein of the S-
layer.  C. difficile overnight cultures were prepared in BHI broth under anaerobic 
conditions and cultured at 37˚C for no longer than 18 hours. The C. difficile cells 
were pelleted by centrifugation at 5000 x g for 10 minutes at room temperature. 
Supernatant was removed and discarded into 2% Virkon to kill bacterial cells. The 
pellet was gently resuspended in 1/10 the initial culture volume using phosphate 
buffered saline (PBS) and centrifuged again. Washing in PBS was carried out three 
times to remove proteins and other material loosely associated with the bacterial 
surface. After the final wash, the bacterial pellet was drained onto paper and 
resuspended in 1/100 volume of low pH glycine (0.2 M glycine-HCl, pH 2.2) and 
incubated with gentle agitation at room temperature for 20 min.  
The bacterial suspension was then centrifuged at 12000 x g in a bench top 
centrifuge at 4°C for 10 min. The supernatant containing proteins extracted from 
the surface was removed to a clean tube and its pH was brought to neutrality by 
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adding 2M Tris-base step-wise until the pH was 7.5 as estimated with a broad 
range pH indicator strip. The protein concentration of the extract was assayed 
using a bicinchoninic acid kit (Sigma). The composition of the extract was analysed 
by SDS-PAGE. 
2.7 Flagella preparation 
      C. difficile was plated on four plates of Brazier’s agar and kept for 48 hours at 
37˚C in an anaerobic cabinet. Bacteria were collected by scraping from the plates 
into 1 ml PBS. The suspension was agitated vigorously using a vortex mixer. The 
bacterial suspension was centrifuged at 5000 x g for 5 minutes to pellet whole cells 
and the supernatant containing extracted flagella was stored at -20˚C pending 
future analysis. 
2.8 Protein expression and purification of target proteins 
     In overview, to express recombinant proteins from the pET-32 EK/LIC vector, 
plasmid DNA was purified from NovaBlue cells and transformed into competent E. 
coli BL21 expression strains, specifically BL21 (DE3) or BL21 (DE3)pLysS. After 
selection on ampicillin medium and confirmation, the strains were used to express 
the recombinant proteins. Bacteria were grown in liquid culture, induced by 
addition of IPTG and then harvested by centrifugation. The cells were ruptured by 
using a sonicator to prepare a lysate for each sample. Cloning into the expression 
vector provided each recombinant protein with a histidine tag which was used for 
purification by Ni-affinity chromatography. Purified proteins were analysed by SDS-
PAGE and Western blotting to check yields and molecular weight. To confirm the 
identity of the recovered protein(s) a single band was cut from SDS-PAGE gels and 
sent for analysis by mass spectrometry. 
2.8.1 Transformation of plasmids into expression strains 
      Once the cloning of each target sequence into the expression vector had been 
confirmed, a single colony of NovaBlue cells carrying the plasmid was picked to 
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2ml of 2xYT with ampicillin and the culture was shaken at 250 rpm overnight at 
37˚C. The overnight cultures were centrifuged and the pellet was used to prepare 
plasmid DNA using QIA prep spin miniprep kits (QIAGEN). To transfer the purified 
plasmid into the expression strains, 20 µl aliquots of competent E. coli BL21(DE3) 
or BL21(DE3)pLysS cells (Novagen) were thawed on ice for 10 minutes. One µl of 
each plasmid was added to a sample of the thawed, competent cells and the 
mixture was placed on ice for 5 minutes after mixing very carefully. The cells were 
shocked by heating to 42˚C for 30 seconds in water bath. They were returned to 
ice for 2 minutes.  
      To each transformation, 80 µl of SOC medium, pre-warmed to room 
temperature, was added and then the mixtures were shaken at 250 rpm at 37˚C 
for 1 hour. Aliquots of 25 µl from each tube were plated on 2xYT-ampicillin and 
incubated at 37˚C overnight. The next day, plates were checked for the 
appearance of colonies. A single colony from each plate was added into 200 µl of 
2xYT-ampicillin and the culture was shaken at 250 rpm overnight at 37˚C. For 
convenience and ease of storage, these cultures were prepared in 96 plates rather 
than individual tubes and from each transformation, 10 separate colonies were 
picked. After overnight culture, the 96 well plate was centrifuged at 1800 x g and 
the bacterial pellet in each well was resuspended in 2xYT-ampicillin containing 
glycerol at a final concentration of 15% (v/v). Plates were stored at -70˚C to create 
a strain collection.     
 
 
2.8.2 Protein expression 
    Ten µl of each bacterial stock was added to 200 ml of 2xYT-ampicillin (50µg/ml) 
and shaken at 180 rpm at 37˚C until the culture reached and absorbance of 0.8 
when measured at 600 nm. The cultures were induced by addition of IPTG (Sigma) 
to a final concentration of 1mM and shaken overnight at the lower temperature of 
30 ˚C. Cells were collected from each overnight culture by spinning at 3000 x g for 
10 minutes. The pellet was resuspended in 10 ml PBS and sonication was applied 
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to rupture the cells. To do this, the tube of suspended cells was placed on a plastic 
beaker containing ice making sure that the tube was completely immersed in ice to 
ensure thorough cooling. The sonicator probe was dipped into the cell suspension 
and activated for 10 seconds followed by a 30 seconds period of cooling. This was 
repeated 10 times. The probe was cleaned with 70% ethanol before moving to the 
next sample.  After sonication, ruptured cells were centrifuged at 3000 x g for 10 
minutes to remove the bacterial debris. The supernatants were frozen at -20˚C 
pending further processing.  
2.8.3 Protein purification 
     Ni affinity chromatography was used to purify the recombinant protein from 
each lysate. Pre-packed 5ml columns (Hi-Trap, GE Healthcare) were used. Before 
running a column, different solutions were prepared: binding buffer (20 mM 
phosphate, 0.5M NaCl, pH 7.4); binding buffer at 10x for adjustment of the pH and 
salt concentrations of lyates before purification; elution buffers (binding buffer 
containing imidazole at concentrations ranging from 40 mM to 0.5 M) to wash 
proteins from the columns and to elute bound proteins; nickel solution  (0.1M 
NiSO4); 50 mM EDTA to prepare columns for regeneration; 20% (v/v) ethanol for 
preserving the columns during long term storage at 4-8 ˚C. 
       To prepare the column, it was washed with 50 ml deionised water using a 
peristaltic pump (1-5 ml/min flow rate), and charged with 2 ml of NiSO4 solution. 
The column was washed again with distilled water to remove any unbound Ni ions 
and equilibrated with 50 ml binding buffer.  Bacterial lysate was mixed with 1/10 
volume of 10x binding buffer and checked that the pH was adjusted to 7.4. The 
lysate was passed through the column, washed with 50 ml binding buffer, and 
then 25 ml of 40mM imidazole in binding buffer was pumped through to remove 
unbound or weakly-associated protein. Protein attached to the column was eluted 
with stepped imidazole beginning with 100 mM and finishing at 500 mM. Fractions 
were collected and analysed by SDS-PAGE and Western blotting. Single candidate 
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bands corresponding to the recombinant protein under analysis were cut from 
each gel and sent for analysis by mass spectrometry.  
      The fractions that contained recombinant protein of the predicted molecular 
weight were pooled and dialysed against 20 mM phosphate buffer, pH 7.4. After 
each round of purification, the column was washed with 50 ml distilled water and 
then treated with 5 ml 50 mM EDTA to remove all Ni ions. Newly regenerated 
columns were recharged with Ni, washed with distilled water and equilibrated 
with binding buffer, as described earlier.  
2.9  Protein electrophoresis 
       Electrophoresis was carried out by two methods: SDS-PAGE and native PAGE. 
SDS-PAGE was carried out according to the Laemmli method. In contrast, native 
PAGE was run to analyse proteins in their native conformation using a 
discontinuous buffer system. In most cases, gels were hand cast and run in the 
mini-PROTEAN 3 system (BioRad).  In some experiments, pre-cast gels of different 
acrylamide concentrations (Invitrogen) were used.  
 
2.9.1 SDS-PAGE analysis 
      Hand cast gels were prepared as separating (typically 10% acrylamide; Table 
2.6) and stacking gels (5% acrylamide). Twenty µl of sample buffer containing ß-
mercapthoethanol was added to 20 µl of the sample and heated to 95˚C for 5 
minutes. Gels were loaded with 10-15 µl of prepared sample and a sample of 
protein markers. After loading, gels were run at 120 volt until the gel front 
approached the bottom edge of the gel. Electrophoresis was terminated and the 
gel was stained with Coomassie brilliant blue solution for 1 hour. The stained gel 
was transferred into destain solution and shaken gently overnight to remove 
excess stain and clear the background. All gels were scanned and the data was 
stored electronically.      
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2.9.1.1 Stock solutions and buffers for SDS-PAGE 
      The following solutions were prepared: 30% acrylamide mixture containing 
87.6 g of acrylamide and 2.4 g of bis-acrylamide dissolved and made up to 300 ml 
with deionised water (alternatively, a pre-prepared commercial acrylamide / bis 
solution, BioRad); 10% (w/v) SDS; 1.5M Tris-HCl, pH 8.8; ; 0.5M Tris-HCl, pH 6.8; 
sample buffer (3.55 ml deionised water, 1.25 ml 0.5M Tris-HCl pH 6.8, 2.5 ml 
glycerol, 2 ml 10% SDS and 0.2 ml of 0.5% (w/v) bromophenol blue to 9.5 ml final 
volume. Fifty µl of ß-mercaptoethanol was added to 950µl of sample buffer before 
use); 10x electrode (running) buffer pH 8.3 containing 30.3 g Tris base, 144 g 
glycine and 10 g SDS, brought to 1000 ml with deionised water;  10% (w/v) 
ammonium persulphate; staining solution (0.25% (w/v) Coomassie brilliant blue in 
a solution of 50% (v/v) methanol, 10% (v/v) acetic acid in water) and destain (15% 
(v/v) methanol, 10% (v/v) acetic acid in water). Table 2.6 shows the mixtures 
prepared for separating and stacking gels. 
 
 
 
 
 Table 2. 6. Solutions of SDS-PAGE separating and stacking gels 
SOLUTIONS 10% SEPARATING GEL 12% SEPARATING GEL 5% STACKING GEL 
H2O 2ml 1.7ml 1.4ml 
30% acryl amide solution 1.7ml 2 ml 0.33ml 
1.5M Tris pH 8.8 1.3ml 1.3ml ---- 
1M Tris pH 6.8 ---- ---- 0.25ml 
10% SDS 0.05 0.05ml 0.02ml 
10% APS 0.05ml 0.05ml 0.02ml 
TEMED 0.002ml 0.002ml 0.002ml 
Total volume 5 ml 5ml 2ml 
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2.9.2 Native PAGE analysis 
     Solutions for native PAGE were practically the same as prepared for SDS-PAGE 
except SDS was omitted. Resolving gels contained 8% or 10% acrylamide, topped 
with a 4% stacking gel (Table 2.7). Twenty µl of sample was mixed with a native 
sample buffer (20 µl) and heated to  95˚C for 5 minutes. Prepared gels were loaded 
with 10-15 µl of samples and a size markers and run at 100 volt until the blue dye 
front approached bottom of the gel. Staining, destaining and documentation were 
carried out as described earlier.  
 
 
Table 2. 7. Solutions of native PAGE Separating and stacking gels 
SOLUTIONS 8% SEPARATING GEL 10% SEPARATING GEL 4% STACKING GEL 
H2O 4.8ml 4.2ml 3.1ml 
30% acryl amide solution 2.7ml 3.3ml 0.65ml 
1.5M Tris pH 8.8 2.5ml 2.5ml ---- 
1M Tris pH 6.8 ---- ---- 1.25ml 
10% APS 0.05ml 0.05ml 0.025ml 
TEMED 0.005ml 0.005ml 0.005ml 
Total volume 10.055ml 10.055ml 5.03ml 
 
  
 
 
2.10  Western blot analysis  
      For immunoblotting, SDS-PAGE gels were run and proteins were transfered to a 
nitrocellulose membrane. To locate each target, specific primary antibody (eg 
against an attached epitope tag) was used to probe the blot before addition of a 
second antibody HRP conjugate and addition of a chromogenic substrate. Each 
membrane was scanned for documentation. 
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2.10.1 Western blot 
      In preparation for transfer of proteins from the SDS-PAGE gel to nitrocellulose, 
four pieces of Whatman paper, nitrocellulose membrane, 2 permeable pads and a 
plastic cassette were assembled. All were soaked in transfer buffer (7.2 g Tris base, 
33.4 g glycine and 600 ml methanol in 3 l total volume) for 5 minutes.  The transfer 
sandwich was constructed by putting a pad and two pieces of Whatman paper into 
place, applying the SDS-PAGE gel, and then carefully smoothing nitrocellulose 
membrane into place over the gel, avoiding bubbles. This was topped with two 
pieces of Whatman paper and another porous pad. So far as practical, all 
components were kept wet with transfer buffer during the assembly process. The 
transfer sandwich was packed inside a blotting cassette and put inside the 
electroblotting tank (BioRad).  
The tank was placed over a magnetic stirrer in a cold room and filled with 
cold transfer buffer. Transfer was conducted at 90 volt for one hour to move 
proteins from the gel to the membrane. After carefully unpacking, the membrane 
was washed with PBS and was stained with Ponceau red (Sigma) to check that 
transfer had taken place. The membrane was blocked overnight by incubating with 
2% (w/v) skimmed milk in PBS (MPBS) at 4 ˚C with gentle shaking. The blocked 
membrane was washed 3 times with PBS and probed for one hour at room 
temperature with the first antibody, diluted in 2% MPBS. Anti S-tag antibody 
(detection of recombinant proteins) and anti-c-myc antibody (detection of 
recombinant scFv antibodies) were diluted 1/5000.  
      The membrane was washed 3 times with PBS-0.1% (v/v) Tween 20 and the 
second antibody, an HRP conjugated antibody, was added in 2% MPBS for another 
hour at room temperature. Anti mouse-HRP was used if the first antibody was anti 
S-tag; anti rabbit-HRP was used if the first antibody was anti-c-myc. In each case, 
the antibodies were diluted 1/5000. After final 3-fold washes with PBS-0.1% Tween 
20, TMB substrate solution (Promega) was added and colour was allowed to 
develop. The reaction was stopped by washing with water.   
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2.11 Tomlinson library 
     The human single fold scFv libraries Tomlinson I and J were constructed at the 
MRC Centre for Protein Engineering and obtained for the study under a Material 
Transfer Agreement. These libraries were used for selecting scFv antibodies able to 
bind to the recombinant clostridial target proteins via phage display. Each library (I 
or J) contained over 100 million different scFv fragments integrated into a 
phagemid vector containing an ampicillin resistance gene. VH and VL domains of 
each scFv were connect together by a flexible glycine-serine linker sequence and 
the antibody coding sequence was followed by a His-tag for purification of scFv 
protein, a c-myc tag for immunochemical detection and an amber codon at the 
junction of the scFv coding sequence and the gene for protein III  of the M13 
phage coat.  
     Phage from each library with the capacity to bind target proteins were isolated 
by incubation in plastic tubes previously coated with the protein target of interest 
(panning). Unbound phage were then washed out; phage attached to the selection 
surface were eluted and amplified by infecting into E. coli TG1 cells. Three rounds 
of selection were used to enrich for phage binders. Screening was carried out to 
confirm the specificity of binding through ELISA. Soluble scFv were expressed from 
clones of interest and purified using the His-tag.  
       The Tomlinson libraries I and J libraries are constructed on single human 
frameworks for the VH heavy chain (V3-23/DP-47 and JH4b) and the Vκ light chain 
(O12/O2/DPK9 and Jκ1). The libraries are diversified at 18 defined positions, 
specifically  heavy chain residues H50, H52, H52a, H53, H 55, H56, H58, H95, H96, 
H97, H98, and light chain residues L5O, L53, L91, L92, L93, L94 and L96. In library I, 
95% of clones carry full-length scFv inserts; this is rather lower for library J (88%). 
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2.11.1 KM13 helper phage  
2.11.1.1 Production of helper phage 
       Two hundred µl aliquots of E. coli TG1 grown to an OD of 0.4 were infected 
with 10 µl of 100-fold serial dilutions taken from a stock of KM13 helper phage 
(estimated at 107 pfu/ml). The mix of bacteria and virus were incubated in a 37°C 
water bath for 30 minutes without shaking. Three ml of molten H-top agar held at 
42°C was added to each dilution and the mixture was poured onto pre-warmed 
TYE plates without antibiotic (TYE: 15 g agar, 8 g NaCl, 10 g tryptone, 5 g yeast 
extract in 1 l). After setting, the plates were incubated at 37°C overnight. A small 
plaque was picked from a plate which showed separated plaques and added into 5 
ml fresh E. coli TG1 grown to 0.4.  
       The infected mix was grown for 2 hours at 37°C with shaking. Five ml of the 
culture was added into 500 ml 2xTY (2xTY: 16 g tryptone, 10 g yeast extract, 5 g 
NaCl in 1 l) in a 2 litre flask and grown with shaking at 37°C for 1 hour. Then 
kanamycin was added to a final concentration of 50 µg/ml to select for infected 
cells. The culture was incubated at a 30°C with shaking overnight. The overnight 
culture was centrifuged at 10,800 x g for 15 minutes. One hundred ml PEG/NaCl 
(20 % (w/v) polyethylene glycol 6000, 2.5 M NaCl) was added to 400 ml culture 
supernatent and left for 1 hour on ice to precipitate the virus.  
      The prepared suspension was centrifuged at 10,800 x g for 30 minutes. The 
pellet was resuspended in 8 ml PBS and 2 ml PEG/NaCl was added and mixed to 
reprecipitate virus. After holding for 20 minutes on ice, it was centrifuged at 3300 x 
g for 30 min. The pellet was spun for the second time to remove any remaining 
residues of PEG/NaCl.  The viral pellet was resuspended in 5 ml PBS and 
centrifuged at 11,600 x g for 10 minutes in a micro centrifuge to remove any 
remaining bacterial debris. The prepared helper phage were stored in 4°C for short 
periods or in PBS with 15% (v/v) glycerol for -70˚C long-term storage. 
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2.11.1.2 Titration of produced helper phage 
     To titrate the helper phage, 5 µl of trypsin stock (10 mg/ml trypsin in 50 mM 
Tris-HCl, 1mM CaCl2, pH 7.4) was added to 45 µl helper phage and incubated at 
37˚C for 30 minutes. One µl of trypsin treated phage was diluted in 1 ml PBS and 
five, 100-fold dilutions were made from this using PBS. Fifty µl samples from the 
dilutions were added to 1 ml of fresh E.coli TG1 culture (OD 0.4). The mixtures 
were added to molten H-top agar and poured onto pre-warmed TYE plate as 
described earlier. Plates were incubated at 37˚C overnight. The same procedure 
was run for phage untreated with trypsin. KM10 encodes a trypsin-sensitive pIII 
protein and hence the expectation was that the titre of trypsin-treated phage 
would be 105-108 lower than for untreated phage.  
2.11.2 Growing the scFv libraries 
      Library stocks of bacteria obtained from the MRC were added into 200 ml of 
pre-warmed 2xTY containing 100µg/ml ampicillin and 1% glucose and shaken at 
37˚ until the OD at 600 nm reached 0.4. Helper phage (2x1011) were added into 50 
ml of culture and the remainder was frozen in aliquots for use as a secondary 
bacterial stock of the library. Infected cultures were incubated static at 37˚C in a 
water bath for 30 minutes to allow efficient infection. Cultures were centrifuged 
for 10 minutes at 3000 x g. 
      The pellet was resuspended in 100 ml of 2xTY containing 100 µg/ml ampicillin, 
50 µg/ml kanamycin and 0.1% glucose and shaken overnight at 30˚C to allow 
phage replication and incorporation of the scFv coding phagemids into virus that 
simultaneously displayed the scFv-pIII fusion protein at their surface. The 
overnight culture was centrifuged at 3300 x g for 30 minutes and then 20 ml of 
PEG/NaCl was added to 80 ml of supernatant to precipitate the virus. It was mixed 
well and incubated on ice for 1 hour, then centrifuged for 30 minutes at 3300 x g. 
The supernatant was removed. As described earlier, remaining PEG/NaCl was 
collected by a second spin and discarded. The final pellet was resuspended in 4 ml 
of PBS and centrifuged at 11,600 x g for 10 minutes to remove remaining bacterial 
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debris. Aliquots of prepared phage were stored at -70˚C in PBS with 15% glycerol. 
These phage were used in selection against recombinant protein targets.   
 
 
 
 
2.11.2.1 Titration of phage from cultured libraries 
      For titration of phage carrying the scFv coding phagemid, 1 µl of phage stock 
was diluted in 100 µl PBS, and a series of six, 100-fold dilutions were prepared. E. 
coli TG1 was grown to an absorbance of 0.4 and 900 µl aliquots were added into 
each dilution of virus. These were incubated at 37˚C for 30 minutes. TYE plates 
containing 100 µg/ml ampicillin and 1% glucose were set out and 10 µl of each 
dilution was sampled and spread for single colonies. Plates were incubated  
overnight at 37˚C. On infection, phagemid from the virus is propagated in the 
bacteria as a plasmid and hence the conversion of bacteria to ampicillin resistance 
defines the number of virus in the stock. It was recommended a phage stock with 
1012-1013 cfu/ml should be used for selection. 
 
 
 
 
 
2.12  Selection of recombinant antibodies by phage 
display 
2.12.1 Selection on immunotubes 
     In selection, scFv with high affinity against the targets (Table 2.3) were isolated 
from the display libraries by panning. Normally three rounds of selection is 
sufficient to isolate binders against each target. 
     An immunotube (Nunc) was coated overnight at 4˚C with 4 ml of a purified 
clostridial target protein at a concentration of 100 µg/ml in PBS. Next day, each 
tube was washed 3 times with PBS and filled to the brim with 2% MPBS as a 
blocking reagent. Tubes were left for 2 hours at room temperature to allow 
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blocking to take place. After 2 hours, the immunotubes were washed 3 times with 
PBS. Library phage (1012 to 1013) were mixed in 4 ml MPBS and added into each 
tube. Tubes were firstly incubated at room temperature for 1 hour and then 
rotated using an under and over turntable rotator for another hour, again at room 
temperature. The supernatant of each tube was thrown away and each tube was 
washed extensively with PBS-0.1% Tween 20: in the first round of selection, 10 
washes were used; for selection rounds two and three, 20 washes were used. The 
excess PBS was removed by inverting each tube on a tissue for a few seconds.  
      The bound phages were eluted by adding 500 µl of trypsin-PBS (50 µl of 10 
mg/ml trypsin stock in 450 µl PBS) and rotating at room temperature for 10 
minutes. From this eluate, 250 µl was added into 1.75 ml of fresh E. coli TG1 (0.4) 
for static incubation at 37˚C for 30 minutes in a water bath. The remaining 250 µl 
of eluate was stored at 4˚C as reserve.  Serial 10-fold dilutions were prepared from 
the infected E. coli and 10 µl aliquots were spotted on TYE plates containing 
100µg/ml ampicilin and 1% glucose and incubated at 37˚C overnight. The number 
of colonies found the following day enabled estimates to be made of the number 
of phage recovered from the selection step.  
     The remaining infected bacteria were contrifuged at 11,600 x g  for 5 minutes in 
a micro centrifuge. The cell pellet was resuspended in 50µl of 2xYT and plated onto 
TYE (100µg/ml ampicillin and 1% glucose) for overnight incubation at 37˚C. From 
the resulting colonies, phage were prepared to take forward further rounds of 
selection. To do this, the bacterial colonies were resuspended from the plate by 
adding 5 ml of 2xYT 15 % glycerol and loosening the cells with a sterile spreader. 
One ml of the resuspended cells were stored at -70˚C as a stock, 50 µl of were 
added into 50 ml of 2xYT (100 µg/ml ampicillin and 1% glucose) and grown at 37˚C 
until the absorbance reached 0.4. Ten ml were recovered and 5x1010 KM10 helper 
phage were added for static incubation at 37˚C in a water bath for 30 minutes. The 
mix was then centrifuged at 3000 x g for 10 minutes and the pellet was 
resuspended in 50 ml 2xYT (100µg/ml ampicillin, 50µg/ml kanamycin and 0.1% 
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glucose) and shaken overnight at 30˚C. The overnight culture was centrifuged at 
3300 x g for 15 minutes and 10 ml of PEG/NaCl was added to 40 ml of the culture 
supernatant. To precipitate the phage, the suspension was mixed and placed on 
ice for 1 hour. After spinning at 3300 x g for 30 minutes, the supernatant was 
discarded and the pellet was spun again to remove any remaining PEG/NaCl. The 
viral pellet was resuspended in 2 ml PBS and again spun at 11,600 g for 10 min to 
remove bacterial debris. One ml of this phage was titred to determine the phage 
yield and then used for the next round of selection.  
 
 
 
2.12.2 Screening phage by ELISA 
     ELISA using antibodies directed against the phage coat was used to monitor the 
specificity of reaction between scFv-pIII fusions and the target proteins. Mixed 
populations of phage recovered after each round of selection were tested in 
“polyclonal phage ELISA”; by picking single bacterial clones and preparing phage, 
virus were also tested in “monoclonal phage ELISA”. 
 
 
2.12.2.1  Polyclonal phage ELISA  
      ELISA plates (96 well; Nunc) were coated with recombinant target proteins 
using the same concentration and buffer as applied in the selection process. For 
coating, 100 µl of protein was added to each well of the ELISA plate which was 
incubated overnight at 4˚C. Plates were then washed three times with PBS and 
blocked by addition of 200µl 2% MPBS per well for 2 hours at room temperature. 
After washing three times with PBS, 10 µl of  PEG precipitated phages recovered 
from each round of selection were added to each well, diluted in 100µl 2% MPBS. 
Plates were incubated for 1 hour at room temperature to allow binding to take 
place. After this, plates were washed 3 times with PBS-0.1% Tween 20 and 100 µl 
of HRP-anti-M13 conjugate (GE Healthcare) was added to each well. The conjugate 
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was diluted 1/5000 in 2% MPBS prior to use. Plates were incubated for 1 hour and 
washed three times with PBS-0.1% Tween 20.  As substrate for the colorometric 
reaction, 100µl of TMB (Promega) was added to each well and left at room 
temperature for 10 minutes to allow development of a blue colour reaction. The 
reaction was stopped by adding 50µl of 1M sulphuric acid and the intensity of the 
resulting yellow colour was measured at 650 nm in a plate reader. 
 
 
 
2.12.2.2  Monoclonal Phage ELISA 
       Individual colonies were picked from titration plates after each round of 
selection and bacteria were added into 100µl 2xYT (100µg/ml ampicillin and 1% 
glucose) in 96 well plates. Plates were shaken at 250 rpm at 37˚C overnight. Two µl 
was sampled from each well and transferred into wells of a fresh plate, each 
containing 200µl of 2xYT (100µg/ml ampicillin and 1% glucose). Remaining 
overnight culture was mixed with glycerol to a final concentration of 15% and 
frozen to archive the strains. 
  Newly inoculated plates were shaken at 250 rpm at 37˚C for 2 hours and 
then 25µl 2xYT was added to each well, each aliquot supplemented with ampicillin 
and glucose as before, but also containing  109 KM10 helper phage. Plates were 
shaken for a further hour at 37˚C then centrifuged at 1800 x g for 10 minutes. Each 
bacterial pellet was resuspended in 200µl 2xYT (100µg/ml ampicillin and 50µg/ml 
kanamycin). After shaking overnight at 250 rpm, the plates were centrifuged at 
1800 x g for 10 minutes and 50µl of the supernatant from each well was sampled 
and used in ELISA reaction as explained above. 
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2.13  Expression and purification of soluble scFv 
antibodies 
      In the display vector, a TAG stop codon was present between the scFv 
sequence and the coding sequence for pIII. In E. coli TG1, this was suppressed and 
a glutamate residue was incorporated instead, thereby creating a scFv-pIII fusion 
for incorporation into phage. Transfection of phagemid DNA into E. coli HB2151, a 
non suppressor strain, resulted in translation stopping at the end of the scFv 
sequence, producing a soluble antibody protein. Soluble scFv can be detected in 
ELISA with anti c-myc reagents, Protein A-HRP or Protein L-HRP. The presence of 
the His-tag also allows convenient purification. 
 
 
 
2.13.1 Expression of solubilised scFv 
      E. coli HB2151 was grown to an OD of 0.4 and then 200 µl aliquots were 
infected with phage eluted from the third round of selection. Infection was 
allowed to take place at 37˚C for 30 minutes without shaking. Four 100-fold serial 
dilutions were prepared and 50µl from each was plated onto TYE (100µg/ml 
ampicillin and 1% glucose). At least 20 individual colonies were picked into 100µl 
2xYT (100µg/ml ampicillin and 1% glucose) in the wells of a 96 well plate that was 
then shaken at 250 rpm overnight at 37˚C.  Two µl was sampled from each well of 
the overnight culture and transferred into the wells of a fresh plate, each well 
containing 200µl 2xYT (100µg/ml ampicillin and 0.1% glucose). Remaining 
overnight culture was mixed with glycerol and frozen as a stock. The new plate was 
shaken at 250 rpm at 37˚C until the OD reached 0.9 (typically, about 3 hours). At 
this point, 25µl of 2xYT (100µg/ml ampicillin and 9mM IPTG) was added to each 
well and shaking was continued overnight at the lower temperature of 30˚C. The 
following day, the plate was spun at 1800 x g for 10 minutes and 50µl of 
supernatant of each well was used ELISA.  
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2.13.2 Detection of soluble antibodies 
     To check for the successful production of soluble antibodies and their 
specificity, the wells of an ELISA plate were coated with 100µl of target protein, 
washed and blocked with 200µl of 3% BSA in PBS, following the protocol described 
earlier. After 2 hours, the plate was washed 3 times with PBS and 50µl of each test 
supernatant thought to contain scFv was added to test wells with 50µl of 3% BSA-
PBS. Plates were incubated for 1 hour at room temperature, washed 3 times with 
PBS-0.1% Tween 20 and 100µl of rabbit anti-c-myc (Sigma) was added to each well. 
The antibody was diluted 1/5000 in 3% BSA-PBS and was allow to interact for 1 
hour at room temperature.  
       After this, plates were washed 3 times with PBS-0.1% Tween 20 and 100µl of 
diluted goat anti-rabbit-HRP (Sigma) was added for another 1 hour at room 
temperature. The conjugate was diluted 1/5000 in 3% BSA-PBS prior to use. After 
washing the plate 3 times with PBS-0.1% Tween 20, 100 µl TMB substrate 
(Promega) was added, quenched and quantified as described earlier.  
 
 
2.13.3 Purification of soluble antibodies 
After selecting HB2151 clones which produced scFv with strong reaction against 
the target, large scale cultures were grown for the purification of solubilised 
recombinant antibodies. A 5ml sample of 2xYT (100µg/ml ampicillin and 1% 
glucose) was inoculated with a single colony of selected HB2151 for each scFv and 
was shaken overnight at 250 rpm at 37˚C. The next day, 3ml of overnight culture 
was added to 300 ml of 2xYT (100µg/ml ampicillin) and shaken at  180 rpm at 37˚C 
and monitored until the absorbance of the culture reached 0.9. scFv expression 
was then induced by adding IPTG to a final concentration of 1mM. Incubation then 
continued with shaking at 180 rpm for 18 hours at a temperature of 30˚C. Bacterial 
cells were collected from the overnight cultures by centrifugation at 3000 x g at 
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4˚C for 10 minutes. ScFv proteins were purified from the supernatant of each 
culture using Ni-afffinity chromatography.  
For purification, the following solutions were prepared: binding buffer (20 mM 
phosphate, 0.5M NaCl, pH 7.4); 10x binding buffer for adjusting the pH and salt 
concentrations prior to chromatography; imidazole at 20, 40, 200 mM in binding 
buffer; 0.1M NiSO4; 50 mM EDTA for regenerating the column after purification. A 
5ml pre-packed His-Trap column (GE Healthcare) was washed with 10 volumes of 
deionised water and charged by addition of 2ml of 0.1M NiSO4 in preparation for 
binding the recombinant antibody via its His-tag. As described earlier, a peristaltic 
pump working at a flow rate of 5 ml/min or less was used to deliver buffer etc to 
the column. After charging with Ni, the column was washed with 50 ml deionised 
water and 50 ml of binding buffer.  
     One hundred ml of supernatant from induced cultures was adjusted for pH by 
adding 10x binding buffer and was then pumped onto the equilibrated column. 
The loaded column was washed with 25 ml of binding buffer followed by 25 ml of 
40 mM imidazole in binding buffer to remove unbound and loosely associated 
proteins from the column. Initial experiments explored elution with  imidazole 
ranging in concentration from 100 to 500 mM and from this, a standard protocol 
was developed in which scFv proteins were eluted with 200 mM of imidazole in 
binding buffer. Fractions were collected during elution and each was analysed by 
SDS-PAGE and also dot blotting. Evidence of a 30 kDa band and positive reactions 
in dot blot identified fractions to be pooled and dialysed against PBS in preparation 
for further use. After purification of each scFv, the column was washed with 50 ml 
distilled water and treated with 5 ml of 50 mM EDTA to remove Ni ions. The 
column was then regenerated by charging with a new aliquot of NiSO4, washing 
with deionised water and equilibrating with binding buffer.  
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2.14  Immunochemical characterisation of recombinant 
antibodies 
      To assess the ability of scFvs to recognise the recombinant clostridial proteins, 
Western blot analysis was conducted with target proteins after separation by 
native and denaturing gel electrophoresis. These experiments were based on 
protocols for SDS-PAGE and native electrophoresis described earlier. The target 
proteins (eg SlpA extracted from C. difficile with glycine buffer) were separated by 
gel electrophoresis and transferred to nitrocellulose membrane. The membrane 
was probed with recombinant antibodies of the required specificity, anti-c-myc 
antibody to bind to the peptide tag on the scFv, anti-rabbit-HRP conjugate and 
TMB substrate as described earlier. For some experiments, gels were loaded with a 
range of proteins for probing (eg SlpA extracted from different C. difficile strains, 
flagellar preparations, and bacterial lysates). Experiments are detailed in the 
Results section of the thesis.  
 
 
 
 
2.15  Immunostaining and electron microscopy of C. 
difficile cells using scFvs 
     Immunofluorescence microscopy was carried out with purified scFv to 
understand whether recombinant antibodies were able to recognise target 
proteins in their native state and in their normal location on the C. difficile cell. C. 
difficile cells were cultured overnight and applied to glass microscope slides by 
cytospin centrifugation. After blocking, the bacteria were probed with scFv against 
the target protein of interest, followed by Protein A-FITC to generate the 
fluorescent signal. Electron microscopy was also used in which target proteins 
were  labelled with scFv and the location of the recombinant antibodies was 
determined with  Protein A-gold, or alternatively anti-c-myc followed by anti-
rabbit-gold conjugates.     
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2.15.1 Indirect immunofluorescence 
      A single colony of C. difficile was picked and inoculated to 10 ml aliquots of BHI 
medium, and grown overnight at 37˚C under anaerobic conditions. The following 
day, the cultures were checked for growth to an approximate absorbance of 0.6. 
The cultures were centrifuged at 3000 x g for one minute and the pellets were 
washed three times with 1ml aliquots of PBS. Each 1 ml aliquot of cells suspension 
was derived from 10 ml overnight culture; each was sampled and 100 µl was used 
in the cytospin (Cytospin 3, Shandon; 500 rpm for 5 minutes) to attach the 
clostridial cells to microscope slides.  
      Alternatively, cell pellets were mixed with 1ml of 4% paraformaldehyde (PFA), 
resuspended and incubated for 15 minutes at room temperature to fix the 
bacteria. Treated cells were collected at 3000 x g for 1 minute and washed three 
times with PBS. To quench the remaining PFA, 1ml of 20 mM NH4Cl2 was added to 
each tube and incubated on the bench for 15 minutes. The cells were pelleted and 
again washed three times with PBS. The pellet from each tube was resuspended in 
1 ml PBS and 100µl aliquots were used for each slide.  
       Bacteria on the slides were treated with a few drops of ethanol to fix the cells 
and they were then washed with PBS and blocked by adding 200µl of  2% BSA-PBS 
as blocking reagent. Blocking solution was incubated on the sample zone for 4 
hours at room temperature inside a humidified environment. The slides were 
washed three times with PBS and 50µl of each purified scFv was applied, diluted to 
1/50 in 0.1% BSA-PBS. Slides were incubated on room temperature for 1 hour.  
      After washing three times with PBS, the slides were probed with 50 µl of a 1/50 
dilution of Protein A-FITC (Sigma) in 0.1% BSA-PBS. The conjugate was allowed to 
act for 1 hour at room temperature. The slides were washed three times with PBS 
and allowed to dry on the bench. Anti-fade agent (Dako; 10-20µl) was applied to 
the bacterial zone and covered with coverslip which was sealed into place with nail 
Chapter 2 Material and methods 103 
polish. The slides were visualised with a fluorescence microscope (Axiovert 100, 
Zeiss).   
2.15.2 Electron microscopy 
       Bacterial cells from C. difficile 630 were prepared as previously explained and 
the washed bacterial suspensions were used to prepare grids for electron 
microscopy. The bacterial pellets were first fixed with 4% paraformaldehyde-0.1% 
glutaraldehyde in PBS for 30 to 60 minutes on ice.  They were then washed by 
gently adding and removing PBS twice for 5 minutes with each wash. The fixed 
bacteria were dehydrated through stepped ethanol solutions: initially, the pellet 
was incubated at room temperature in 50% ethanol for two exposures each of ten 
minutes; following this, three exposures of ten minutes each were in 70%, 90% 
and absolute ethanol, all at -40˚ C.   
      Embedding of specimens began with pre-treatment with different percentages 
of HM2O resin. The dehydrated bacterial pellet was added at -40˚C to: 50%:50% 
(v/v) dried absolute ethanol and HM20 resin for a maximum one hour;   25%:75% 
(v/v) ethanol and resin overnight; overnight incubation in HM20 alone. After this 
treatment, the specimen was transferred to gelatine capsules at -40˚C and 
exposed to UV (340 nm) for 24-48 hours to polymerise the resin. Sections of 60-70 
nm were then cut onto nickel 300 mesh grids coated with formvar. 
     For immunolabelling, 40 µl of a 1/10 dilution of purified scFvs was added to 
clean layer of parafilm inside a chamber and grids were floated on the droplets for 
one hour. After washing three times with PBS, the grids were labelled with a 
conjugate of Protein A-5nm colloidal gold, diluted in 1% BSA in PBS. Alternatively, 
the grids were probed with 1/10 dilution of anti-c-myc in PBS, washed with PBS 
then probed with anti-rabbit-gold conjugate. Each  incubation was for one hour 
and was followed with three washes with PBS.   
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All grids were treated with 2% aqueous uranyl acetate for 10 minutes and 
Reynolds lead citrate for 5 minutes. Grids were then checked in a LEO 912AB 
transmission electron microscope and images captured for further analysis.  
2.16  Functional characterisation of anti-flagellar scFv 
antibodies 
         Many C. difficile strains are motile as a consequence of the multiple flagella 
on their surfaces. The recombinant scFv antibodies against FliD and FliC were 
checked in a motility inhibition test to assess if they were able to block this aspect 
of bacterial behaviour. Three C. difficile strains were used in this study: 630 and 
R20291 which are both motile; M120 which is non-motile and therefore served as 
a negative control. Further controls were the use of scFvs against SlpA, a protein 
known to be present at the bacterial surface, but a target that was unlikely to 
effect motility when scFvs were attached.   
2.16.1 Counting of C.difficile from overnight culture  
       Ten ml of overnight cultures of C. difficile were prepared under anaerobic 
conditions at 37˚C. The cultures were centrifuged at 3000 x g for 10 minutes and 
bacterial pellets were resuspended in 1 ml of PBS. Four, 10-fold serial dilutions 
were prepared and 50µl from each was plated on supplemented Brazier’s agar, 
prepared and supplemented as described earlier.  The plates were incubated at 
37˚C for 48 hours in an anaerobic cabinet and colonies were counted to establish 
the number of colony forming units in the original overnight liquid culture.  
2.16.2 Motility inhibition test 
     To test the effect of recombinant antibodies on the movement of bacteria, 
aliquots were prepared, each containing 105 C. difficile cells. These aliquots – 
roughly 10µl of overnight culture – were incubated with 150µl of supernatant from 
an induced culture of E. coli HB2151 and known to be expressing the anti-FliD or 
anti-FliC of interest. Bacteria were incubated with the crude scFv sample for 1 hour 
at 37˚C in an anaerobic cabinet. Then, 10µl of the mixture was stabbed into 0.2% 
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BHI agar and kept at 37˚C in the anaerobic cabinet and monitored for growth over 
48 to 72 hours. Controls were set up with the test strains of bacteria but no scFv. 
The antibody LA6, a scFv against SlpA, was used in place of the anti-FliD, anti-FliC 
antibodies as a control that was not expected to block bacterial motility. Motility 
was evident as diffusion of bacteria out from the site of inoculation, moving 
through the low concentration agar. 
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3 Results 
3.1 PCR for clostridial targets 
As described earlier, a number of bacterial proteins were chosen as targets for 
the study based upon their known or likely surface location. Coding sequences 
were amplified by PCR from the genome of Clostridium difficile 630 for 
cloning, expression and purification as recombinant proteins. Carrying this 
out, two polymerases were tested, GoTaq from Promega, a conventional Taq 
DNA polymerase and Phusion DNA polymerase, a high fidelity enzyme from 
New England BioLabs. Amplifications were carried out in standard PCR 
reactions using gene-specific primers that carried sequences required for later 
cloning into the pET32 EK/LIC system (Table 3.1). Initially, products were 
analysed from the PCR reaction carried out with Taq DNA polymerase and 
genomic DNA (g-DNA) of C. difficile 630 as the template. Gels showed the 
amplification products were of the expected size for all samples with a good 
intensity and clear backgrounds. 
                 In Figure 3.1, the second lane from the left hand side shows PCR 
products for cwp84. Based on primer annealing sites (Table 3.2) the expected 
size for the band is 2265 bp; a product of approximately this size can be seen 
when compared to the DNA ladder (lane 1). In Table 3.2, it is predicted that 
the expected size for the cspA product is 192bp. The migration of DNA in lane 
3 in Figure 3.1 is in agreement with this prediction. For cwp66, two reactions 
were run as can be seen in lanes 4 and 10. These reactions recovered the 5’ 
region of cwp66 and its 3’ coding sequence respectively. Considering the sizes 
calculated in Table 3.2 for 5’ and 3’ regions of cwp66, lane 4 in Figure 3.1 
shows a single band close to 750 bp as expected and the amplification product 
seen in lane 10 is also of the expected size. The band in lane 5 in (Figure 3.1) is 
also of a size consistent with that predicted for fbpA (1689 bp, Table 3.2) as is 
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the amplification product for groEL (a band just under 1500 bp compared with 
the expected size of 1461 bp).  
               In Figure 3.1, lanes 7 and 8 show the PCR products for the fliD and acd 
reactions. The band in lane 7 for fliD is consistent with the predicted size 
(1497 bp). Table 3.2 predicts a product of 1650 bp band for acd and although 
a band can be seen in lane 8 (Figure 3.1) in the right position, an unexpected 
product of 1000 bp can also be seen. The PCR product for fliC was of the 
correct size (780 bp; lane 9 of Figure 3.1). In lane 11, the sortaseB 
amplification generated a band slightly over 500 bp in size. This is in 
agreement with the predicted size of 584 bp.  
           To reduce the chances of errors arising in the amplification products, 
PCRs were also carried out with Phusion DNA polymerase. This enzyme was 
supplied with two buffers, HF and GC, the manufacturer suggesting HF as the 
default buffer. Figure 3.2 shows the results of amplification with Phusion DNA 
polymerase using buffer HF; all products are of the predicted size except for 
cwp84 and fbpA. Lane 2 shows the reaction for cwp84 and, as detailed earlier, 
the reaction should yield a product of 2265 bp. Amplification with Phusion 
DNA polymerase band buffer HF generated a band of less than 500 bp. In lane 
5, no band can be seen; the fbpA reaction was supposed to generate a 
product of 1689 bp (Table 3.2. When comparing predicted sizes of other PCR 
products with the actual data, Figure 3.2 lanes 3 (cspA), 4 (5' cwp66), 6 
(groEL), 7 (fliD), 8 (acd), 9 (fliC), 10 (3' cwp66) and 11 (sortase B) shows that all 
products were in the right positions.    
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Figure 3.1.  PCR products obtained with sense and antisense primers using Taq DNA polymerase 
(Promega).  
From left: lane 1, 1kb DNA ladder(Promega); lane 2, cwp84; lane 3, cspA; lane4, 5' cwp66; lane 5, 
fbpA; lane 6, groEL; lane 7, fliD; lane 8, acd; lane 9, fliC; lane 10, 3' cwp66; lane 11, sortaseB. 
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Figure 3.2.  PCR products of targets with Phusion DNA polymerase (New England BioLabs).  
 
From left: lane 1, 1kb DNA ladder (Promega); lane 2, cwp84; lane 3, cspA; lane 4, 5' cwp66; lane 5, 
fbpA; lane 6, groEL; lane 7, fliD; lane 8, acd; lane 9, fliC; lane 10, 3' cwp66; lane 11, sortase B.  
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Table 3. 1. Sequences of sense and antisense primers for amplification of C. difficile targets by PCR 
for ligation independent cloning. 
 
TARGET NAME (CD) 
PRIMERS 
SENSE ( UP SIDE SEQUENCE) 
ANTISENSE( DOWN SIDE SEQUENCE) 
cwp84  (2787) 
5΄ GAC GAC GAC AAG ATA GAT GGA GTA GAA ACT GCA GAG 3΄ 
5΄ GA GGA GAA GCC CGG TTC ATT TCC ATT TCC ACC AAC 3΄ 
cspA  (0892) 
5΄ GAC GAC GAC AAG ATG AAA AAC GGA ATA GTA AAA TGG 3΄ 
5΄ GA GGA GAA GCC CGG TAC GTT TTC AGC TTG AGG TCC 3΄ 
5’ cwp66  (2789) 
5΄ GAC GAC GAC AAG ATA ACG GGT TCT GGA AGA TGG 3΄ 
5΄ GA GGA GAA GCC CGG TTT AGC TGC TAA TAC ACC CAC 3΄ 
fbpA  (2592) 
5΄ GAC GAC GAC AAG ATA CAT CAA CCT GAA GAT GAT GAG 3΄ 
5΄ GA GGA GAA GCC CGG TTT AAC CTT AAG CTT GGC TAC 3΄ 
groEL  (0194) 
5΄ GAC GAC GAC AAG   ATTGGA GTA ACT ATA GCA AAA GAG 3΄ 
5΄ GA GGA GAA GCC CGG TCC GCC ACC CAT TCC TGG 3΄ 
fliD  (0237) 
5΄ GAC GAC GAC AAG ATT CCA GTA AGA GTT ACA GGC 3΄ 
5΄ GA GGA GAA GCC CGG TTG TGA GAA ATA GTT CAT TTG 3΄ 
acd  (1304) 
5΄ GAC GAC GAC AAG ATT GAA CCA ACT GCC GAA AGT AGC 3΄ 
5΄ GA GGA GAA GCC CGG TTC CAT AAT TCC AGA AAT TCC 3΄ 
fliC  (0239) 
5΄ GAC GAC GAC AAG ATG GAG AAG TTA TCT TCT GGG 3΄ 
5΄ GA GGA GAA GCC CGG TAA AAC TCC TTG TGG TTG TTG 3΄ 
3’ cwp66 (2789) 
5΄ GAC GAC GAC AAG ATA GTT ACT CAA ATT GGT GGC 3΄ 
5΄ GAC GAC GAC AAG ATA GTT ACT CAA ATT GGT GGC 3΄ 
sortaseB  (2718) 
5΄ GAC GAC GAC AAG ATC AAT CAT GAT ACT AAA ATA TCC 3΄ 
5΄ GA GGA GAA GCC CGG TCT ACCATGAATCAC C 3΄ 
cwp66  (2789) 
5΄ GAC GAC GAC AAG ATA ACG GGT TCT GGA AGA TGG 3΄ 
5΄ GAC GAC GAC AAG ATA GTT ACT CAA ATT GGT GGC 3΄ 
In the primer sequences, bold text shows the complementary sequence of prepared LIC vector  
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Table 3. 2. Predicted size and molecular weight of the targets 
 
Predicted sizes show the theoretical sizes of the PCR products in bp for each reaction (column 3), the 
anticipated size of proteins encoded by the PCR products (kDa) and data for proteins expressed from 
the pET32 EK/LIC expression vector(+tag kDa). 
 
 
 
 
 
 
 
 
 
 
 
 
 
TARGET NAME ACCESSION NUMBER 
PREDICTED 
SIZE (bp) 
PREDICTED MOLECULAR 
MASS OF PROTEIN (kDa) 
PREDICTED 
MOLECULAR MASS + 
TAG (kDa) 
cwp84 YP_001089300.1 2265 82.04 102.51 
cspA YP_001087366.1 192 7.06 27.53 
5’ cwp66 YP_001089302.1 744 26.6 47.07 
fbpA YP_001089109.1 1689 64.71 85.18 
groEL YP_001086664.1 1461 51.73 72.2 
fliD YP_001086705.1 1497 55.31 75.78 
acd YP_001087799.1 1650 59.75 80.22 
fliC YP_001086707.1 780 27.57 48.04 
3’ cwp66 YP_001087366.1 900 33.47 53.94 
sortaseB YP_001089230.1 579 22.91 43.38 
cwp66 YP_001089302.1 1722 62.75 83.22 
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Further PCRs were run to assess the influence of buffers HF and GC on 
amplification of cwp84, fbpA and full-length cwp66 sequences with Phusion DNA 
polymerase. In Figure 3.3, lanes 2 and 3 compare the outcome of PCR reactions for 
cwp84 using Phusion DNA polymerase and buffers HF or GC respectively. Based on 
the data in Table 3.2, the amplified fragment should be 2265 bp, a result which is 
evident in lane 3 when GC buffer was used for the PCR reaction. Using HF buffer in 
the reaction resulted in a product too low in molecular weight (lane 3). The sample 
loaded to lane 6 was a cwp84 amplification using Taq DNA polymerase. Lanes 4, 5 
and 7 in Figure 3.3 show the reactions for fbpA.  Phusion DNA polymerase was 
used for PCRs loaded to lanes 4 and 5, Taq DNA polymerase for lane 7. No product 
was obtained using HF Buffer (lane 4) but when GC buffer was chosen (lane 5), the 
fbpA reaction generated a product consistent with the predicted size (1689 bp). 
This result was also obtained with Taq (lane 7). The PCRs for cwp66 were 
successful (1700 bp band) using Phusion DNA polymerase with GC buffer (lane 8) 
and Taq polymerase (lane 9). Again, no product was obtained from this reaction 
when HF buffer was used with Phusion DNA polymerase (Figure 3.3, lane 10). 
       Having optimised the reactions, further PCRs were carried out so that the 
products could be extracted from agarose gels for cloning. Eleven reactions were 
run with Phusion DNA polymerase to generate amplicons for the targets cspA, 5’ 
cwp66, groEL, fliD, acd, fliC, 3’ cwp66, putative sortaseB (HF buffer) and with GC 
buffer for cwp84, fbpA and the full length cwp66 sequence. The reaction products 
were all loaded to agarose gels and the relevant bands were excised and purified 
using a gel extraction kit from QIAGEN. After extraction, the PCR products were all 
analysed again by agarose gel electrophoresis to re-check their size. Figure 3.4 
shows that all 11 samples of extracted DNA contain products of a size consistent 
with that predicted in Table 3.2.  The amount of DNA present in each extracted 
sample was estimated by nanodrop (Table 3.3) in preparation for cloning.  
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Figure 3.3. Comparison of PCR reactions using Phusion DNA polymerase with buffers HF and GC buffers, 
and Taq polymerase.  
Lane 1, 1kb DNA ladder (Promega); lane 2, cwp84 with HF buffer; lane 3, cwp84 with GC buffer; lane 4, 
fbpA with HF buffer; lane 5, fbpA with GC buffer; lane 6, cwp84 with Taq polymerase; lane 7, fbpA with 
Taq polymerase; lane 8, cwp66 with GC buffer; lane 9, cwp66 with Taq polymerase; lane 10, cwp66 with 
HF buffer. Phusion DNA polymerase was used in all reactions in which HF or GC buffer was tested. 
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Figure 3.4. Agarose gel electrophoresis of extracted PCR products. Lane 1, 1kb DNA ladder; lane 2, cwp84; 
lane 3, cspA; lane4, 5’ cwp66; lane 5, fbpA; lane 6, groEL; lane 7, fliD; lane 8, acd; lane 9, fliC; lane 10, 3’ 
cwp66; lane 11, sortaseB; lane 12, cwp66. All PCR reactions were carried out with Phusion DNA 
polymerase with buffer HF (lanes 3, 4, 6, 7, 8, 9, 10, 11) or GC buffer (for lanes 2, 5 and 12.)  
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3.2  Cloning and expression of targets using LIC cloning 
system 
      Having optimised their amplification, PCR products were then used for cloning 
so that the target proteins could be expressed. This phase of the project entailed a 
series of different steps for each target. Each PCR product was first  cloned into the 
pET-32 EK/LIC vector and transformed into a strain of Escherichia coli (NovaBlue) 
for initial characterisation. This included colony PCR to confirm that the plasmids 
carried in each strain contained the correct insert and one of the intended size. 
The insert DNA was also sequenced from each terminus using vector-specific 
primers annealing to the S.tag and T7 terminator sequences. Three types of E. coli 
DE3 cells were also evaluated for their capacity to express the recombinant 
clostridial proteins and the expressed protein products were purified by nickel 
affinity chromatography for verification by mass spectrometry (LC-MS/MS). 
 
 
3.2.1 Cloning of the targets      
       Extracted PCR products for each target were first treated with T4 DNA 
polymerase to generate the overhanging termini required for LIC cloning, and then 
they were annealed to the prepared pET-32 vector. Competent E. coli NovaBlue 
cells were used as the strain for initial transformation of the ligation products. 
Transformations resulted in large numbers of colonies when incubated overnight 
on selective agar plates, comparable to the positive control insert supplied with 
the vector kit. Few or no colonies were seen for negative controls. Colonies were 
picked for colony PCR using target-specific primers (Table 3.1). This showed most 
transformants carried inserts of the size expected for each target (Figure 3.5). 
Working from the top of Figure 3.5, it is apparent that 6 out of 10 colonies carrying 
the cwp84 sequence were positive in having an insert of the expected size (2265 
bp) whereas for cspA (189 bp) and 5’ cwp66 (744 bp) all 10 colonies that were 
picked were positive. The fourth row in the Figure 3.5 shows fbpA transformants in 
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which an insert of 1689 bp was expected. Just one colony from the 10 selected 
lacked an insert. For the 6 other targets, colony PCR from all transformants 
showed amplified fragments of the predicted sizes (Figure 3.5).
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CWP84 
2265 BP, 6 OUT OF 10 
COLONIES CARRIED 
INSERTS OF THE CORRECT 
SIZE. 
 
 
cspA 
189bp, all 10 colonies 
carried inserts of the 
correct size. 
 
5' cwp66 
744 bp, all 10 colonies 
carried inserts of the 
correct size. 
 
fbpA 
1689 bp, 9 out of 10 
colonies carried inserts of 
the correct size. 
 
groEL 
1461 bp, all 10 colonies 
carried inserts of the 
correct size. 
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fliD 
1497 bp, all 10 colonies 
carried inserts of the 
correct size. 
 
acd 
1650 bp, all 10 colonies 
carried inserts of the 
correct size. 
 
fliC 
780 bp, all 10 colonies 
carried inserts of the 
correct size. 
 
3' cwp66 
900bp, all 10 colonies 
carried inserts of the 
correct size. 
 
sortaseB 
584 bp, all 10 colonies 
carried inserts of the 
correct size. 
 
 Colony PCR of NovaBlue 
transformants cwp66 
1722 bp, all 10 colonies 
carried inserts of the 
correct size. 
 
 
Figure 3. 5.  Colony PCR of NovaBlue transformants 
 lane 1 of all gels, 1kb DNA ladder. 
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3.2.2 DNA sequencing analysis 
     The sequence of each insert was determined using S.tag and T7 terminator 
primers.  Based on the sequence of the pET-32 EK/LIC vector system, different 
restriction endonuclease sites flank the insert. These were all checked in the 
sequence data collected from each target. In addition, an enterokinase site (EK 
site), and His.tag sequence were other markers to be checked in the sequences 
(Table 3.4).  
      To check inserts which were less than 1000 bp, data collected from S.tag or T7 
primed sequencing was compared to ensure that the same results had been 
obtained and the data was aligned to related DNA sequence from C. difficile 630. 
For inserts more than 1000 bp in length, contigs were assembled from the two 
sequencing reactions and again compared to data from C. difficile 630. The 
assembled data were translated to their amino acid sequence and applied into 
BLAST engine (http://www.ncbi.nlm.nih.gov/sutils/genom_table.cgi). Table 3.4 
shows an overview of the cloned sequences with features that were checked such 
as the EK site, restriction enzyme sites, His.tag and stop codons. 
                For one clone carrying cwp84, sequence analysis showed the termini of 
the insert were in complete agreement with the reference entry at GenBank, but 
as shown in Figure 3.6, a central region had been deleted.  This construct was 
designated r-cwp84. Comparing three sequences, r-cwp84 lacked 335 nucleotides 
in the middle.  The cloned sequence for cspA was analysed from two S.tag and T7-
primer reactions. Data from T7 sequencing was used in an alignment with 
cspA630, the sequence of cspA from C. difficile 630. The DNA and translated 
sequences showed completely identitiy with cspA630 (Figure 3.8). For the fbpA 
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insert, a fragment of 1689 bp was found in the plasmid which encoded the same 
protein sequence as fbpA of 630 strain (Figure 3.9) and similar results were 
obtained with groEL (1461 bp;  Figure 3.10), acd (1650 bp; Figure 3.12), and fliC 
(780 bp; Figure 3.13). For cwp66, two constructs were generated carrying the 5’ (r-
5cwp66) and 3’ (r-3cwp66) regions of the coding sequence. These were aligned 
separately with the sequence of cwp66 from C. difficile 630 as can seen in Figure 
3.14. In BLAST analysis, both recombinant targets showed a high identity with the 
reference sequence (Figure 3.14). In other experiments, the whole sequence of 
cwp66 was also cloned and analysis clearly showed identity when compared with 
the sequence from C. difficile 630 (Figure 3.15). The last sequence analysed was a 
putative sortase (designated r-srB, 579 bp). Both alignment and BLAST results 
showed the clone had the intended sequence (Figure 3.16). All target sequences 
were also analysed in nucleotide BLAST. This showed the inserts were of the right 
length in the expression plasmid except cwp84 (data not shown; see earlier 
comments). 
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Table 3. 4. Features checked during analysis of cloned target sequences  
 
TARGET 
PREDICTED 
LENGTH(BP) 
CALCULATED 
LENGTH(BP) 
RESTRICTION 
SITES 
EK SITE 
HIS. 
TAG 
STOP 
CODON 
cwp84 2265 1933 + + + + 
cspA 189 189 + + + + 
5'cwp66 744 744 + + + + 
fbpA 1689 1689 + + + + 
groEL 1461 1461 + + + + 
fliD 1497 1497 + + + + 
acd 1650 1650 + + + + 
fliC 780 780 + + + + 
3'cwp66 900 900 + + + + 
srB 579 579 + + + + 
cwp66 1722 1722 + + + + 
 
 
 
 
 
 
 
 
 
 
 
                                       Trx•Tag                                                                                          His.Tag                                                                          
         …TATACATATGAGC...315bp...CTGGCCGGTTCTGGTTCTGGCCATATGCACCATCATCATCATCATTCTTCTGGTCTGGTGCCACGCGGTTCT 
      
                                   S.Tag primer                                    LICsite 
                             S.Tag                         BgII          KpnI                           EK site   *    SmaI            BseRI           NcoI 
GGTATGAAAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATGGACAGCCCAGATCTGGGTACCGATGACGACGACAAGAGCCCGGGCTTCTCCTCAACCATG 
        
                   EcoRV   BamHI      EcoRI       SacI           SalI        HindIII          NotI              XhoI       His•Tag         End 
GCGATATCGGATCCGAATTCGAGCTCCGTCGACAAGCTTGCGGCCGCACTCGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAA 
                                                                                     T7 terminator  
CAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTG 
 
T7 terminator primer 
 
 
Figure 3.6. Features of the pET-32 EK/LIC expression plasmid that flank the cloning site. 
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designed        AGCAGAGATTCTGAAAAACTTGACTCTGTTATGTTTGAAACAGATTCTGTAGGAGCAAAA 1035 
r-cwp84         AGCAGAGATTCTGAAAAACTTGACTCTGTTATGTTTGAAACAGATTCTGTAG-------- 1027 
630cwp84        AGCAGAGATTCTGAAAAACTTGACTCTGTTATGTTTGAAACAGATTCTGTAGGAGCAAAA 1140 
 
designed        TATGAAGTATATTATGCACCAGTAGTAAATGGAGTTCCTCAAAACAATTCAATGACAAAA 1095 
r-cwp84         ------------------------------------------------------------ 
630cwp84        TATGAAGTATATTATGCACCAGTAGTAAATGGAGTTCCTCAAAACAATTCAATGACAAAA 1200                                                                            
 
designed        CTTGCAAGTGGAACAGTATCATATTCTGGATACATAAATGTACCTACTAATTCTTACAGC 1155 
r-cwp84         ------------------------------------------------------------ 
630cwp84        CTTGCAAGTGGAACAGTATCATATTCTGGATACATAAATGTACCTACTAATTCTTACAGC 1260                                                                            
 
designed        TTACCAAAAGGTAAAGGAGCAATAGTAGTAGTTATAGACAACACAGCAAATCCTAATAGA 1215 
r-cwp84         ------------------------------------------------------------ 
630cwp84        TTACCAAAAGGTAAAGGAGCAATAGTAGTAGTTATAGACAACACAGCAAATCCTAATAGA 1320                                                                            
 
designed        GAAAAATCAACTTTAGCATATGAAACTAATATAGATGCATATTATTTATATGAGGCTAAA 1275 
r-cwp84         ------------------------------------------------------------ 
630cwp84        GAAAAATCAACTTTAGCATATGAAACTAATATAGATGCATATTATTTATATGAGGCTAAA 1380                          
 
designed        GCAAACTTAGGTGAAAGCTACATACTTCAAAACAATAAGTTTGAAGACATAAATACATAT 1335 
r-cwp84         ------------------------------------------------------------ 
630cwp84        GCAAACTTAGGTGAAAGCTACATACTTCAAAACAATAAGTTTGAAGACATAAATACATAT 1440                                                                            
 
designed        AGTGAATTTTCTCCTTGTAACTTTGTTATAAAAGCTATAACAAAAACATCTTCTGGACAA 1395 
r-cwp84         ---------------------------ATAAAAGCTATAACAAAAACATCTTCTGGACAA 1060 
630cwp84        AGTGAATTTTCTCCTTGTAACTTTGTTATAAAAGCTATAACAAAAACATCTTCTGGACAA 1500 
 
 
Figure 3.7. Alignment shows the intended sequence (“designed”), that recovered from cloning (“r-
cwp84”) and the cwp84 sequence from Clostridium difficile 630 (“630cwp84”). 
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A 
 
cspA630         MKNGIVKWFNNEKGFGFISVEGEDDVFVHFSAIQNDGYKTLEEGEKVSFDITQGNRGPQA  
r-cspA          MKNGIVKWFNNEKGFGFISVEGEDDVFVHFSAIQNDGYKTLEEGEKVSFDITQGNRGPQA  
                ************************************************************ 
 
cspA360         ENVNRI 66 
r-cspA          ENV--- 63 
                                                  
 
 
 
B 
 
ref|NC_009089.1|  Clostridium difficile 630 chromosome, complete genome 
Length=4290252 
 
 
                                                         Sort alignments for this subject sequence by: 
                                                           E value  Score  Percent identity 
                                                           Query start position  Subject start position 
 Features in this part of subject sequence: 
   cold shock protein 
 
 Score =  128 bits (322),  Expect = 2e-30, Method: Compositional matrix adjust. 
 Identities = 63/63 (100%), Positives = 63/63 (100%), Gaps = 0/63 (0%) 
 Frame = -3 
 
Query  1        MKNGIVKWFNNEKGFGFISVEGEDDVFVHFSAIQNDGYKTLEEGEKVSFDITQGNRGPQA  60 
                MKNGIVKWFNNEKGFGFISVEGEDDVFVHFSAIQNDGYKTLEEGEKVSFDITQGNRGPQA 
Sbjct  1074175  MKNGIVKWFNNEKGFGFISVEGEDDVFVHFSAIQNDGYKTLEEGEKVSFDITQGNRGPQA  1073996 
 
Query  61       ENV  63 
                ENV 
Sbjct  1073995  ENV  1073987 
 
 
 
 
Figure 3.8. Alignment of the predicted protein sequence of r-cspA with cspA630 (A) and BLAST output 
from a search of the protein database (B). 
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A 
r-fbpA          --------------------------IHQPEDDEVIFNIRNNKENFRLVLSASASNPRVY 34 
fbpa630         MALDGLVIHSIVDELSSKLTGGKIDKIHQPEDDEVIFNIRNNKENFRLVLSASASNPRVY 60 
                                          ********************************** 
r-fbpA          LTSNYQKENPLKAPMFCMLLRKYIQGGNIVEISQIGFERIIKISVESLDELKEKTVKNIM 94 
fbpa630         LTSNYQKENPLKAPMFCMLLRKYIQGGNIVEISQIGFERIIKISVESLDELKEKTVKNIM 120 
                ************************************************************ 
r-fbpA          IEIMGRHSNIIITHGEENKIIDSIKRVPFSISRVRQVLPGHDYSLPPEQNKLNPLDDISK 154 
fbpa630         IEIMGRHSNIIITHGEENKIIDSIKRVPFSISRVRQVLPGHDYSLPPEQNKLNPLDDISK 180 
                ************************************************************ 
r-fbpA          DLFIKNLEELEGPIFKSIYSKFLGISPIIAKEICYRAGVNQNAIIKDISDEQFDALHKVF 214 
fbpa630         DLFIKNLEELEGPIFKSIYSKFLGISPIIAKEICYRAGVNQNAIIKDISDEQFDALHKVF 240 
                ************************************************************ 
r-fbpA          CNLFNDINSNKYSPCIIIDKKVDRVVDFSCINLTLFSDLSYINKDSMSRILEDFYRTKDI 274 
fbpa630         CNLFNDINSNKYSPCIIIDKKVDRVVDFSCINLTLFSDLSYINKDSMSRILEDFYRTKDI 300 
                ************************************************************ 
r-fbpA          KDRINQRSSDLKKSISVKLDRLYNKLKKQEEELSESENADIYKIKGELITSYIYMVEKGM 334 
fbpa630         KDRINQRSSDLKKSISVKLDRLYNKLKKQEEELSESENADIYKIKGELITSYIYMVEKGM 360 
                ************************************************************ 
r-fbpA          ESIEVANFYDENCNDVIIELNKNLTPSENAQKYFKKYNKMKHAKVEISHQISLNKEEIDY 394 
fbpa630         ESIEVANFYDENCNDVIIELNKNLTPSENAQKYFKKYNKMKHAKVEISHQISLNKEEIDY 420 
                ************************************************************ 
r-fbpA          LENIILSIENCENLAELQDIKEELAKVGYIKTQKKNSKKDTIPSTKPHEFVSSDGFKILV 454 
fbpa630         LENIILSIENCENLAELQDIKEELAKVGYIKTQKKNSKKDTIPSTKPHEFVSSDGFKILV 480 
                ************************************************************ 
r-fbpA          GKNNKQNDYLTLRLADNDDLWMHTKNIPGSHVIIKCAGKEVPDNTVFEGAMLAAFFSKSK 514 
fbpa630         GKNNKQNDYLTLRLADNDDLWMHTKNIPGSHVIIKCAGKEVPDNTVFEGAMLAAFFSKSK 540 
                ************************************************************ 
r-fbpA          LSSQVPVDYTKRKNVKKPSGSKPGMVIYETNSTIYVTPEEETVAKLKVK-- 563 
fbpa630         LSSQVPVDYTKRKNVKKPSGSKPGMVIYETNSTIYVTPEEETVAKLKVKSE 591 
                *************************************************   
      
B> ref|NC_009089.1|  Clostridium difficile 630 chromosome, complete genome 
Length=4290252 
 Features in this part of subject sequence: 
   fibronectin-binding protein 
 Score = 1108 bits (2867),  Expect = 0.0, Method: Compositional matrix adjust. 
 Identities = 563/563 (100%), Positives = 563/563 (100%), Gaps = 0/563 (0%) 
 Frame = +3 
Query  1            IHQPEDDEVIFNIRNNKENFRLVLSASASNPRVYLTSNYQKENPLKAPMFCMLLRKYIQG  60 
                IHQPEDDEVIFNIRNNKENFRLVLSASASNPRVYLTSNYQKENPLKAPMFCMLLRKYIQG 
Sbjct  2998230  IHQPEDDEVIFNIRNNKENFRLVLSASASNPRVYLTSNYQKENPLKAPMFCMLLRKYIQG  2998409 
Query  61       GNIVEISQIGFERIIKISVESLDELKEKTVKNIMIEIMGRHSNIIITHGEENKIIDSIKR  120 
                GNIVEISQIGFERIIKISVESLDELKEKTVKNIMIEIMGRHSNIIITHGEENKIIDSIKR 
Sbjct  2998410  GNIVEISQIGFERIIKISVESLDELKEKTVKNIMIEIMGRHSNIIITHGEENKIIDSIKR  2998589 
Query  121      VPFSISRVRQVLPGHDYSLPPEQNKLNPLDDISKDLFIKNLEELEGPIFKSIYSKFLGIS  180 
                VPFSISRVRQVLPGHDYSLPPEQNKLNPLDDISKDLFIKNLEELEGPIFKSIYSKFLGIS 
Sbjct  2998590  VPFSISRVRQVLPGHDYSLPPEQNKLNPLDDISKDLFIKNLEELEGPIFKSIYSKFLGIS  2998769 
Query  181      PIIAKEICYRAGVNQNAIIKDISDEQFDALHKVFCNLFNDINSNKYSPCIIIDKKVDRVV  240 
                PIIAKEICYRAGVNQNAIIKDISDEQFDALHKVFCNLFNDINSNKYSPCIIIDKKVDRVV 
Sbjct  2998770  PIIAKEICYRAGVNQNAIIKDISDEQFDALHKVFCNLFNDINSNKYSPCIIIDKKVDRVV  2998949 
Query  241      DFSCINLTLFSDLSYINKDSMSRILEDFYRTKDIKDRINQRSSDLKKSISVKLDRLYNkl  300 
                DFSCINLTLFSDLSYINKDSMSRILEDFYRTKDIKDRINQRSSDLKKSISVKLDRLYNKL 
Sbjct  2998950  DFSCINLTLFSDLSYINKDSMSRILEDFYRTKDIKDRINQRSSDLKKSISVKLDRLYNKL  2999129 
Query  301      kkqeeelseseNADIYKIKGELITSYIYMVEKGMESIEVANFYDENCNDVIIELNKNLTP  360 
                KKQEEELSESENADIYKIKGELITSYIYMVEKGMESIEVANFYDENCNDVIIELNKNLTP 
Sbjct  2999130  KKQEEELSESENADIYKIKGELITSYIYMVEKGMESIEVANFYDENCNDVIIELNKNLTP  2999309 
Query  361      SENAQKYFKKYNKMKHAKVEISHQISLNKEEIDYLENIILSIENCENLAELQDIKEELAK  420 
                SENAQKYFKKYNKMKHAKVEISHQISLNKEEIDYLENIILSIENCENLAELQDIKEELAK 
Sbjct  2999310  SENAQKYFKKYNKMKHAKVEISHQISLNKEEIDYLENIILSIENCENLAELQDIKEELAK  2999489 
Query  421      VGYIKTQKKNSKKDTIPSTKPHEFVSSDGFKILVGKNNKQNDYLTLRLADNDDLWMHTKN  480 
                VGYIKTQKKNSKKDTIPSTKPHEFVSSDGFKILVGKNNKQNDYLTLRLADNDDLWMHTKN 
Sbjct  2999490  VGYIKTQKKNSKKDTIPSTKPHEFVSSDGFKILVGKNNKQNDYLTLRLADNDDLWMHTKN  2999669 
Query  481      IPGSHVIIKCAGKEVPDNTVFEGAMLAAFFSKSKLSSQVPVDYTKRKNVKKPSGSKPGMV  540 
                IPGSHVIIKCAGKEVPDNTVFEGAMLAAFFSKSKLSSQVPVDYTKRKNVKKPSGSKPGMV 
Sbjct  2999670  IPGSHVIIKCAGKEVPDNTVFEGAMLAAFFSKSKLSSQVPVDYTKRKNVKKPSGSKPGMV  2999849 
Query  541      IYETNSTIYVTPEEETVAKLKVK  563 
                IYETNSTIYVTPEEETVAKLKVK 
Sbjct  2999850  IYETNSTIYVTPEEETVAKLKVK  2999918 
 
Figure 3. 9. Alignment of the predicted protein sequence of r-fbpA with fbpA630 (A) and BLAST output 
from a search of the protein database (B).
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A 
groEL630        MAKEIKFSEETRRALEAGVNKLADTVKVTLGPKGRNVILDKKFGSPLITNDGVTIAKEIE 60 
r-groEL         --------------------------------------------------IGVTIAKEIE 10 
                                                                   ********* 
groEL630        LEDRFENMGAQLVKEVATKTNDVAGDGTTTATVLAQAIIREGLKNVTAGANPILLRKGIQ 120 
r-groEL         LEDRFENMGAQLVKEVATKTNDVAGDGTTTATVLAQAIIREGLKNVTAGANPILLRKGIQ 70 
                ************************************************************ 
groEL630        KAVTVAVEELKNQSRIVETQEAISQVASISAGDEEVGKLIAEAMEIVGKDGVITVEESQT 180 
r-groEL         KAVTVAVEELKNQSRIVETQEAISQVASISAGDEEVGKLIAEAMEIVGKDGVITVEESQT 130 
                ************************************************************ 
groEL630        MNTELDAVEGMQFDRGFVSAYMVTDVDKMEAVLNDPYILITDKKISNIQELLPVLEQIVQ 240 
r-groEL         MNTELDAVEGMQFDRGFVSAYMVTDVDKMEAVLNDPYILITDKKISNIQELLPVLEQIVQ 190 
                ************************************************************ 
groEL630        QGKKLLIIAEDVEGEALSTLVVNKLRGTFDVVAVKAPGFGDRRKEMLQDIAILTGAQVIS 300 
r-groEL         QGKKLLIIAEDVEGEALSTLVVNKLRGTFDVVAVKAPGFGDRRKEMLQDIAILTGAQVIS 250 
                ************************************************************ 
groEL630        EELGYDLKEADLSMLGRASSVKVTKESTTIVDGSGDKKAIEDRVTQIKHQVEQTTSDFDR 360 
r-groEL         EELGYDLKEADLSMLGRASSVKVTKESTTIVDGSGDKKAIEDRVTQIKHQVEQTTSDFDR 310 
                ************************************************************ 
groEL630        EKLMERLAKLAGGVAVVKVGAATEVELKERKLRIEDALNATRAAVEEGIVAGGGTAFVSV 420 
r-groEL         EKLMERLAKLAGGVAVVKVGAATEVELKERKLRIEDALNATRAAVEEGIVAGGGTAFVSV 370 
                ************************************************************ 
groEL630        IPAIGTLIESLEGEVKLGAQIVKKALEEPLRQIAINAGLEGAVIVQNVVNSEAETGFDAL 480 
r-groEL         IPAIGTLIESLEGEVKLGAQIVKKALEEPLRQIAINAGLEGAVIVQNVVNSEAETGFDAL 430 
                ************************************************************ 
groEL630        NEKYVNMIEAGIVDPTKVSRSALQNAASIASTFLTTEAAVADLPEKEDAGMPGMGGGMPG 540 
r-groEL         NEKYVNMIEAGIVDPTKVSRSALQNAASIASTFLTTEAAVADLPEKEDAGMPGMGGG--- 487 
                *********************************************************    
groEL630        MM 542 
r-groEL         --                   
 
 
B    > ref|NC_009089.1|  Clostridium difficile 630 chromosome, complete genome Length=4290252 Features 
in this part of subject sequence: 
   60 kDa chaperonin 
 Score =  863 bits (2230),  Expect = 0.0, Method: Compositional matrix adjust. 
 Identities = 478/478 (100%), Positives = 478/478 (100%), Gaps = 0/478 (0%) 
 Frame = +2 
 
Query  2       GVTIAKEIELEDRFENMGAQLVKEVATKTNDVAGDGTTTATVLAQAIIREGLKNVTAGAN  61 
               GVTIAKEIELEDRFENMGAQLVKEVATKTNDVAGDGTTTATVLAQAIIREGLKNVTAGAN 
Sbjct  252413  GVTIAKEIELEDRFENMGAQLVKEVATKTNDVAGDGTTTATVLAQAIIREGLKNVTAGAN  252592 
 
Query  62      PILLRKGIQKAVTVAVEELKNQSRIVETQEAISQVASISAGDEEVGKLIAEAMEIVGKDG  121 
               PILLRKGIQKAVTVAVEELKNQSRIVETQEAISQVASISAGDEEVGKLIAEAMEIVGKDG 
Sbjct  252593  PILLRKGIQKAVTVAVEELKNQSRIVETQEAISQVASISAGDEEVGKLIAEAMEIVGKDG  252772 
 
Query  122     VITVEESQTMNTELDAVEGMQFDRGFVSAYMVTDVDKMEAVLNDPYILITDKKISNIQEL  181 
               VITVEESQTMNTELDAVEGMQFDRGFVSAYMVTDVDKMEAVLNDPYILITDKKISNIQEL 
Sbjct  252773  VITVEESQTMNTELDAVEGMQFDRGFVSAYMVTDVDKMEAVLNDPYILITDKKISNIQEL  252952 
 
Query  182     LPVLEQIVQQGKKLLIIAEDVEGEALSTLVVNKLRGTFDVVAVKAPGFGDRRKEMLQDIA  241 
               LPVLEQIVQQGKKLLIIAEDVEGEALSTLVVNKLRGTFDVVAVKAPGFGDRRKEMLQDIA 
Sbjct  252953  LPVLEQIVQQGKKLLIIAEDVEGEALSTLVVNKLRGTFDVVAVKAPGFGDRRKEMLQDIA  253132 
 
Query  242     ILTGAQVISEELGYDLKEADLSMLGRASSVKVTKESTTIVDGSGDKKAIEDRVTQIKHQV  301 
               ILTGAQVISEELGYDLKEADLSMLGRASSVKVTKESTTIVDGSGDKKAIEDRVTQIKHQV 
Sbjct  253133  ILTGAQVISEELGYDLKEADLSMLGRASSVKVTKESTTIVDGSGDKKAIEDRVTQIKHQV  253312 
 
Query  302     EQTTSDFDREKLMERlaklaggvavvkvgaaTEVELKERKLRIEDALNATRaaveegiva  361 
               EQTTSDFDREKLMERLAKLAGGVAVVKVGAATEVELKERKLRIEDALNATRAAVEEGIVA 
Sbjct  253313  EQTTSDFDREKLMERLAKLAGGVAVVKVGAATEVELKERKLRIEDALNATRAAVEEGIVA  253492 
 
Query  362     gggtaFVSVIPAIGTLIESLEGEVKLGAQIVKKALEEPLRQIAINAGLEGAVIVQNVVNS  421 
               GGGTAFVSVIPAIGTLIESLEGEVKLGAQIVKKALEEPLRQIAINAGLEGAVIVQNVVNS 
Sbjct  253493  GGGTAFVSVIPAIGTLIESLEGEVKLGAQIVKKALEEPLRQIAINAGLEGAVIVQNVVNS  253672 
 
Query  422     EAETGFDALNEKYVNMIEAGIVDPTKVSRSALQNAASIASTFLTTEAAVADLPEKEDA  479 
               EAETGFDALNEKYVNMIEAGIVDPTKVSRSALQNAASIASTFLTTEAAVADLPEKEDA 
Sbjct  253673  EAETGFDALNEKYVNMIEAGIVDPTKVSRSALQNAASIASTFLTTEAAVADLPEKEDA  253846 
 
Figure 3. 10 Alignment of the predicted protein sequence of r-groEL with groEL630 (A) and BLAST output 
from a search of the protein database (B).
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A 
r-fliD            ----IPVRVTGLSGNFDMEGIIEASMIRDKEKVNKAKQDQQIVKWKQEIYRDIIKESKNL 56 
fliD630           MSSISPVRVTGLSGNFDMEGIIEASMIRDKEKVNKAKQDQQIVKWKQEIYRDIIKESKNL 60 
                       *******************************************************  
r-fliD            YDKYLNGDSPNSITNKKAYSATRITSSDESIIVAKGSAGAEKINYQFAVSQMAEPAKVTI 116 
fliD630           YDKYLNGDSPNSITNKKAYSATRITSSDESIIVAKGSAGAEKINYQFAVSQMAEPAKVTI 120 
                  ************************************************************ 
r-fliD            KLNSSDPIVQQFPPNASGASSLNIGGVNIPISEQDTTSTIVSKINSLCADNDIRASYSEM 176 
fliD630           KLNSSDPIVQQFPPNASGASSLNIGGVNIPISEQDTTSTIVSKINSLCADNDIRASYSEM 180 
                  ************************************************************ 
r-fliD            TGELIISRKQTGSSSDIDLKVIGNDSLAGQIASDNGITFTTDASGTKSAVVYGKNLEADV 236 
fliD630           TGELIISRKQTGSSSDIDLKVIGNDSLAGQIASDNGITFTTDASGTKSAVVYGKNLEADV 240 
                  ************************************************************ 
r-fliD            TDDQGRVTHISKEQNSFKIDNIDYNVNSKGSAKLVSVTDTEEATKNMKAFVDVYNALMDK 296 
fliD630           TDDQGRVTHISKEQNSFKIDNIDYNVNSKGSAKLVSVTDTEEATKNMKAFVDDYNALMDK 300 
                  **************************************************** ******* 
r-fliD            VYGLVTTKKSKDYPPLTDEQKDDMTTEEIEKWEKKAKEGILRNDDELRAFVEDIQSMFFG 356 
fliD630           VYGLVTTKKSKDYPPLTDEQKDDMTTEEIEKWEKKAKEGILRNDDELRAFVEDIQSMFFG 360 
                  ************************************************************ 
r-fliD            DADTIIALRKLGISEHENYNKKGQISFNADTFSKALIDDSDKVYKALAGYSSNYDDKGMF 416 
fliD630           DADTIIALRKLGISEHENYNKKGQISFNADTFSKALIDDSDKVYKALAGYSSNYDDKGMF 420 
                  ************************************************************ 
r-fliD            EKLKKIVFEYSGSSASKLTKKAGMENSSSASQNVYSKQIAEQERNISRLVEKMNDKEKRL 476 
fliD630           EKLKKIVFEYSGSSASKLTKKAGMENSSSASQNVYSKQIAEQERNISRLVEKMNDKEKRL 480 
                  ************************************************************ 
r-fliD            YAKYSALESLLNKYSSQMNYFSQ---- 499 
fliD630           YAKYSALESLLNKYSSQMNYFSQAQGN 507 
 
B  > ref|NC_009089.1|  Clostridium difficile 630 chromosome, complete genome 
          Length=4290252 
          Features in this part of subject sequence: 
          flagellar cap protein 
          Score =  974 bits (2519),  Expect = 0.0, Method: Compositional matrix adjust. Identities = 497/498 
(99%), Positives = 497/498 (99%), Gaps = 0/498 (0%) 
          Frame = +3 
 
Query  2       PVRVTGLSGNFDMEGIIEASMIRDKEKVNKAKQDQQIVKWKQEIYRDIIKESKNLYDKYL  61 
               PVRVTGLSGNFDMEGIIEASMIRDKEKVNKAKQDQQIVKWKQEIYRDIIKESKNLYDKYL 
Sbjct  298995  PVRVTGLSGNFDMEGIIEASMIRDKEKVNKAKQDQQIVKWKQEIYRDIIKESKNLYDKYL  299174 
Query  62      NGDSPNSITNKKAYSATRITSSDESIIVAKGSAGAEKINYQFAVSQMAEPAKVTIKLNSS  121 
               NGDSPNSITNKKAYSATRITSSDESIIVAKGSAGAEKINYQFAVSQMAEPAKVTIKLNSS 
Sbjct  299175  NGDSPNSITNKKAYSATRITSSDESIIVAKGSAGAEKINYQFAVSQMAEPAKVTIKLNSS  299354 
Query  122     DPIVQQFPPNASGASSLNIGGVNIPISEQDTTSTIVSKINSLCADNDIRASYSEMTGELI  181 
               DPIVQQFPPNASGASSLNIGGVNIPISEQDTTSTIVSKINSLCADNDIRASYSEMTGELI 
Sbjct  299355  DPIVQQFPPNASGASSLNIGGVNIPISEQDTTSTIVSKINSLCADNDIRASYSEMTGELI  299534 
Query  182     ISRKQTGSSSDIDLKVIGNDSLAGQIASDNGITFTTDASGTKSAVVYGKNLEADVTDDQG  241 
               ISRKQTGSSSDIDLKVIGNDSLAGQIASDNGITFTTDASGTKSAVVYGKNLEADVTDDQG 
Sbjct  299535  ISRKQTGSSSDIDLKVIGNDSLAGQIASDNGITFTTDASGTKSAVVYGKNLEADVTDDQG  299714 
Query  242     RVTHISKEQNSFKIDNIDYNVNSKGSAKLVSVTDTEEATKNMKAFVDVYNALMDKVYGLV  301 
               RVTHISKEQNSFKIDNIDYNVNSKGSAKLVSVTDTEEATKNMKAFVD YNALMDKVYGLV 
Sbjct  299715  RVTHISKEQNSFKIDNIDYNVNSKGSAKLVSVTDTEEATKNMKAFVDDYNALMDKVYGLV  299894 
Query  302     TTKKSKDYPPLTDEQKDDMTTeeiekwekkakeGILRNDDELRAFVEDIQSMFFGDADTI  361 
               TTKKSKDYPPLTDEQKDDMTTEEIEKWEKKAKEGILRNDDELRAFVEDIQSMFFGDADTI 
Sbjct  299895  TTKKSKDYPPLTDEQKDDMTTEEIEKWEKKAKEGILRNDDELRAFVEDIQSMFFGDADTI  300074 
Query  362     IALRKLGISEHENYNKKGQISFNADTFSKALIDDSDKVYKALAGYSSNYDDKGMFEKLKK  421 
               IALRKLGISEHENYNKKGQISFNADTFSKALIDDSDKVYKALAGYSSNYDDKGMFEKLKK 
Sbjct  300075  IALRKLGISEHENYNKKGQISFNADTFSKALIDDSDKVYKALAGYSSNYDDKGMFEKLKK  300254 
Query  422     IVFEYSGSSASKLTKKAGMENSSSASQNVYSKQIAEQERNISRLVEKMNDKEKRLYAKYS  481 
               IVFEYSGSSASKLTKKAGMENSSSASQNVYSKQIAEQERNISRLVEKMNDKEKRLYAKYS 
Sbjct  300255  IVFEYSGSSASKLTKKAGMENSSSASQNVYSKQIAEQERNISRLVEKMNDKEKRLYAKYS  300434 
Query  482     ALESLLNKYSSQMNYFSQ  499 
               ALESLLNKYSSQMNYFSQ 
Sbjct  300435  ALESLLNKYSSQMNYFSQ  300488 
 
Figure 3. 11.  Alignment of the predicted protein sequence of r-fliD with fliD630 (A) and BLAST output 
from a search of the protein database (B). 
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A 
acd630          MKKKAALATLAMLPLGVVNAHADGDIGIVTINYLNVRNEPTAESSIAFVAKKDDKVLIKD 60 
r-acd           -------------------------------------IEPTAESSIAFVAKKDDKVLIKD 23 
                                                      ********************** 
acd630          SSNGWYKIKAESGQEGWASSKYIAKSNSDSLRTSTNKEKQVISNSLNMRNGAGTSYRVIT 120 
r-acd           SSNGWYKIKAESGQEGWASSKYIAKSNSDSLRTSTNKEKQVISNSLNMRNGAGTSYRVIT 83 
                ************************************************************ 
acd630          VLKKGQKVEVISESNGWSKIKYDGRLGYVSSSYLGDVSNSTNKSKTKQVNTTSLNVRSGP 180 
r-acd           VLKKGQKVEVISESNGWSKIKYDGRLGYVSSSYLGDVSNSTNKSKTKQVNTTSLNVRSGP 143 
                ************************************************************ 
acd630          NTSYGLLGKLPKGSKVEVISESNGWSKIKYNGKDAYVSSMYLSDVSQSNSDNSSQSNDKK 240 
r-acd           NTSYGLLGKLPKGSKVEVISESNGWSKIKYNGKDAYVSSMYLSDVSQSNSDNSSQSNDKK 203 
                ************************************************************ 
acd630          NTDKVVNTASLNVRSGPGSTYSKLGKVYKGSKVTVLSESSGWAKINFNNKEAFVVGNYLS 300 
r-acd           NTDKVVNTASLNVRSGPGSTYSKLGKVYKGSKVTVLSESSGWAKINFNNKEAFVVGNYLS 263 
                ************************************************************ 
acd630          TSADTSNNNSNSNYDNSSNSNGNNSSSSGQVNGMSGISGAKIDYKSLSYTLESHISKQVE 360 
r-acd           TSADTSNNNSNSNYDNSSNSNGNNSSSSRQVNGMSGISGAKIDYKSLSYTLESHISKQVE 323 
                **************************** ******************************* 
acd630          KAASGGNVIAPSNRKSTPSPEFSTFSAQRTSSFVNASSSDIEYYLNPKNFTNTTKGMMQF 420 
r-acd           KAASRGNVIAPSNRKSTPSPEFSTFSAQRTSSFVNASSSDIEYYLNPKNFTNTTKGMMQF 383 
                **** ******************************************************* 
acd630          LKINSYRDGISESSLNSYLNGLSSSVFKNQGAAFINAAKKYNIDVVYLVSHAMWETAYGK 480 
r-acd           LKINSYRDGISESSLNSYLNGLSSSVFKNQGAAFINAAKKYNIDVVYLVSHAMWETAYGK 443 
                ************************************************************ 
acd630          STLAQGQTLTSYKGQPLSKPVKVYNFFGIGAIDKSANVSGAEAAYSNGWTSVETTIDGSA 540 
r-acd           STLAQGQTLTSYKGQPLSKPVKVYNFFGIGAIDKSANVSGAEAAYSNGWTSVETTIDGSA 503 
                ************************************************************ 
acd630          KWISQNYVNSSKYNQNTIYKMKWNYDYTWHQYATDVNWANGISGIMENLIGLYRGGSSLV 600 
r-acd           KWISQNYVNSSKYNQNTIYKMKWNYDYTWHQYATDVNWANGISGIME------------- 550 
                ***********************************************             
acd630          FEVPQYK 607 
r-acd           ------- 
 
B> ref|NC_009089.1|  Clostridium difficile 630 chromosome, complete genome 
Length=4290252 
Sort alignments for this subject sequence by: 
E value  Score  Percent identity 
Query start position  Subject start position 
Features in this part of subject sequence: 
   putative mannosyl-glycoprotein endo-beta-N-acetylglucosam... 
 
 Score =  961 bits (2484),  Expect = 0.0, Method: Compositional matrix adjust. 
 Identities = 547/549 (99%), Positives = 547/549 (99%), Gaps = 0/549 (0%) 
 Frame = +1 
 
Query  2        EPTAESSIAFVAKKDDKVLIKDSSNGWYKIKAESGQEGWASSKYIAKSNSDSLRTSTNKE  61 
                EPTAESSIAFVAKKDDKVLIKDSSNGWYKIKAESGQEGWASSKYIAKSNSDSLRTSTNKE 
Sbjct  1509841  EPTAESSIAFVAKKDDKVLIKDSSNGWYKIKAESGQEGWASSKYIAKSNSDSLRTSTNKE  1510020 
Query  62       KQVISNSLNMRNGAGTSYRVITVLKKGQKVEVISESNGWSKIKYDGRLGYVSSSYLGDVS  121 
                KQVISNSLNMRNGAGTSYRVITVLKKGQKVEVISESNGWSKIKYDGRLGYVSSSYLGDVS 
Sbjct  1510021  KQVISNSLNMRNGAGTSYRVITVLKKGQKVEVISESNGWSKIKYDGRLGYVSSSYLGDVS  1510200 
Query  122      NSTNKSKTKQVNTTSLNVRSGPNTSYGLLGKLPKGSKVEVISESNGWSKIKYNGKDAYVS  181 
                NSTNKSKTKQVNTTSLNVRSGPNTSYGLLGKLPKGSKVEVISESNGWSKIKYNGKDAYVS 
Sbjct  1510201  NSTNKSKTKQVNTTSLNVRSGPNTSYGLLGKLPKGSKVEVISESNGWSKIKYNGKDAYVS  1510380 
Query  182      SMYLSDVsqsnsdnssqsndkknTDKVVNTASLNVRSGPGSTYSKLGKVYKGSKVTVLSE  241 
                SMYLSDVSQSNSDNSSQSNDKKNTDKVVNTASLNVRSGPGSTYSKLGKVYKGSKVTVLSE 
Sbjct  1510381  SMYLSDVSQSNSDNSSQSNDKKNTDKVVNTASLNVRSGPGSTYSKLGKVYKGSKVTVLSE  1510560 
Query  242      SSGWAKINFNNKEAFVVGNYLSTSADTsnnnsnsnydnssnsngnnssssRQVNGMSGIS  301 
                SSGWAKINFNNKEAFVVGNYLSTSADTSNNNSNSNYDNSSNSNGNNSSSS QVNGMSGIS 
Sbjct  1510561  SSGWAKINFNNKEAFVVGNYLSTSADTSNNNSNSNYDNSSNSNGNNSSSSGQVNGMSGIS  1510740 
Query  302      GAKIDYKSLSYTLESHISKQVEKAASRGNVIAPSNRKSTPSPEFSTFSAQRTSSFVNASS  361 
                GAKIDYKSLSYTLESHISKQVEKAAS GNVIAPSNRKSTPSPEFSTFSAQRTSSFVNASS 
Sbjct  1510741  GAKIDYKSLSYTLESHISKQVEKAASGGNVIAPSNRKSTPSPEFSTFSAQRTSSFVNASS  1510920 
Query  362      SDIEYYLNPKNFTNTTKGMMQFLKINSYRDGIsesslnsylnglsssVFKNQGAAFINAA  421 
                SDIEYYLNPKNFTNTTKGMMQFLKINSYRDGISESSLNSYLNGLSSSVFKNQGAAFINAA 
Sbjct  1510921  SDIEYYLNPKNFTNTTKGMMQFLKINSYRDGISESSLNSYLNGLSSSVFKNQGAAFINAA  1511100 
Query  422      KKYNIDVVYLVSHAMWETAYGKSTLAQGQTLTSYKGQPLSKPVKVYNFFGIGAIDKSANV  481 
                KKYNIDVVYLVSHAMWETAYGKSTLAQGQTLTSYKGQPLSKPVKVYNFFGIGAIDKSANV 
Sbjct  1511101  KKYNIDVVYLVSHAMWETAYGKSTLAQGQTLTSYKGQPLSKPVKVYNFFGIGAIDKSANV  1511280 
Query  482      SGAEAAYSNGWTSVETTIDGSAKWISQNYVNSSKYNQNTIYKMKWNYDYTWHQYATDVNW  541 
                SGAEAAYSNGWTSVETTIDGSAKWISQNYVNSSKYNQNTIYKMKWNYDYTWHQYATDVNW 
Sbjct  1511281  SGAEAAYSNGWTSVETTIDGSAKWISQNYVNSSKYNQNTIYKMKWNYDYTWHQYATDVNW  1511460 
Query  542      ANGISGIME  550 
                ANGISGIME 
Sbjct  1511461  ANGISGIME  1511487 
 
Figure 3. 12. Alignment of the predicted protein sequence of r-acd with acd630 (A) and BLAST output 
from a search of the protein database (B).
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A 
fliC630         MRVNTNVSALIANNQMGRNVNGQSKSMEKLSSGVRIKRAADDAAGLAISEKMRAQIKGLD 60 
r-fliC          --------------------------MEKLSSGVRIKRAADDAAGLAISEKMRAQIKGLD 34 
                                          ********************************** 
 
fliC630         QAGRNVQDGISVVQTAEGSLEETGNILQRMRTLSLQSANEINNTEEREKIADELTQLKDE 120 
r-fliC          QAGRNVQDGISVVQTAEGSLEETGNILQRMRTLSLQSANEINNTEEREKIADELTQLKDE 94 
                ************************************************************ 
 
fliC630         IERISSSTEFNGKKLLDGTSSTIRLQVGASYGTNVSGTSNNNNEIKIQLVNTASIMASAG 180 
r-fliC          IERISSSTEFNGKKLLDGTSSTIRLQVGASYGTNVSGTSNNNNEIKIQLVNTASIMASAG 154 
                ************************************************************ 
 
fliC630         ITTASIGSMKAGGTTGTDAAKTMVSSLDAALKSLNSSRAKLGAQQNRLESTQNNLNNTLE 240 
r-fliC          ITTASIGSMKAGGTTGTDAAKTMVSSLDAALKSLNSSRAKLGAQQNRLESTQNNLNNTLE 214 
                ************************************************************ 
 
fliC630         NVTAAESRIRDTDVASEMVNLSKMNILVQASQSMLAQANQQPQGVLQLLG 290 
r-fliC          NVTAAESRIRDTDVASEMVNLSKMNILVQASQSMLAQANQQPQGVL---- 260 
                **********************************************     
B> ref|NC_009089.1|  Clostridium difficile 630 chromosome, complete genome 
Length=4290252 
 Features in this part of subject sequence: 
   flagellin subunit 
 Score =  457 bits (1175),  Expect = 1e-128, Method: Compositional matrix adjust. 
 Identities = 260/260 (100%), Positives = 260/260 (100%), Gaps = 0/260 (0%) 
 Frame = +3 
 
Query  1       MEKLSSGVRIKRAADDAAGLAISEKMRAQIKGLDQAGRNVQDGISVVQTAEGSLEETGNI  60 
               MEKLSSGVRIKRAADDAAGLAISEKMRAQIKGLDQAGRNVQDGISVVQTAEGSLEETGNI 
Sbjct  301020  MEKLSSGVRIKRAADDAAGLAISEKMRAQIKGLDQAGRNVQDGISVVQTAEGSLEETGNI  301199 
 
Query  1       LQRMRTLSLQSANEINNTEEREKIADELTQLKDEIERISSSTEFNGKKLLDGTSSTIRLQ  120 
               LQRMRTLSLQSANEINNTEEREKIADELTQLKDEIERISSSTEFNGKKLLDGTSSTIRLQ 
Sbjct  301200  LQRMRTLSLQSANEINNTEEREKIADELTQLKDEIERISSSTEFNGKKLLDGTSSTIRLQ  301379 
 
Query  121     VGASYgtnvsgtsnnnnEIKIQLVNTASIMASAGITTASIGSMKaggttgtdaaKTMVSS  180 
               VGASYGTNVSGTSNNNNEIKIQLVNTASIMASAGITTASIGSMKAGGTTGTDAAKTMVSS 
Sbjct  301380  VGASYGTNVSGTSNNNNEIKIQLVNTASIMASAGITTASIGSMKAGGTTGTDAAKTMVSS  301559 
 
Query  181     LDAALKSLNSSRAKLGAQQNRLESTQNNLNNTLENVTAAESRIRDTDVASEMVNLSKMNI  240 
               LDAALKSLNSSRAKLGAQQNRLESTQNNLNNTLENVTAAESRIRDTDVASEMVNLSKMNI 
Sbjct  301560  LDAALKSLNSSRAKLGAQQNRLESTQNNLNNTLENVTAAESRIRDTDVASEMVNLSKMNI  301739 
 
Query  241     LVQASQSMLAQANQQPQGVL  260 
               LVQASQSMLAQANQQPQGVL 
Sbjct  301740  LVQASQSMLAQANQQPQGVL  3017996 
 
 
Figure 3. 13. Alignment of the predicted protein sequence of r-fliC with fliC630 (A) and BLAST output from 
a search of the protein database (B).
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A 
cwp66-630       MKISKKIVSLLTMTFLTVTLYGNTSNASTKDTLTGSGRWETAIKISQAGWTKSESAVLVN 60 
r-5cwp66        --------------------------------ITGSGRWETAIKISQAGWTKSESAVLVN 28 
                                                :*************************** 
cwp66-630       DNSIADALSATPFAKAKDAPILLTQSNKLDSRTKAELKRLGVKNVYLIGGSIALSSEIEK 120 
r-5cwp66        DNSIADALSATPFAKAKDAPILLTQSNKLDSRTKAELKRLGVKNVYLIGGSIALSSEIEK 88 
                ************************************************************ 
cwp66-630       QLNAENINFERISGNSRYDTSLKLAEKLDREKSISKIVVVNGEKGLADAVSVGAIAAQEN 180 
r-5cwp66        QLNAENINFERISGNSRYDTSLKLAEKLDREKSISKIVVVNGEKGLADAVSVGAIAAQEN 148 
                ************************************************************ 
cwp66-630       MPIILSDSENGTEVADNFIDSKDIAKSYVIGGTYSISNSVERSLPNATRIAGSSRSETNA 240 
r-5cwp66        MPIILSDSENGTEVADNFIDSKDIAKSYVIGGTYSISNSVERSLPNATRIAGSSRSETNA 208 
                ************************************************************ 
cwp66-630       KIIEEFYKDTDIKNIYVTKDGTKNKNDLIDSLAVGVLAAKNSSPIVLAGNKLDTTQKDVL 300 
r-5cwp66        KIIEEFYKDTDIKNIYVTKDGTKNKNDLIDSLAVGVLAAK-------------------- 248 
                ****************************************                    
cwp66-630       NTKIIDKVTQIGGLGNENVVEDILDIQEETKYTVETIDELNAAIKRADANDIIKFKPEKE 360 
r-3cwp66        ------IVTQIGGLGNENVVEDILDIQEETKYTVETIDELNAAIKRADANDIIKFKPEKE 54 
                       ***************************************************** 
cwp66-630       KTINNSFSIETKKTVTIELDGRYRQTITLDIPNGKFNNYAEIEGGVKLKNIKNESLVNKG 420 
r-3cwp66        KTINNSFSIETKKTVTIELDGRYRQTITLDIPNGKFNNYAEIEGGVKLKNIKNESLVNKG 114 
                ************************************************************ 
cwp66-630       SIQDLDIYDENGCKIENESSGEIWFVTIVEEANDVYIVNSGDITKISNNSSSTIIRNSGN 480 
r-3cwp66        SIQDLDIYDENGCKIENESSGEIWFVTIVEEANDVYIVNSGDITKISNNSSSTIIRNSGN 174 
                ************************************************************ 
cwp66-630       IDTVTGKKEPAISGNKPKVNDTEKETKAARGLNPRVEACSVPKKDYVMITIPNSPKDSRY 540 
r-3cwp66        IDTVTGKKEPAISGNKPKVNDTEKETKAARGLNPRVEACSVPKKDYVMITIPNSPKDSRY 234 
                ************************************************************ 
cwp66-630       KIYYRVVYNKPYAMDVGDKINIGEWTVAPTDEEPFLEKAKNGCYVEAVEVNTSTKEVSRW 600 
r-3cwp66        KIYYRVVYNKPYAMDVGDKINIGEWTVAPTDEEPFLEKAKNGCYVEAVEVNTSTKEVSRW 294 
                ************************************************************ 
cwp66-630       GRTNATDDGF 610 
r-3cwp66        GRTNAT---- 300 
                ****** 
B> ref|NC_009089.1|  Clostridium difficile 630 chromosome, complete genome 
Length=4290252 
 
 Sort alignments for this subject sequence by:E value  Score  Percent identity                                        
Query start position  Subject start position 
 Features in this part of subject sequence: 
   cell surface protein 
 
 Score =  485 bits (1248),  Expect = 5e-137, Method: Compositional matrix adjust. 
 Identities = 247/248 (99%), Positives = 248/248 (100%), Gaps = 0/248 (0%) 
 Frame = -2 
Query  1        ITGSGRWETAIKISQAGWTKSESAVLVNDNSIADALSATPFAKAKDAPILLTQSNKLDSR  60 
                +TGSGRWETAIKISQAGWTKSESAVLVNDNSIADALSATPFAKAKDAPILLTQSNKLDSR 
Sbjct  3246740  LTGSGRWETAIKISQAGWTKSESAVLVNDNSIADALSATPFAKAKDAPILLTQSNKLDSR  3246561 
Query  61       TKAELKRLGVKNVYLIGGSIALSSEIEKQLNAENINFERISGNSRYDTSLKLAEKLDREK  120 
                TKAELKRLGVKNVYLIGGSIALSSEIEKQLNAENINFERISGNSRYDTSLKLAEKLDREK 
Sbjct  3246560  TKAELKRLGVKNVYLIGGSIALSSEIEKQLNAENINFERISGNSRYDTSLKLAEKLDREK  3246381 
Query  121      SISKIVVVNGEKGLADAVSVGAIAAQENMPIILSDSENGTEVADNFIDSKDIAKSYVIGG  180 
                SISKIVVVNGEKGLADAVSVGAIAAQENMPIILSDSENGTEVADNFIDSKDIAKSYVIGG 
Sbjct  3246380  SISKIVVVNGEKGLADAVSVGAIAAQENMPIILSDSENGTEVADNFIDSKDIAKSYVIGG  3246201 
Query  181      TYSISNSVERSLPNATRIAGSSRSETNAKIIEEFYKDTDIKNIYVTKDGTKNKNDLIDSL  240 
                TYSISNSVERSLPNATRIAGSSRSETNAKIIEEFYKDTDIKNIYVTKDGTKNKNDLIDSL 
Sbjct  3246200  TYSISNSVERSLPNATRIAGSSRSETNAKIIEEFYKDTDIKNIYVTKDGTKNKNDLIDSL  3246021 
Query  241      AVGVLAAK  248 
                AVGVLAAK 
Sbjct  3246020  AVGVLAAK  3245997 
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C> ref|NC_009089.1|  Clostridium difficile 630 chromosome, complete genome 
Length=4290252 Sort alignments for this subject sequence by:                                                           E 
value  Score  Percent identity Query start position  Subject start position 
 Features in this part of subject sequence: 
   cell surface protein 
 Score =  568 bits (1463),  Expect = 8e-162, Method: Compositional matrix adjust. 
 Identities = 299/299 (100%), Positives = 299/299 (100%), Gaps = 0/299 (0%) 
 Frame = -2 
Query  2        VTQIGGLGNENVVEDILDIQEETKYTVETIDELNAAIKRADANDIIKFKPEKEKTINNSF  61 
                VTQIGGLGNENVVEDILDIQEETKYTVETIDELNAAIKRADANDIIKFKPEKEKTINNSF 
Sbjct  3245915  VTQIGGLGNENVVEDILDIQEETKYTVETIDELNAAIKRADANDIIKFKPEKEKTINNSF  3245736 
Query  62       SIETKKTVTIELDGRYRQTITLDIPNGKFNNYAEIEGGVKLKNIKNESLVNKGSIQDLDI  121 
                SIETKKTVTIELDGRYRQTITLDIPNGKFNNYAEIEGGVKLKNIKNESLVNKGSIQDLDI 
Sbjct  3245735  SIETKKTVTIELDGRYRQTITLDIPNGKFNNYAEIEGGVKLKNIKNESLVNKGSIQDLDI  3245556 
Query  122      YDENGCKIENESSGEIWFVTIVEEANDVYIVNSGDITKisnnssstiirnsgniDTVTGK  181 
                YDENGCKIENESSGEIWFVTIVEEANDVYIVNSGDITKISNNSSSTIIRNSGNIDTVTGK 
Sbjct  3245555  YDENGCKIENESSGEIWFVTIVEEANDVYIVNSGDITKISNNSSSTIIRNSGNIDTVTGK  3245376 
Query  182      KEPAISGNKPKVNDTEKETKAARGLNPRVEACSVPKKDYVMITIPNSPKDSRYKIYYRVV  241 
                KEPAISGNKPKVNDTEKETKAARGLNPRVEACSVPKKDYVMITIPNSPKDSRYKIYYRVV 
Sbjct  3245375  KEPAISGNKPKVNDTEKETKAARGLNPRVEACSVPKKDYVMITIPNSPKDSRYKIYYRVV  3245196 
Query  242      YNKPYAMDVGDKINIGEWTVAPTDEEPFLEKAKNGCYVEAVEVNTSTKEVSRWGRTNAT  300 
                YNKPYAMDVGDKINIGEWTVAPTDEEPFLEKAKNGCYVEAVEVNTSTKEVSRWGRTNAT 
Sbjct  3245195  YNKPYAMDVGDKINIGEWTVAPTDEEPFLEKAKNGCYVEAVEVNTSTKEVSRWGRTNAT  3245019 
 
 
 
 
Figure 3. 14. Alignment of the predicted protein sequence of r-5́cwp66 and r-3́cwp66  with cwp66 630 (A) 
and BLAST output from a search of the protein database (B and C). 
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A 
cwp66-630       MKISKKIVSLLTMTFLTVTLYGNTSNASTKDTLTGSGRWETAIKISQAGWTKSESAVLVN 60 
r-cwp66         --------------------------------ITGSGRWETAIKISQAGWTKSESAVLVN 28 
                                                :*************************** 
cwp66-630       DNSIADALSATPFAKAKDAPILLTQSNKLDSRTKAELKRLGVKNVYLIGGSIALSSEIEK 120 
r-cwp66         DNSIADALSATPFAKAKDAPILLTQSNKLDSRTKAELKRLGVKNVYLIGGSIALSSEIEK 88 
                ************************************************************ 
cwp66-630       QLNAENINFERISGNSRYDTSLKLAEKLDREKSISKIVVVNGEKGLADAVSVGAIAAQEN 180 
 r-cwp66        QLNAENINFERISGNSRYDTSLKLAEKLDREKSISKIVVVNGEKGLADAVSVGAIAAQEN 148 
                ************************************************************ 
cwp66-630       MPIILSDSENGTEVADNFIDSKDIAKSYVIGGTYSISNSVERSLPNATRIAGSSRSETNA 240 
r-cwp66         MPIILSDSENGTEVADNFIDSKDIAKSYVIGGTYSISNSVERSLPNATRIAGSSRSETNA 208 
                ************************************************************ 
cwp66-630       KIIEEFYKDTDIKNIYVTKDGTKNKNDLIDSLAVGVLAAKNSSPIVLAGNKLDTTQKDVL 300 
r-cwp66         KIIEEFYKDTDIKNIYVTKDGTKNKNDLIDSLAVGVLAAKNSSPIVLAGNKLDTTQKDVL 268 
                ************************************************************ 
cwp66-630       NTKIIDKVTQIGGLGNENVVEDILDIQEETKYTVETIDELNAAIKRADANDIIKFKPEKE 360 
r-cwp66         NTKIIDKVTQIGGLGNENVVEDILDIQEETKYTVETIDELNAAIKRADANDIIKFKPEKE 328 
                ************************************************************ 
cwp66-630       KTINNSFSIETKKTVTIELDGRYRQTITLDIPNGKFNNYAEIEGGVKLKNIKNESLVNKG 420 
r-cwp66         KTINNSFSIETKKTVTIELDGRYRQTITLDIPNGKFNNYAEIEGGVKLKNIKNESLVNKG 388 
                ************************************************************ 
cwp66-630       SIQDLDIYDENGCKIENESSGEIWFVTIVEEANDVYIVNSGDITKISNNSSSTIIRNSGN 480 
r-cwp66         SIQDLDIYDENGCKIENESSGEIWFVTIVEEANDVYIVNSGDITKISNNSSSTIIRNSGN 448 
                ************************************************************ 
cwp66-630       IDTVTGKKEPAISGNKPKVNDTEKETKAARGLNPRVEACSVPKKDYVMITIPNSPKDSRY 540 
r-cwp66         IDTVTGKKEPAISGNKPKVNDTEKETKAARGLNPRVEACSVPKKDYVMITIPNSPKDSRY 508 
                ************************************************************ 
cwp66-630       KIYYRVVYNKPYAMDVGDKINIGEWTVAPTDEEPFLEKAKNGCYVEAVEVNTSTKEVSRW 600 
r-cwp66         KIYYRVVYNKPYAMDVGDKINIGEWTVAPTDEEPFLEKAKNGCYVEAVEVNTSTKEVSRW 568 
                ************************************************************ 
cwp66-630       GRTNATDDGF 610 
r-cwp66         GRTNAT---- 574 
 
 
 
 
 
 
 
 
B> ref|NC_009089.1|  Clostridium difficile 630 chromosome, complete genome 
Length=4290252 Sort alignments for this subject sequence by:                                                           
E value  Score  Percent identity  Query start position  Subject start position 
 Features in this part of subject sequence:  cell surface protein 
 Score = 1104 bits (2856),  Expect = 0.0, Method: Compositional matrix adjust. 
 Identities = 573/574 (99%), Positives = 574/574 (100%), Gaps = 0/574 (0%) 
 Frame = -2 
 
Query  1        ITGSGRWETAIKISQAGWTKSESAVLVNDNSIADALSATPFAKAKDAPILLTQSNKLDSR  60 
                +TGSGRWETAIKISQAGWTKSESAVLVNDNSIADALSATPFAKAKDAPILLTQSNKLDSR 
Sbjct  3246740  LTGSGRWETAIKISQAGWTKSESAVLVNDNSIADALSATPFAKAKDAPILLTQSNKLDSR  3246561 
Query  61       TKAELKRLGVKNVYLIGGSIALSSEIEKQLNAENINFERISGNSRYDTSLKLAEKLDREK  120 
                TKAELKRLGVKNVYLIGGSIALSSEIEKQLNAENINFERISGNSRYDTSLKLAEKLDREK 
Sbjct  3246560  TKAELKRLGVKNVYLIGGSIALSSEIEKQLNAENINFERISGNSRYDTSLKLAEKLDREK  3246381 
Query  121      SISKIVVVNGEKGLADAVSVGAIAAQENMPIILSDSENGTEVADNFIDSKDIAKSYVIGG  180 
                SISKIVVVNGEKGLADAVSVGAIAAQENMPIILSDSENGTEVADNFIDSKDIAKSYVIGG 
Sbjct  3246380  SISKIVVVNGEKGLADAVSVGAIAAQENMPIILSDSENGTEVADNFIDSKDIAKSYVIGG  3246201 
Query  181      TYSISNSVERSLPNATRIAGSSRSETNAKIIEEFYKDTDIKNIYVTKDGTKNKNDLIDSL  240 
                TYSISNSVERSLPNATRIAGSSRSETNAKIIEEFYKDTDIKNIYVTKDGTKNKNDLIDSL 
Sbjct  3246200  TYSISNSVERSLPNATRIAGSSRSETNAKIIEEFYKDTDIKNIYVTKDGTKNKNDLIDSL  3246021 
Query  241      AVGVLAAKNSSPIVLAGNKLDTTQKDVLNTKIIDKVTQIGGLGNENVVEDILDIQEETKY  300 
                AVGVLAAKNSSPIVLAGNKLDTTQKDVLNTKIIDKVTQIGGLGNENVVEDILDIQEETKY 
Sbjct  3246020  AVGVLAAKNSSPIVLAGNKLDTTQKDVLNTKIIDKVTQIGGLGNENVVEDILDIQEETKY  3245841 
Query  301      TVETIDELNAAIKRADANDIIKFKPEKEKTINNSFSIETKKTVTIELDGRYRQTITLDIP  360 
                TVETIDELNAAIKRADANDIIKFKPEKEKTINNSFSIETKKTVTIELDGRYRQTITLDIP 
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Sbjct  3245840  TVETIDELNAAIKRADANDIIKFKPEKEKTINNSFSIETKKTVTIELDGRYRQTITLDIP  3245661 
Query  361      NGKFNNYAEIEGGVKLKNIKNESLVNKGSIQDLDIYDENGCKIENESSGEIWFVTIVEEA  420 
                NGKFNNYAEIEGGVKLKNIKNESLVNKGSIQDLDIYDENGCKIENESSGEIWFVTIVEEA 
Sbjct  3245660  NGKFNNYAEIEGGVKLKNIKNESLVNKGSIQDLDIYDENGCKIENESSGEIWFVTIVEEA  3245481 
Query  421      NDVYIVNSGDITKisnnssstiirnsgniDTVTGKKEPAISGNKPKVNDTEKETKAARGL  480 
                NDVYIVNSGDITKISNNSSSTIIRNSGNIDTVTGKKEPAISGNKPKVNDTEKETKAARGL 
Sbjct  3245480  NDVYIVNSGDITKISNNSSSTIIRNSGNIDTVTGKKEPAISGNKPKVNDTEKETKAARGL  3245301 
Query  481      NPRVEACSVPKKDYVMITIPNSPKDSRYKIYYRVVYNKPYAMDVGDKINIGEWTVAPTDE  540 
                NPRVEACSVPKKDYVMITIPNSPKDSRYKIYYRVVYNKPYAMDVGDKINIGEWTVAPTDE 
Sbjct  3245300  NPRVEACSVPKKDYVMITIPNSPKDSRYKIYYRVVYNKPYAMDVGDKINIGEWTVAPTDE  3245121 
Query  541      EPFLEKAKNGCYVEAVEVNTSTKEVSRWGRTNAT  574 
                EPFLEKAKNGCYVEAVEVNTSTKEVSRWGRTNAT 
Sbjct  3245120  EPFLEKAKNGCYVEAVEVNTSTKEVSRWGRTNAT  3245019 
 
 
 
Figure 3. 15. Alignment of the predicted protein sequence of r-cwp66 with cwp66 630 (A) and BLAST 
output from a search of the protein database (B). 
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A 
srB             MKKLYRIVINIILVLVILYSGFNIYSKLTKYNHDTKISSELQKKEYKKEDLSKINSDFKF 60 
rsrB            -------------------------------NHDTKISSELQKKEYKKEDLSKINSDFKF 29 
                                               ***************************** 
 
srB             WLSVENTNINYPVVQSKDNSYYLDKDFYKKDSISGTLFMDYRNKSIDDKNIIIYGHNMKN 120 
rsrB            WLSVENTNINYPVVQSKDNSYYLDKDFYKKDSISGTLFMDYRNKSIDDKNIIIYGHNMKN 89 
                ************************************************************ 
 
srB             KTMFNNLNKFKDADFFKKNNKIKITLNGKEFLYDVFSAYIVESDYDYLKTNFNNESDYQN 180 
rsrB            KTMFNNLNKFKDADFFKKNNKIKITLNGKEFLYDVFSAYIVESDYDYLKTNFNNESDYQN 149 
                ************************************************************ 
 
srB             YINDITSKSLYKSPIKVNSNDKIVTLSTCTYEFDDARMVIHGRLI 225 
rsrB            YINDITSKSLYKSPIKVNSNDKIVTLSTCTYEFDDARMVIHGR-- 192 
                *******************************************   
 
 
 
 
 
                 
B> ref|NC_009089.1|  Clostridium difficile 630 chromosome, 
complete genome 
Length=4290252  Sort alignments for this subject sequence by:                                                           
E value  Score  Percent identity   Query start position  Subject start position 
 Features in this part of subject sequence: 
   putative sortase B 
 
 Score =  323 bits (829),  Expect = 1e-88, Method: Compositional matrix adjust. 
 Identities = 192/192 (100%), Positives = 192/192 (100%), Gaps = 0/192 (0%) 
 Frame = +3 
 
 
 
Query  1        NHDTKISSELQKKEYKKEDLSKINSDFKFWLSVENTNINYPVVQSKDNSYYLDKDFYKKD  60 
                NHDTKISSELQKKEYKKEDLSKINSDFKFWLSVENTNINYPVVQSKDNSYYLDKDFYKKD 
Sbjct  3148470  NHDTKISSELQKKEYKKEDLSKINSDFKFWLSVENTNINYPVVQSKDNSYYLDKDFYKKD  3148649 
 
Query  61       SISGTLFMDYRNKSIDDKNIIIYGHNMKNKTMfnnlnkfkdadffkknnkikitlnGKEF  120 
                SISGTLFMDYRNKSIDDKNIIIYGHNMKNKTMFNNLNKFKDADFFKKNNKIKITLNGKEF 
Sbjct  3148650  SISGTLFMDYRNKSIDDKNIIIYGHNMKNKTMFNNLNKFKDADFFKKNNKIKITLNGKEF  3148829 
 
Query  121      LYDVFSAYIVESDYDYLKTNFNNESDYQNYINDITSKSLYKSPIKVNSNDKIVTLSTCTY  180 
                LYDVFSAYIVESDYDYLKTNFNNESDYQNYINDITSKSLYKSPIKVNSNDKIVTLSTCTY 
Sbjct  3148830  LYDVFSAYIVESDYDYLKTNFNNESDYQNYINDITSKSLYKSPIKVNSNDKIVTLSTCTY  3149009 
 
Query  181      EFDDARMVIHGR  192 
                EFDDARMVIHGR 
Sbjct  3149010  EFDDARMVIHGR  3149045 
 
 
 
Figure 3. 16. Alignment of the predicted protein sequence of r-sortaseB with sortaseB630 (A) and BLAST 
output from a search of the protein database (B). 
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3.2.3 Expression of the target proteins 
           One positive clone for each target was selected and plasmid DNA was 
purified from cultures of E. coli NovaBlue cells. Purified plasmid DNA was 
transformed into competent E. coli BL21 (DE3), the strain to be used for 
expression, and colonies from overnight agar cultures were picked for target 
expression studies. Each was tested in the presence or absence of IPTG inducer 
(Figure 3.17). Dot blots from the cultures were analysed by probing for the S.tag 
sequence. This revealed that the recombinant proteins could be expressed even 
without IPTG. Expression of Cwp84 in dot blots showed weak signal in the absence 
of IPTG and after the addition of the inducer. Whilst signal intensity for many other 
targets was good under non-induced and induced conditions, expression of the N 
terminal part of Cwp66 showed some dependence upon IPTG (column 3) as did 
expression of FbpA (column 4).  
          Specifically, GroEL was expressed even without IPTG and the signal from dot 
blots for both cultures was intense. Column 6 shows FliD expression which can be 
described as semi intense in signal under the two experimental conditions. In the 
next column, the expressed protein was Acd where IPTG did not appear necessary 
for protein production. In the next three columns, (FliC, C-terminus of Cwp66 and 
Sortase B) very good signal strength was observed. The last column shows that 
expression of the full-length Cwp66 in the presence IPTG was stronger than in the 
absence of inducer (Figure 3.16).   
             Using this information, large cultures of BL21 (DE3) cells were prepared for 
expression of each target, analysis in Western blots and purification of the target 
proteins. Before purification, a Western blot was run for all extracted samples 
from the bacterial cells. The data are shown in Figures 3.18 and 3.19.  
Chapter 3 Results 
 
135 
In Figure 3.18, lane 1 shows the expression of Cwp84 but no band indicating 
the presence of the recombinant protein can be seen. In contrast, lane 2 shows a 
strong band at a molecular weight over 22 kDa corresponding to CspA (Table 3.2; 
predicted molecular weigh 27.5 kDa).  In the same Figure, a band just under 50 kDa 
in lane 3 shows expression of the N-terminus of Cwp66, a recombinant protein 
with a predicted molecular weight of 47.1 kDa (Table 3.2). Lane 4 shows that like 
lane 1, no signal was detected to show expression of a protein corresponding to 
FbpA. In lanes 5 and 6 of Figure 3.18, two bands in excess of 64 kDa show the 
expression of GroEL and FliD (72.2 and 75.8 kDa; Tables 3.2).  
Figure 3.19 shows the analysis of bacterial extracts for evidence of the 
expression of other target proteins. In lane 1, there was no evidence for the 
successful expression of Acd but a band of good signal strength can be seen in lane 
2 (FliC, 48 kDa; Table 3.2). Two strong bands are also visible in lanes 3 and 4 
showing the successful expression of the C-terminus of Cwp66 and Sortase B 
respectively (predicted molecular weights of 53.9 and 43.4 kDa, Table 3.2). The last 
lane of Figure 3.19 shows a band over 64 kDa likely to be Cwp66. 
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Figure 3.17. Dot blot analysis of the expression of target proteins in E. coli BL21(DE3) in the presence or 
absence of IPTG.  
After application of bacterial extracts to the membrane and blocking, recombinant proteins were 
detected with anti S-tag antibody, anti-mouse-HRP and TMB substrate.
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Figure 3. 18. Western blot analysis of extracts of E. coli BL21(DE3) cells expressing six target proteins   
From the left: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lane 1, Cwp84; lane 2, 
CspA; lane 3, N-terminus of Cwp66; lane 4, FbpA; lane 5, GroEL; lane 6, FliD.  
After transfer and blocking, recombinant proteins were detected with anti S-tag antibody, anti-mouse-
HRP and TMB substrate. 
   
 
 
        
 
 
Figure 3. 19.Western blot analysis of extracts of E. coli BL21(DE3) cells expressing five target proteins  
From the left: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lane 1, Acd; lane 2, 
FliC; lane 3, C-terminus of Cwp66; lane 4, SortaseB; lane 5, Cwp66. 
After transfer and blocking , recombinant proteins were detected with anti S-tag antibody, anti mouse-
HRP and TMB substrate.  
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Inserts of 6 sequences – cwp84, fbpA, acd, fliC, 3’ cwp66 and cwp66 – were 
not expressed particularly well from the pET32 vector system, as judged by 
Western blotting. In an attempt to overcome this problem, plasmid DNA was 
transformed into E. coli BL21(DE3) pLysS and C43 (DE3)  competent cells. Results 
from both the new expression hosts is shown in Figure 3.20 and 3.21. In Figure 
3.20, lanes 1 and 2 are samples from bacterial expressing Cwp84 and FbpA; the 
blots do not show signals that could be attributed to the recombinant proteins. 
Lane 3 in Figure 3.20 shows a band over 64 kDa that could be the recombinant 
Acd.  In contrast, there is clear evidence of a band in lane 4 of same Figure close to 
50 kDa that might represent FliC (predicted molecular weight 48 kDa, Table 3.2). 
The results in lane 5 are more complex but amongst the many bands, a particularly 
strong signal can be seen a molecular weight over 50 kDa. As with FliC expression, 
single, clear band appears in lane 6 of Figure 3.20 that might represent Cwp66 
(predicted molecular mass 83.3 kDa).  
Further attempts were made to express these more problematic target 
proteins by transforming the relevant constructs into E. coli C43 (DE3). The results 
of expression experiments and Western blotting analysis are shown in Figure 3.21. 
Once again, there was no evidence of successful expression of Cwp84 and FbpA, 
(lanes 1, 2 and 5) and a clear band over 64 kDa (lane 3) suggested that 
recombinant Acd had been produced. Lanes 4 and 6 illustrate the production of 
the C-terminus of Cwp66 with good signal strength from a protein over 50 kDa in 
molecular weight. In Figure 3.21 two separate transformants were prepared for 
constructs of FbpA (lanes 2 and 5) and C-terminus of Cwp66 (lanes 4 and 6).  
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Figure 3. 20. Western blot analysis of extracts of E. coli BL21(DE3) pLysS expressing clostridial target 
proteins 
From the left: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lane 1, Cwp84; lane 2, 
FbpA; lane 3, Acd; lane  4, FliC; lane 5, C-terminus of Cwp66; lane 6, Cwp66 
After transfer and blocking, recombinant proteins were detected with anti S-tag antibody, anti mouse-
HRP and TMB substrate.  
 
 
 
 
Figure 3.21. Western blot analysis of extracts of E. coli C43(DE3) expressing clostridial target proteins 
From the left: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lane 1, Cwp84; lane 2, 
FbpA(1
st
 transformant); lane  3, Acd; lanes 4 and 6(two transformants of target),  C-terminus of Cwp66; 
lane 5,  FbpA(2
nd
 transformants) 
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3.2.4 Purification of recombinant proteins 
Recombinant proteins produced from the pET32 expression system in E. coli 
strains BL21(DE3), BL21(DE3) pLysS and C43(DE3)]  were purified by Ni-chelation  
chromatography. For each protein, lysates were produced from cultures induced 
overnight with IPTG and these were passed through a 5 ml pre-packed column that 
had been equilibrated previously with binding buffer. The columns were washed 
with binding buffer and attached proteins were eluted with 200-300 mM imidazole 
in 10 fractions. Fractions from each column were analysed by SDS-PAGE. 
 
3.2.4.1 Purification of Cwp84 
       Cwp84 was transformed into all three E. coli strains BL21(DE3), BL21(DE3) 
pLysS and C43(DE3) but a recombinant protein of the expected protein molecular 
weight (102 kDa) could not be detected under any of the experimental conditions 
tested.  
 
3.2.4.2 Purification of recombinant CspA 
In order to obtain sufficient recombinant CspA for further experimentation, 
different culture volumes were tested. Lysates from 100 and 200 ml cultures 
yielded better results than bigger culture volumes. For cultures of these sizes, 
lysates were passed through a column that had been first equilibrated with binding 
buffer. The column was washed with 50 ml of this buffer and further treated with 
50 ml of binding containing 20 mM imidazole to remove proteins that were loosely 
associated. Proteins were then recovered with higher concentrations of imidazole. 
Figure 3.22 shows the purification of CspA from lysate of a 100 ml culture. The 
flow through after loading  (lane 1) contained a significant number of proteins and 
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a range of species were eliminated from the column by washing (lanes 2 and 3). 
Elevation of the imidazole concentration to 200 mM initially recovered a protein of 
the predicted molecular weight along with contaminating species (lane 4). 
Subsequent fractions contained a high concentration of the recombinant protein 
with modest contamination (lanes 5 and 6) before concentration declined (lanes 7 
to 9). The molecular weight of the purified protein (27 kDa) was consistent with 
that expected for CspA with the purification and detection tags encoded by pET32 
(Table 3.2).  
     In an effort to enhance the purity of the protein and its concentration, the 
method was repeated with extra washing using buffer containing imidazole. Figure 
3.23 shows that extensive washing with imidazole rising to 100 mM essentially 
eliminated contaminating proteins; CspA was then eluted in high concentration 
with 200 mM imidazole.  In Figure 3.23, the protein-charged column was washed 
with binding buffer containing 40 mM imidazole (lane 4), 60 mM (lanes 5 to 10), 
and 100 mM (lanes 11 to 16). CspA was eluted with a sharp profile on raising the 
imidazole to 200 mM (lanes 17 to 21). Those fractions that appeared to contain a 
single band for CspA (Figure 3.22 lanes 5 to 9; Figure 3.23 lanes 18 to 21) were 
pooled and dialysed in preparation for later experiments. 
 
3.2.4.3 Purification of recombinant N-terminus of Cwp66 
      Based on the primer design and tags present in pET32, the expressed protein 
was expected to have a molecular weight of 47.1 kDa (Table 3.2). To purify this 
protein, lysates prepared from induced cultures of different volumes were applied 
to an equilibrated column. Figure 3.23 shows that a wide range of proteins were 
washed from the column with binding buffer (lane 1) and 40 mM imidazole (lane 
2). The recombinant protein was eluted on switching to 200 mM imidazole. Initial 
recoveries were contaminated with other proteins (lane 4) but purity improved in 
later fractions (lane 5).  An intense band with a molecular weight close to 50 kDa 
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was consistent with that predicted for the purified N-terminal region of Cwp66. 
The purity of the sample in lane 5 was judged sufficient for the purposes of later 
experiments. 
3.2.4.4 Purification of FbpA 
     None of the E. coli strains tested expressed a protein likely to be FbpA 
(predicted molecular weight of 85.2 kDa; Table 3.2). 
 
3.2.4.5 Purification of GroEL 
      As in other purifications, lysates from induced cultures expressing GroEL were 
applied to columns and eluted with different concentration of imidazole in binding 
buffer. The impact of different concentrations of imidazole were explored but the 
best results were obtained using 200 mM imidazole in binding buffer. Figure 3.25 
shows the presence of a prominent protein over 64 kDa in molecular weight, the 
fraction loaded to lane 6 showing better purity than that eluted earlier (lane 5). 
The expected molecular weight for this protein is 72.2 kDa (Table 3.2). This is 
consistent with the prominent protein visible in lane 6 of Figure 3.25. 
3.2.4.6  Purification of FliD: 
      The expected band for FliD was 75.8 kDa (Table 3.2) and a protein of this size 
was obtained by purification on Ni-chromatography. Two lysates were run on 
columns to purify the recombinant FilD using different concentrations of imidazole 
in the binding buffer. Figure 3.26 shows a stepwise elution of FliD with different 
concentration of imidazole from 60 to 300 mM over 30 fractions. This Figure 
reveals that although elution of FliD started at 60 mM imidazole, 200 mM of 
imidazole was the best concentration with intense bands evident in SDS-PAGE. 
Lane 1 shows that a great many proteins were present in the original lysate but 
amongst these is a clear band that could be FliD (75.8 kDa). The column flow 
through is shown in lane 2 and washing with 40 mM imidazole (lane 3) shows no 
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evidence of release of a protein similar in size to that expected for FliD. A shift to 
60 mM imidazole in binding buffer initially showed no sign of release of FliD (lanes 
4 and 5) but a protein that could be the recombinant proteins appears in later 
fractions (lanes 6-9). The next 7 fractions (lanes 10-16) were eluted with 100 mM 
imidazole in binding buffer. Although some FliD  may be lost from the column, 
contaminants of lower molecular weight are also eliminated. Increasing the 
concentration of   imidazole to 200 mM shows the recovery of a protein of the 
predicted molecular weight of FliD (lanes 17 to 27). The recombinant protein is 
reasonably pure, although slight contamination with a species of around 36 kDa 
can be seen in some lanes. The final elution step used buffer containing 300 mM 
imidazole. FliD was recovered (lanes 28 to 33) but the concentration was low.  
   Based on this experiment, a second column was loaded with the bacterial 
lysate, washed with binding buffer containing 40 mM imidazole and eluted with 
200 mM imidazole. Figure 3.27 shows the success of this protocol; FliD was 
isolated in reasonable purity. Lanes 3 to 9 show the fractions eluted with 200 mM 
imidazole in binding buffer. Immediately after the change of buffer, no proteins 
were released (lane 3). Following this, proteins appeared that were slightly lower 
in molecular weight than FliD (lane 4), resolving to FliD and a smaller protein (lane 
5). Thereafter, the dominant species was FliD (lanes 6-9).  
3.2.4.7 Purification of Acd:  
      The lysates of bacterial cultures expressing Acd were applied into the column in 
different volumes and under different conditions but it proved impossible to purify 
the recombinant protein. This was consistent with the very low signal obtained in 
dot blots (Figure 3.17).  
 
Chapter 3 Results 
 
143 
3.2.4.8 Purification of FliC: 
      Recombinant FliC was purified in the same way as other recombinant proteins; 
the loaded column was washed first with binding buffer, and then 40 mM 
imidazole before a solution of binding buffer with 200 mM imidazole was used to 
elute the attached protein. Figures 3.28 and 3.29 show a clear band just less than 
50 kDa which is the expected size for FliC (48.0 kDa, Table 3.2). Both Figures show 
that FliC was not eluted in a completely pure state. In Figure 3.28, lanes 1 and 2 
show samples for the bacterial lysate  and the column flow through. Washing the 
column with binding buffer failed to release protein (lane 3) while lane 4 shows a 
range of proteins were washed out with 40 mM imidazole. Other lanes in Figure 
3.28 illustrate elution of attached proteins with 200 mM imidazole. 
        Although a prominent protein of the right molecular weight can be seen in 
lane 7, there are many other contaminants present. The later fraction (lane 8) 
shows a relatively pure band close to 50 kDa but the concentration is low. Another 
column was set up to attempt to purify FliC using the same conditions (Figure 
3.29). SDS-PAGE analysis of all samples from the second attempt showed only one 
fraction (Figure 3.29, lane 18) with a band likely to correspond to the recombinant 
protein.  
3.2.4.9 Purification of C-terminus of Cwp66 
       In purifying the C-terminal region of Cwp66, a protein of 53.9 kDa was sought 
(Table 3.2).  The loaded column was first washed with binding buffer and then 40 
mM imidazole (each 50 ml) to remove loosely-associated proteins (samples not 
shown). Buffer containing 200 mM imidazole was then used for elution. Figure 
3.30, lanes 1 to 8 shows analysis of fractions eluted in this way. Although the 
prominent band evident in these samples was higher in molecular weight than 
expected, samples shown in lanes 4 to 7 were pooled and dialysed in preparation 
for the next phases of the analysis, given that these fractions contained fewer 
contaminating proteins than others (eg the species evident in lane 8). 
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3.2.4.10 Purification of Sortase B 
        Sortase B is another protein which was expressed and purified by Ni 
chromatography. Table 3.2 shows the expected size for Sortase B should be 43.4 
kDa. SDS-PAGE analysis of samples from purification of recombinant Sortase B can 
be seen in Figure 3.31. The equilibrated column was loaded with bacterial lysate 
(lane 1) and washed with binding buffer (50 ml; lane 2).  The original lysate shows 
a strong sharp band under 50 kDa that might represent Sortase B. Washing with 
binding buffer (lane 2) removed a range of unbound proteins of variable molecular 
weight and this was enhanced by washing with 40 mM imidazole (lane 3). 
Preliminary experiments with eluting concentrations of imidazole between 100 
and 300 mM showed (data not shown) 200 mM imidazole to be the optimum 
concentration to elute Sortase B. Therefore this solution was used (lanes 4 to 9) to 
recover 6 fractions containing a protein of the expected mass. These fractions 
were mixed and dialysed for the next step.    
3.2.4.11 Purification of Cwp66 
     The last recombinant protein to be expressed and purified was Cwp66 
(predicted mass of 83.3 kDa, Table 3.2). Purification of this recombinant protein 
was carried out using very similar methods to those already described. The 
equilibrated column was firstly was loaded with bacterial lysate and then washed 
with binding buffer. Lane 1 in Figure 3.32 shows a strong band of the expected 
molecular weight for recombinant Cwp66 was present in the original lysate and 
that this was released from the column by washing with binding buffer (lane 2) and 
40 mM imidazole (lane 3). After washing, the column was eluted with 200 mM 
imidazole to collect fractions. Lanes 4 to 9 in Figure 3.32 show the analysis of 
fractions 9-14 from this elution. A prominent band of a size consistent with Cwp66 
can be seen. These fractions were pooled and dialysed for the next step. 
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Figure 3. 22. SDS-PAGE analysis of the purification of recombinant CspA  
From the left: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lane 1; flow through 
from loading of lysate to the column; lane 2; washings recovered with binding buffer; lane 3; washings 
recovered with 40mM imidazole in binding buffer; lanes 4 to 9, fractions eluted with 200 mM imidazole in 
binding buffer.  
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Figure 3. 23. SDS-PAGE analysis of the purification of recombinant CspA 
Upper gel: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lane 1, original lysate;  
lane 2, flow through from the column on loading; lane 3, washings recovered with binding buffer; lane 4, 
washings recovered with 40 mM imidazole; lanes 5 to 9, washings recovered with 60 mM imidazole. 
Middle gel:  M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lane 10, washings 
recovered with 60 mM imidazole; lanes 11 to 16, washings recovered with 100 mM imidazole; lanes 17 to 
18, fractions eluted with 200 mM imidazole 
Lower gel: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lanes 19 to 21, fractions 
eluted with 200 mM imidazole.
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Figure 3. 24. SDS-PAGE analysis of the purification of recombinant N-terminus Cwp66 
From the left: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lane 1; washings 
recovered with binding buffer; lane 2, washings recovered with 40 mM imidazole in binding buffer; lanes 
3 to 6, fractions eluted with 200 mM imidazole in binding buffer. 
 
 
 
 
 
 
Figure 3. 25. SDS-PAGE analysis of the purification of recombinant GroEL 
From the left: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lane 1, original lysate; 
lane 2; washings recovered with binding buffer lane 3, washings recovered with 40 mM imidazole in 
binding buffer; lanes 4 to 6; fractions eluted with 200 mM imidazole in binding buffer.
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Figure 3. 26. SDS-PAGE analysis of the purification of recombinant FliD  
Top gel: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lane 1, sample before 
application to the column; lane 2, flow through from the column after loading; lane 3, washings 
recovered with 40 mM imidazole; lanes 4 to 9, washings recovered with 60 mM imidazole 
Second gel: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lanes 10 to 16, washings 
recovered with 100 mM imidazole, lanes 17 to 18, fractions eluted with 200 mM imidazole 
Third gel: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lanes 19 to 27, fractions 
eluted with 200 mM imidazole. 
Bottom gel: M, SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lanes 28 to -33, 
fractions elution with 300 mM imidazole.
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Figure 3. 27. SDS-PAGE analysis of purification of recombinant FliD 
From left: M, SeeBlue Plus2 Pre-Stained molecular weight markers (Invitrogen); lane 1, flow through from 
the column after loading; lane 2, washings recovered with 40 mM imidazole ; lanes 3 to 9, fractions  
eluted with 200 mM imidazole.  
 
 
 
 
Figure 3. 28. SDS-PAGE analysis of purification of recombinant FliC 
From  left: M, SeeBlue Plus2 Pre-Stained molecular weight markers (Invitrogen); lane 1, original lysate; 
lane 2, flow through from the column after loading ; lane 3, washings recovered with binding buffer; lane 
4, washings recovered with 40mM imidazole; lanes 5 to 9, fractions eluted with 200 mM imidazole.
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Figure 3. 29. SDS-PAGE analysis of purification of recombinant FliC 
Gel 1: From  left: M, SeeBlue Plus2 Pre-Stained molecular weight markers (Invitrogen); lane 1, original 
lysate; lane 2, washing recovered with binding buffer; lane 3, washing recovered with 40mM imidazole; 
lanes 4 to 9, fractions eluted with 200 mM imidazole.  
Gel2; From left: M, SeeBlue Plus2 Pre-Stained molecular weight markers (invitrogen); lanes 11 to 19, 
fractions recovered  with 200 mM imidazole.
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Figure 3. 30. SDS-PAGE analysis of purification of recombinant C-terminus Cwp66 
From left: M, SeeBlue Plus2 Pre-Stained molecular weight markers (Invitrogen); lanes 1 to 8,   fractions 
eluted with 200 mM imidazole (fractions 15-22). 
 
 
 
 
 
Figure 3. 31. SDS-PAGE analysis of purification of recombinant Sortase B 
From left: M, SeeBlue Plus2 Pre-Stained molecular weight markers (Invitrogen); lane 1, original lysate; 
lane 2, washing recovered   with binding buffer; lane 3, washing recovered  with 40 mM imidazole; lanes  
5 to 9,  eluted fractions with 200 mM midazole( fractions 1-6).
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Figure 3. 32. SDS-PAGE analysis of purification of recombinant Cwp66 
From left: M, SeeBlue Plus2 Pre-Stained molecular weight markers (Invitrogen); lane 1, original lysate; 
lane 2, washing recovered with binding buffer; lane 3, washing recovered with 40 mM imidazole; lane 4-
9,  eluted fractions  with 200 mM midazole(fractions 9 to 14).
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3.2.5 Mass spectrometry of recombinant proteins 
 
     To confirm the identities of the expressed proteins and their similarity with the 
intended target proteins from C. difficile 630, a sample of each of the purified 
proteins was analysed by mass spectrometry. The single band related to each 
target was cut from an SDS-PAGE gel and sent to a central proteomic facility at the 
University of Glasgow where an LC-MS/MS system was used to analyse the 
samples. Mascot search results showed that most matched successfully with 
proteins from C. difficile 630. However the sequence coverage was variable for 
different recombinant proteins which could explained by their lysine content. 
Hence, in this phase of the project, all the targets which were successfully 
expressed and purified were confirmed as the intended proteins and were related 
to their counterparts from C. difficile 630 with the exception of those proteins 
(Cwp84, FbpA and Acd) that could not be expressed in an E. coli host. The following 
Figures show the results from mass spectrometry analysis of the expressed targets 
(Figures 3.33-3.40). In all Figures, the matched peptides are in red and bold text. 
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Match to: gi|126698469 Score: 120 
cold shock protein [Clostridium difficile 630] 
Found in search of F:\Naziri-7-12-9.wiff 
    
Nominal mass (Mr): 7448; Calculated pI value: 4.75 
NCBI BLAST search of gi|126698469 against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Clostridium difficile 630 
gi|115249906 from Clostridium difficile 630 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 25% 
 
Matched peptides shown in Bold Red 
 
     1 MKNGIVKWFN NEKGFGFISV EGEDDVFVHF SAIQNDGYKT LEEGEKVSFD  
    51 ITQGNRGPQA ENVNRI 
______________________________________________________________________________________________________________ 
Figure 3. 33. Result of Mascot search using data from mass spectrometry analysis of recombinant CspA.  
The sequence in bold red text shows peptides identified in the analysis that match the sequence of the 
target protein from C. difficile 630. The data shows that 25% of the sequence of native CspA could be 
recovered from the recombinant protein.  
 
 
Match to: gi|11066029 Score: 786 
Cwp66 [Clostridium difficile] 
Found in search of F:\Naziri-7-12-9.wiff 
Nominal mass (Mr): 66895; Calculated pI value: 5.19 
NCBI BLAST search of gi|11066029 against nr 
Unformatted sequence string for pasting into other applications 
Taxonomy: Clostridium difficile 
Fixed modifications: Carbamidomethyl (C)Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 20% 
Matched peptides shown in Bold Red 
      1 MNISKQIVSL LTMTFLTVTL YGNTSNASTK DTLTGSGRWE TAIKISQAGW  
     51 TKSESAVLVN DNSIADALSA TPFAKAKDAP ILLTQSNKLD SRTKAELKRL  
   101 GVKNVYLIGG SIALSSEIEK QLNAENINFE RISGNSRYDT SLKLAEKLDR  
   151 EKSISKIVVV NGEKGLADAV SVGAIAAQEN MPIILSDSEN GTEVADNFID  
   201 SKDIAKSYVI GGTYSISNSV ERSLPNATRI AGSSRSETNA KIIEEFYKDT  
   251 DIKNIYVTKD GTKNKNDLID SLAVGVLAAK NSSPIVLAGN KLDTTQKDVL  
   301 NTKIIDKVTQ IGGLGNENVV EDILDIQEET KYTVETIDEL NAAIKRADAN  
   351 DIIKFKPEKE KTINNSFSIE TKKTVTIELD GRYRQTITLD IPNGKFNNYA  
   401 EIEGGVKLKN IKNESLVNKG SIQDLDIYDE NGCKIENESS GEIWFVTIVE  
   451 EANDVYIVNS GDITKISNNS SSTIIRNSGN IDTVTGKKEP AISGNKPKVN  
   501 DTEKETKAAR GLNPRVEACS VPKKDYVMIT IPNSPKDSRY KIYYRVVYNK  
   551 PYAMDVGDKI NIGEWTVAPT DEEPFLEKAK NGCYVEAVEV NTSTKEVSRW  
   601 GRTNATDDGF 
_____________________________________________________________________  
Figure 3. 34.  Result of Mascot search using data from mass spectrometry analysis of recombinant N-
terminus of Cwp66.  
The sequence in bold red text shows peptides identified in the analysis that match the sequence of the 
target protein from C. difficile 630. The data shows that 20% of the sequence of native N-terminus of 
Cwp66 could be recovered from the recombinant protein. 
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Match to: gi|126697767 Score: 1583 
60 kDa chaperonin [Clostridium difficile 630] 
Found in search of F:\Naziri-7-12-9.wiff 
Nominal mass (Mr): 57735; Calculated pI value: 4.74 
NCBI BLAST search of gi|126697767 against nr 
Unformatted sequence string for pasting into other applications 
Taxonomy: Clostridium difficile 630 
Links to retrieve other entries containing this sequence from NCBI Entrez: 
gi|118597108 from Clostridium difficile 630 
gi|115249204 from Clostridium difficile 630 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 45% 
Matched peptides shown in Bold Red 
   1 MAKEIKFSEE TRRALEAGVN KLADTVKVTL GPKGRNVILD KKFGSPLITN  
    51 DGVTIAKEIE LEDRFENMGA QLVKEVATKT NDVAGDGTTT ATVLAQAIIR  
   101 EGLKNVTAGA NPILLRKGIQ KAVTVAVEEL KNQSRIVETQ EAISQVASIS  
   151 AGDEEVGKLI AEAMEIVGKD GVITVEESQT MNTELDAVEG MQFDRGFVSA  
   201 YMVTDVDKME AVLNDPYILI TDKKISNIQE LLPVLEQIVQ QGKKLLIIAE  
   251 DVEGEALSTL VVNKLRGTFD VVAVKAPGFG DRRKEMLQDI AILTGAQVIS  
   301 EELGYDLKEA DLSMLGRASS VKVTKESTTI VDGSGDKKAI EDRVTQIKHQ  
   351 VEQTTSDFDR EKLMERLAKL AGGVAVVKVG AATEVELKER KLRIEDALNA  
   401 TRAAVEEGIV AGGGTAFVSV IPAIGTLIES LEGEVKLGAQ IVKKALEEPL  
   451 RQIAINAGLE GAVIVQNVVN SEAETGFDAL NEKYVNMIEA GIVDPTKVSR  
   501 SALQNAASIA STFLTTEAAV ADLPEKEDAG MPGMGGGMPG MM 
Figure 3. 35. Result of Mascot search using data from mass spectrometry analysis of recombinant GroEL  
The sequence in bold red text shows peptides identified in the analysis that match the sequence of the 
target protein from C. difficile 630. The data shows that 45% of the sequence of native GroEL could be 
recovered from the recombinant protein.  
 
 
 
Match to: gi|126697808 Score: 1515 
flagellar cap protein [Clostridium difficile 630] 
Found in search of F:\Naziri-7-12-9.wiff 
Nominal mass (Mr): 56099; Calculated pI value: 5.37 
NCBI BLAST search of gi|126697808 against nr 
Unformatted sequence string for pasting into other applications 
Taxonomy: Clostridium difficile 630 
Links to retrieve other entries containing this sequence from NCBI Entrez: 
gi|13324551 from Clostridium difficile 
gi|115249245 from Clostridium difficile 630 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 60% 
Matched peptides shown in Bold Red 
     1 MSSISPVRVT GLSGNFDMEG IIEASMIRDK EKVNKAKQDQ QIVKWKQEIY  
    51 RDIIKESKNL YDKYLNGDSP NSITNKKAYS ATRITSSDES IIVAKGSAGA  
   101 EKINYQFAVS QMAEPAKVTI KLNSSDPIVQ QFPPNASGAS SLNIGGVNIP  
   151 ISEQDTTSTI VSKINSLCAD NDIRASYSEM TGELIISRKQ TGSSSDIDLK  
   201 VIGNDSLAGQ IASDNGITFT TDASGTKSAV VYGKNLEADV TDDQGRVTHI  
   251 SKEQNSFKID NIDYNVNSKG SAKLVSVTDT EEATKNMKAF VDDYNALMDK  
   301 VYGLVTTKKS KDYPPLTDEQ KDDMTTEEIE KWEKKAKEGI LRNDDELRAF  
   351 VEDIQSMFFG DADTIIALRK LGISEHENYN KKGQISFNAD TFSKALIDDS  
   401 DKVYKALAGY SSNYDDKGMF EKLKKIVFEY SGSSASKLTK KAGMENSSSA  
   451 SQNVYSKQIA EQERNISRLV EKMNDKEKRL YAKYSALESL LNKYSSQMNY  
   501 FSQAQGN 
Figure 3. 36. Result of Mascot search using data from mass spectrometry analysis of recombinant FliD  
The sequence in bold red text shows peptides identified in the analysis that match the sequence of the 
target protein from C. difficile 630. The data shows that 60% of the sequence of native FliD could be 
recovered from the recombinant protein. 
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Match to: gi|126697810 Score: 961 
flagellin subunit [Clostridium difficile 630] 
Found in search of F:\Naziri-7-12-9.wiff 
Nominal mass (Mr): 30755; Calculated pI value: 7.88 
NCBI BLAST search of gi|126697810 against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Clostridium difficile 630 
Links to retrieve other entries containing this sequence from NCBI Entrez: 
gi|6456511 from Clostridium difficile 
gi|10281483 from Clostridium difficile 
gi|115249247 from Clostridium difficile 630 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 51% 
Matched peptides shown in Bold Red 
     1 MRVNTNVSAL IANNQMGRNV NGQSKSMEKL SSGVRIKRAA DDAAGLAISE  
    51 KMRAQIKGLD QAGRNVQDGI SVVQTAEGSL EETGNILQRM RTLSLQSANE  
   101 INNTEEREKI ADELTQLKDE IERISSSTEF NGKKLLDGTS STIRLQVGAS  
   151 YGTNVSGTSN NNNEIKIQLV NTASIMASAG ITTASIGSMK AGGTTGTDAA  
   201 KTMVSSLDAA LKSLNSSRAK LGAQQNRLES TQNNLNNTLE NVTAAESRIR  
   251 DTDVASEMVN LSKMNILVQA SQSMLAQANQ QPQGVLQLLG  
Figure 3. 37. Result of Mascot search using data from mass spectrometry analysis of recombinant FliC  
The sequence in bold red text shows peptides identified in the analysis that match the sequence of the 
target protein from C. difficile 630. The data shows that 51% of the sequence of native FliC could be 
recovered from the recombinant protein.  
 
 
 
Match to: gi|11066029 Score: 826 
Cwp66 [Clostridium difficile] 
Found in search of C:\Documents and Settings\rjb12n\My Documents\Ali-14-5-10.wiff 
Nominal mass (Mr): 66895; Calculated pI value: 5.19 
NCBI BLAST search of gi|11066029 against nr 
Unformatted sequence string for pasting into other applications 
Taxonomy: Clostridium difficile 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 23% 
Matched peptides shown in Bold Red 
 
     1 MNISKQIVSL LTMTFLTVTL YGNTSNASTK DTLTGSGRWE TAIKISQAGW  
    51 TKSESAVLVN DNSIADALSA TPFAKAKDAP ILLTQSNKLD SRTKAELKRL  
   101 GVKNVYLIGG SIALSSEIEK QLNAENINFE RISGNSRYDT SLKLAEKLDR  
   151 EKSISKIVVV NGEKGLADAV SVGAIAAQEN MPIILSDSEN GTEVADNFID  
   201 SKDIAKSYVI GGTYSISNSV ERSLPNATRI AGSSRSETNA KIIEEFYKDT  
   251 DIKNIYVTKD GTKNKNDLID SLAVGVLAAK NSSPIVLAGN KLDTTQKDVL  
   301 NTKIIDKVTQ IGGLGNENVV EDILDIQEET KYTVETIDEL NAAIKRADAN  
   351 DIIKFKPEKE KTINNSFSIE TKKTVTIELD GRYRQTITLD IPNGKFNNYA  
   401 EIEGGVKLKN IKNESLVNKG SIQDLDIYDE NGCKIENESS GEIWFVTIVE  
   451 EANDVYIVNS GDITKISNNS SSTIIRNSGN IDTVTGKKEP AISGNKPKVN  
   501 DTEKETKAAR GLNPRVEACS VPKKDYVMIT IPNSPKDSRY KIYYRVVYNK  
   551 PYAMDVGDKI NIGEWTVAPT DEEPFLEKAK NGCYVEAVEV NTSTKEVSRW  
   601 GRTNATDDGF  
 ______________________________________________________________________________________________________________ 
Figure 3. 38. Result of Mascot search using data from mass spectrometry analysis of recombinant C-
terminus of Cwp66.  
The sequence in bold red text shows peptides identified in the analysis that match the sequence of the 
target protein from C. difficile 630. The data shows that 23% of the sequence of native Cwp66 could be 
recovered from the recombinant protein. 
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Match to: gi|11066029 Score: 1384 
Cwp66 [Clostridium difficile] 
Found in search of F:\Naziri-7-12-9.wiff 
Nominal mass (Mr): 66895; Calculated pI value: 5.19 
NCBI BLAST search of gi|11066029 against nr 
Unformatted sequence string for pasting into other applications 
Taxonomy: Clostridium difficile 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 48% 
Matched peptides shown in Bold Red 
     1 MNISKQIVSL LTMTFLTVTL YGNTSNASTK DTLTGSGRWE TAIKISQAGW  
    51 TKSESAVLVN DNSIADALSA TPFAKAKDAP ILLTQSNKLD SRTKAELKRL  
   101 GVKNVYLIGG SIALSSEIEK QLNAENINFE RISGNSRYDT SLKLAEKLDR  
   151 EKSISKIVVV NGEKGLADAV SVGAIAAQEN MPIILSDSEN GTEVADNFID  
   201 SKDIAKSYVI GGTYSISNSV ERSLPNATRI AGSSRSETNA KIIEEFYKDT  
   251 DIKNIYVTKD GTKNKNDLID SLAVGVLAAK NSSPIVLAGN KLDTTQKDVL  
   301 NTKIIDKVTQ IGGLGNENVV EDILDIQEET KYTVETIDEL NAAIKRADAN  
   351 DIIKFKPEKE KTINNSFSIE TKKTVTIELD GRYRQTITLD IPNGKFNNYA  
   401 EIEGGVKLKN IKNESLVNKG SIQDLDIYDE NGCKIENESS GEIWFVTIVE  
   451 EANDVYIVNS GDITKISNNS SSTIIRNSGN IDTVTGKKEP AISGNKPKVN  
   501 DTEKETKAAR GLNPRVEACS VPKKDYVMIT IPNSPKDSRY KIYYRVVYNK  
   551 PYAMDVGDKI NIGEWTVAPT DEEPFLEKAK NGCYVEAVEV NTSTKEVSRW  
   601 GRTNATDDGF  
Figure 3. 39. Result of Mascot search using data from mass spectrometry analysis of recombinant Cwp66 
The sequence in bold red text shows peptides identified in the analysis that match the sequence of the 
target protein from C. difficile 630. The data shows that 48% of the sequence of native Cwp66 could be 
recovered from the recombinant protein.  
 
 
 
 
Match to: gi|126700333 Score: 712 
putative sortase B [Clostridium difficile 630] 
Found in search of F:\Naziri-7-12-9.wiff 
Nominal mass (Mr): 26762; Calculated pI value: 9.09 
NCBI BLAST search of gi|126700333 against nr 
Unformatted sequence string for pasting into other applications 
 
Taxonomy: Clostridium difficile 630 
Links to retrieve other entries containing this sequence from NCBI Entrez: 
gi|255307756 from Clostridium difficile ATCC 43255 
gi|115251770 from Clostridium difficile 630 
Fixed modifications: Carbamidomethyl (C) 
Variable modifications: Oxidation (M) 
Cleavage by Trypsin: cuts C-term side of KR unless next residue is P 
Sequence Coverage: 52% 
Matched peptides shown in Bold Red 
     1 MKKLYRIVIN IILVLVILYS GFNIYSKLTK YNHDTKISSE LQKKEYKKED  
    51 LSKINSDFKF WLSVENTNIN YPVVQSKDNS YYLDKDFYKK DSISGTLFMD  
   101 YRNKSIDDKN IIIYGHNMKN KTMFNNLNKF KDADFFKKNN KIKITLNGKE  
   151 FLYDVFSAYI VESDYDYLKT NFNNESDYQN YINDITSKSL YKSPIKVNSN  
   201 DKIVTLSTCT YEFDDARMVI HGRLI 
Figure 3. 40. Result of Mascot search using data from mass spectrometry analysis of recombinant Sortase 
B. 
The sequence in bold red text shows peptides identified in the analysis that match the sequence of the 
target protein from C. difficile 630. The data shows that 52% of the sequence of native Sortase b could be 
recovered from the recombinant protein. 
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3.3 Tomlinson phage display 
              Having successfully prepared recombinant target proteins in E. coli, the 
project moved to use these as targets for the isolation of recombinant scFv 
antibodies using phage display. The Tomlinson libraries I and J were used for phage 
display for several reasons. Firstly, they are highly diverse, estimated to contain 
around 108 unique specificities created through synthetic diversification of key 
residues in the CDRs of single human heavy and light chain scaffolds. Secondly, the 
libraries are well-suited to simple panning methods and the use of a trypsin-
sensitive helper phage (KM13), combined with a protocol for trypsin elution of 
phage from the target, minimises the carry forward of virus with irrelevant 
properties. Finally, the antibodies that the libraries contain are scFvs, encoded on a 
phagemid vector. These can be easily and conveniently expressed and purified in 
high yield once target-specific scFvs have been isolated.  
 
3.3.1 Helper phage preparation and titration  
        Phage KM13 provided with the Tomlinson library was used to prepare 100 fold 
serial dilutions. Each dilution was used to infect E.coli TG1 cells which were then 
plated in TYE H-top agar and incubated, allowing phage plaques to appear. To 
produce larger quantities of the helper phage, a small, clear plaque was picked and 
added into a fresh culture of E.coli TG1 that was growing in exponential phase. 
After incubation, the supernatant was recovered from the culture and was treated 
with PEG/NaCl to precipitate the KM13 phage. The pellet of viral particles was 
resuspended in PBS. This preparation was considered as a stock of helper phage 
and to determine titre, samples were titrated after trypsin treatment and without 
this treatment. In both, serial dilutions were prepared and infected to TG1 cells 
which were then plated in TYE H-top agar to allow plaque formation. Table 3.6 
shows the difference observed in titration of trypsin-treated phage and untreated 
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phage. Firstly, the Table shows a high titre stock of helper phage had been 
prepared (about 4 x 1013 pfu/ml). Secondly, the data shows the sensitivity of KM13 
to trypsin treatment as a difference in titre of about 5 logs was observed between 
treated and untreated samples. This KM13 helper phage was used as a stock in the 
later steps of phage display. 
 
3.3.2 Preparation and titration phage fromscFv libraries I and J: 
     The bacterial stocks of libraries I and J were grown in liquid medium and once 
exponential phase had been reached, samples were infected with KM13 helper 
phage. The remaining culture was used to prepare a secondary stock of both 
libraries. The infected cultures were grown on to allow the formation of  phage 
displaying scFv on the surface. These were precipitated from culture supernatants 
using PEG/NaCl and stored in PBS ready for panning against target proteins. Each 
scFv phage library was titrated separately by serial dilution, infection of TG1 
bacteria and plating on TYE-ampicillin plates. Table 3.7 shows the numbers of 
ampicillin resistant colonies recovered in this way from libraries I and J.  
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Table 3. 5 Titration of  KM13 helper phage 
 
NON-TRYPSIN TREATED PHAGE(PFU/ML) TRYPSIN TREATED PHAGE(PFU/ML) DIFFERENCE 
3.69 x 10
13
 1.15 x 10
8
 2.54 x 10
5
 
  
           
 
 
 
 
 
Table 3. 6. Titration of scFv display  I and J 
 
LIBRARY I LIBRARY J 
8.1 x 10
14
 4.8 x 10
14
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3.3.3 Antibody selection from phage libraries I and J 
     Both libraries I and J contain more than 108 unique scFvs, and these resources 
were used to select recombinant antibodies with the capacity to bind the purified 
recombinant proteins described earlier and different forms of SlpA, the major 
surface layer protein of C. difficile. Selection of recombinant antibodies was carried 
out in two groups; in group one, libraries I and J were used separately for panning 
but in group two libraries I and J were mixed to reduce the complexities of the 
experiment. Group one screened for antibodies that would bind CspA, GroEL, FliD 
and the LMW form of SlpA as the targets. Group two comprised panning with the 
N-terminus of Cwp66, FliC, the C-terminus of Cwp66, Sortase B, Cwp66 and native 
SlpA extracted from C. difficile.  To select the antibodies, immunotubes were 
coated with each target at 100µg/ml and panning was carried out as described 
below. In later rounds of selection, the concentration of each target was decreased 
to 75 and 50 µg/ml for the second and third rounds respectively.  
       Each round of selection comprised several steps: coating of the immunotube 
with the target; blocking unoccupied sites on the immunotube using skimmed milk 
in PBS; adding library phage and allowing target interaction; washing out unbound 
phage and elution of absorbed virus; amplification of the eluted phage for use in 
the next round of selection. In each round, TG1 cells were used to determine by 
titration the numbers of phage added to the immunotube (input) and the numbers 
of phage recovered at elution (output). Using data at input and output, the 
percentage recovery of phage in each round of selection was calculated by division 
of output by input titre. Tables 3.8 – 3.17 show the data for all targets over three 
rounds of selection.  
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Table 3. 7.  Recovery of phage during the selection against CspA 
 
LIBRARY TOMLINSON I TOMLINSON J 
Selection Input Output % Recovery Input Output % Recovery 
Round 1 8.1x 10
13
 1.6x 10
5
 1.9x 10
-7
 4.8x 10
13
 3.2x 10
5
 6.6x 10
-7
 
Round 2 10
13
 2.3x 10
6
 2.3x 10
-5
 3x 10
13
 1.3x 10
6
 4.3x 10
-6
 
Round3 7.1x 10
13
 1.2x 10
7
 1.6x 10
-5
 3.8x 10
13
 3.2x10
8
 8.4x10
-4
 
   
 
 
 
 
Table 3. 8. Recovery of phage during the selection against  GroEL 
 
LIBRARY TOMLINSON I TOMLINSON J 
Selection Input Output % Recovery Input Output % Recovery 
Round 1 8.1x 10
13
 1.6x 10
5
 1.9x 10
-7
 4.8x 10
13
 6.8x 10
5
 1.4x 10
-6
 
Round 2 8.7x 10
13
 6.1x 10
6
 7x 10
-6
 5x 10
13
 7.2x 10
6
 1.4x 10
-5
 
Round3 6.6x 10
13
 4.32x 10
8
 6.5x 10
-4
 8.3x 10
13
 4.2x 10
8
 5x 10
-4
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Table 3. 9. Recovery of phage during the selection against FliD 
 
LIBRARY TOMLINSON I TOMLINSON  J 
Selection Input Output %  Recovery Input Output % Recovery 
Round 1 8.1x 10
13
 8x 10
4
 9.8x 10
-8
 4.8x 10
13
 4x 10
4
 8.3x 10
-8
 
Round 2 3x 10
13
 10
6
 3.3x 10
-6
 2x 10
13
 1.3x 10
6
 6.5x 10
-6
 
Round3 9.4x 10
13
 6.3x 10
8
 6.7x 10
-4
 8.8x 10
13
 1.06x 10
9
 1.2x 10
-3
 
 
 
 
 
 
Table 3. 10. Recovery of phage during the selection against LMW 
 
LIBRARY TOMLINSON I TOMLINSON J 
Selection Input Output % Recovery Input Output % Recovery 
Round 1 8.1x 10
13
 1.2x 10
4
 1.4x 10
-8
 4.8x 10
13
 4x 10
4
 8.3x 10
-8
 
Round 2 8.2x 10
13
 5.2x 10
6
 6.3x 10
-6
 5.4x 10
13
 7.2x 10
6
 1.6x 10
-5
 
Round3 9x 10
13
 4.64x 10
7
 5.1x 10
-5
 9.7x 10
13
 8.3x 10
8
 8.5x 10
-4
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Table 3. 11. Recovery of phage during the selection against N-terminus of  Cwp66 
 
LIBRARY TOMLINSON I+J 
Selection Input Output %  Recovery 
Round 1 6.45x 10
13
 2.8x 10
5
 4.3x 10
-7
 
Round 2 6x 10
13
 1.1x 10
6
 1.8x 10
-6
 
Round3 1.3x 10
13
 6.6x 10
7
 1.1x 10
-4
 
 
 
 
 
Table 3. 12. Recovery of phage during the selection against FliC 
 
LIBRARY TOMLINSON I+J 
Selection Input Output %  Recovery 
Round 1 6.45x 10
13
 1.6x 10
5
 2.4x 10
-7
 
Round 2 5x 10
13
 7.1x 10
6
 1.4x 10
-5
 
Round3 8.1 x10
13
 1.06x 10
7
 1.3x 10
-5
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Table 3. 13. Recovery of phage during the selection against C-terminus of Cwp66 
 
LIBRARY TOMLINSON I+J 
Selection Input Output % of Recovery 
Round 1 6.45x10
13
 2.4x 10
5
 3.7x 10
-7
 
Round 2 9.7x 10
13
 2.1 x10
6
 2.1x 10
-6
 
Round3 9.1x 10
13
 9.3x 10
6
 10
-5
 
 
 
 
 
Table 3. 14. Recovery of phage during the selection against Sortase B 
 
LIBRARY TOMLINSON I+J 
Selection Input Output %  Recovery 
Round 1 6.45x 10
13
 1.4x 10
6
 2.1x 10
-6
 
Round 2 10
13
 4.4x 10
4
 4.4x 10
-7
 
Round3 1.2x 10
13
 7.1x 10
6
 5.9x 10
-5
 
 
 Chapter 4                                        Discussion                                                                  166  
        
 
 
Table 3. 15. Recovery of phage during the selection against Cwp66 
 
LIBRARY TOMLINSON I+J 
Selection Input Output %  Recovery 
Round 1 6.45x 10
13
 8x 10
5
 1.2x 10
-6
 
Round 2 3x 10
13
 7x 10
6
 2.3x 10
-5
 
Round3 1.2x 10
13
 4.7x 10
5
 3.9x 10
-6
 
 
 
 
 
Table 3. 16 Recovery of phage during the selection against SlpA 
 
LIBRARY TOMLINSON I+J 
Selection Input Output %  Recovery 
Round 1 6.45x 10
13
 3.6x10
4
 5.5x 10
-8
 
Round 2 2x 10
13
 2.7x 10
5
 1.3x 10
-6
 
Round3 1.1x 10
13
 1.6x 10
5
 1.4x 10
-6
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3.3.4 Antibody screening 
3.3.4.1 Monoclonal phage ELISA 
      Whilst the recoveries of virus from panning suggested enrichment of target-
specific scFvs, this could only be confirmed by immunoassay. To do this, individual 
colonies from the 3rd round of each selection were picked for analysis. In the group 
one screens – those in which libraries I and J were used separately for selection 
against CspA, GroEL, FliD and LMW of SlpA – 48 colonies were picked from each 
library in the final selection step. For group two screens in which the two libraries 
were combined for selection, a total of 48 colonies were picked. Group two 
screens panned for scFvs against the N-terminus of Cwp66, FliC, the C-terminus of 
Cwp66, Sortase B, Cwp66 and native SlpA.  
      Individual colonies were picked at random from the third round of selection 
against each target and grown overnight in 96 well plates. Cultures were re-
inoculated to medium, grown into exponential phase and infected with helper 
phage. Having thereby generated monoclonal phage particles displaying scFvs, 
they were then transferred to ELISA plates pre-coated with the relevant target 
protein. The binding of phage to the targets was detected with anti-M13-HRP 
reagents. Figures 3.41 – 3.47 illustrate the ability of individual phage clones to 
recognise and bind to the selecting target.  
           In Figures 3.41 to 3.44, phage ELISA revealed that 50-100% of all clones were 
reactive against the intended target although there was some variation in the 
signal strength as measured by absorbance at 450 nm. Figure 3.41 shows that 
more than 60% of all selected colonies from both libraries panned against CspA 
were positive in phage ELISA. The strongest reactions against CspA came from 
clones from library I as measured by absorbance at 450 nm. Higher reaction 
frequency can be seen in Figure 3.42 in which more than 90% the clones picked 
from selection against GroEL were positive in phage  ELISA. In this experiment, the 
Chapter 3 Results 
 
168 
strongest reaction came from clones from library J. An interesting contrast is 
evident in Figure 3.43 in which higher frequency of reaction with FliD arose from 
selection using library J than library I. The strongest reactions in this ELISA also 
came from clones from library J. The same pattern emerged from experiments 
with LMW (Figure 3.44), with 90% of clones picked for analysis showing strong 
positive reaction for the target, particularly from library J, although strong 
reactions can be also seen for clones from library I.  
    Figures 3.45 to 3.47 show the properties of phage recovered from selections 
with a mixture of libraries I and J. Figures 3.45 and 3.47 show contrasting results 
from screens using isolated regions of Cwp66 ( N and C terminal regions, Figure 
3.45) and the intact Cwp66 protein (Figure 3.47, left panel). Nearly all clones 
picked from screens against N and C-terminal part of Cwp66 are positive with a 
high absorbances in phage ELISA (Figure 3.45). In contrast, only 30% of clones 
isolated against Cwp66 were positive in phage ELISA, just half of them with high 
signal strength (Figure 3.47, left panel). Figure 3.46 shows identification of target-
specific clones in phage ELISA against FliC (left panel) and Sortase B (right panel). 
For all targets, phage ELISA identified ample numbers of positive clones for the 
next steps of the project, however to maximise the chances of success, all clones 
identified as showing target-specificity in phage ELISA were taken forward.  
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                                    a                                                                    b 
Figure 3. 41. Monoclonal phage ELISA of phage fromTomlinson libraries I and J against recombinant CspA 
Binding of individual phage particles from the third round of selection was detected using anti-M13-HRP 
and TMB as the enzyme substrate 
a) 48 colonies picked randomly from 3
rd
 round of selection using of library I 
b) 48 colonies picked randomly from 3
rd
 round of selection using of library J  
 
 
 
 
                                     a                                                                b 
Figure 3. 42. Monoclonal phage ELISA of phage from Tomlinson libraries I and J against recombinant 
GroEL 
Binding of individual phage particles from the third round of selection was detected using anti-M13-HRP 
and TMB as the enzyme substrate 
a) 48 colonies picked randomly from 3
rd
 round of selection using of library I 
b) 48 colonies picked randomly from 3
rd
 round of selection using of library J 
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                                   a                                                              b 
Figure 3. 43. Monoclonal phage ELISA of phage fromTomlinson libraries I and J against recombinant FliD 
Binding of individual phage particles from the third round of selection was detected using anti-M13-HRP 
and TMB as the enzyme substrate 
a) 48 colonies picked randomly from 3
rd
 round of selection using of library I 
b) 48 colonies picked randomly from 3
rd
 round of selection using of library J  
 
 
                                   a                                                              b 
Figure 3. 44.Monoclonal phage ELISA of  phage from Tomlinson  libraries I and J against recombinant 
LMW  
Individual phage particles from third round of selection from Libraries I and J in a ELISA test using 
antiM13-HRP and TMB as the enzyme substrate 
a) 48 colones picked randomly from 3
rd
 round of selection of library I 
b) 48 colones picked randomly from 3
rd
 round of selection of library J 
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                                       a                                                                 b 
Figure 3. 45. Monoclonal phage ELISA of phage fromTomlinson libraries I+J against recombinant  N-
terminus (left) and C-terminus (right) of Cwp66 
Binding of individual phage particles from the third round of selection was detected using anti-M13-HRP 
and TMB as the enzyme substrate 
a) 48 colonies picked randomly from 3
rd
 round of selection using of libraries I+J 
b) 48 colonies picked randomly from 3
rd
 round of selection using of libraries I+J  
 
 
                                     a                                                                 b 
Figure 3. 46. Monoclonal phage ELISA of phage from Tomlinson libraries I+ J against recombinant FliC 
(left) and Sortase B (right) 
Binding of individual phage particles from the third round of selection was detected using anti-M13-HRP 
and TMB as the enzyme substrate 
a) 48 colonies picked randomly from 3
rd
 round of selection using of library I+J 
b) 48 colonies picked randomly from 3
rd
 round of selection using of library I+J 
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                                    a                                                                    b 
Figure 3. 47. Monoclonal phage ELISA of phage fromTomlinson libraries I and J against recombinant 
Cwp66 (left) and extracted SlpA (right) 
Binding of individual phage particles from the third round of selection was detected using anti-M13-HRP 
and TMB as the enzyme substrate 
a) 48 colonies picked randomly from 3
rd
 round of selection using of library I+J 
b) 48 colonies picked randomly from 3
rd
 round of selection using of library I+J  
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3.3.4.2 Screening of monoclonal soluble recombinant antibodies 
In phage display using the Tomlinson libraries and related systems, phage 
are produced in E. coli TG1, a strain that suppresses the TAG stop codon at the 
junction between the recombinant scFv antibody and gIII, the gene for a minor 
phage coat protein pIII. This fuses the scFv to the coat protein so that the scFv is 
displayed at the surface of the virus. TAG stop codons present in the scFv reading 
frame will be similarly suppressed and hence the next phase of analysis was to 
express soluble scFv (ie unfused to pIII, achieved by expression in a non-suppressor 
strain of E. coli) to see if target reactivity was retained. 
Also, it is likely that binding of phage to the target is a multivalent 
interaction. Five copies of pIII are present at the phage surface and whilst it is 
unlikely that all 5 will be scFv-pIII fusions, scFvs may be isolated that possess very 
low affinity for the target and only bind during panning and phage ELISA as a result 
of multivalent scFv display. To exclude scFvs of this sort, the antibodies were 
expressed as soluble scFvs in E. coli HB2151 (a non-suppressor strain) thereby 
restricting them to monovalent interaction with target in ELISA. The scFvs can be 
detected in ELISA because they retain the c-myc detection tag (Figure 3.65) and 
can be purified on a large scale because of the histidine repeats at the C-terminus 
of the scFv sequence.  
Soluble scFv proteins were prepared from all clones identified as positive in 
monoclonal phage ELISA. Initially, phage were prepared from each clone by 
growing the bacteria into exponential phase, infecting with helper phage and 
growing on overnight. These phage antibodies from the supernatant of overnight 
cultures were used to infect E. coli HB2151 cells; successfully infected HB2151 cells 
were selected by plating on medium containing ampicillin. New liquid cultures 
were then established and expression of soluble scFv was induced by addition of 
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IPTG. Culture supernatants were first tested for the presence of soluble scFv by dot 
blotting. The ability of scFv to bind to the target proteins was then assessed by 
ELISA. To speed throughput and ease record keeping, these experiments were 
carried out in 96 well plates.    
 
3.3.4.2.1 Dot blot analysis for soluble recombinant antibodies 
 
             Depending on the number of clones to be screened, a grid was drawn out 
on nitrocellulose membrane and samples of each culture supernatant were added. 
As soluble scFvs retain the c-myc tag towards the C-terminus of the scFv protein, 
the presence of recombinant antibody could be detected with anti c-myc and anti-
rabbit-HRP reagents. Data is shown in Figures 3.48 to 3.54. Although the Figures 
clearly show that a positive response was obtained for many, if not all the 
supernatants that were tested,  the intensity of signals are different which might 
reflect differing scFv yields from the clones under test or variable volumes of 
culture supernatant. In all figures, a wide variation in signal intensity is evident, 
with variable frequencies of positive reaction. 
      For instance in Figure   3.48 many positive signals can be seen but two highly 
intense reactions are evident (A4 and G12), one clone from each of the Tomlinson 
libraries. The signals for soluble svFvs against GroEL (Figure 3.49) are generally 
stronger and there is greater representation of high signals from libraries I and J 
(Figure 3.49). Dot blot analysis of soluble scFvs against FliD in Figure 3.50 reveals a 
marked difference between the two libraries with many more positive signals from 
library I than library J, a pattern that is also evident in Figure 3.51 (soluble 
antibodies against LMW).  
     Results from Figure 3.52 to 3.54 are from screens in which the two libraries 
were mixed at the start of the panning process. Strong positive reactions can be 
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seen in all cases though in one (Figure 3.53, right panel, anti-Sortase B antibodies) 
only a single strong signal appeared.  
 
 
 
 
3.3.4.2.2 Detection of soluble antibodies by ELISA 
 
The foregoing experiments tested only for the production of scFv proteins. 
To test for target specificity, the supernatants of induced HB2151 cultures were 
used in immunoassays against the recombinant target proteins. Binding of scFv to 
target-coated ELISA plates was detected with anti-c-myc and anti rabbit-HRP 
regents and signals were quantified by absorbance at 450 nm. Results are shown in 
Figures 3.55 to 3.62.  Results from Figure 3.55 show most of the antibodies from 
library J against recombinant CspA (right part of the plate, b) have a strong binding 
reaction when compared to clones from library I (left part of the plate, a). 
      The reaction of selected monoclonal antibodies against GroEL in Figure 3.56 
revealed far fewer positive clones but the best were derived from library J (right 
part of the plate, b).  Figure 3.57 shows results with FliC (left panel, a) and SortaseB 
(right panel, b). While more than 90% of antibodies against Sortase B could react 
with their target, this decreased to around 40% for the binders selected against 
FliC. Monoclonal soluble scFv against LMW were selected from both libraries as 
can been seen in Figure 3.58. The data confirmed that strong binders were isolated 
from both libraries, but the frequency was greater from library J (right panel, b). In 
Figure 3.59, the majority of scFvs against the N-terminus of Cwp66 were able to 
bind to the target, a finding that was paralleled for the scFvs against C-terminus of 
Cwp66 (Figure 3.61, right panel). In contrast, only modest numbers of monoclonal 
antibodies were reactive with Cwp66 (around 25% of the 48 clones picked for 
analysis; Figure 3.61, left panel). Almost all clones selected from library I against 
FliD were reactive in soluble scFv ELISA (Figure 3.60, left panel) whereas about 50% 
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of clones from library J were positive (Figure 3.60, right panel). Figure 3.62 shows 
that the majority of the soluble scFvs against SlpA were reactive with the target.               
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                               a                                                    b                                 
Figure 3. 48. Dot blot analysis of expression of soluble scFv against recombinant CspA 
Supernatants from induced cultures of E. coli HB2151 were blotted on Hybond membrane and scFv 
detected with reagents to the c-myc tag. 
(a) Supernatants derived from the 3
rd
 round of selection using library I 
(b) Supernatants derived from the 3
rd
 round of selection using library J  
 
 
 
 
                          
                            a                                                     b 
Figure 3. 49. Dot blot analysis of expression of soluble scFv against recombinant GroEL 
Supernatants from induced cultures of E. coli HB2151 were blotted on Hybond membrane and scFv 
detected with reagents to the c-myc tag. 
(a) Supernatants derived from the 3
rd
 round of selection using library I 
(b) Supernatants derived from the 3
rd
 round of selection using library J 
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                                a                                                     b 
Figure 3. 50. Dot blot analysis of expression of soluble scFv against recombinant FliC 
Supernatants from induced cultures of E. coli HB2151 were blotted on Hybond membrane and scFv 
detected with reagents to the c-myc tag. 
(a) Supernatants derived from the 3
rd
 round of selection using library I 
(b) Supernatants derived from the 3
rd
 round of selection using library J  
 
 
 
 
                        
                                 a                                                    b                                                                                    
Figure 3. 51. Dot blot analysis of expression of soluble scFv against recombinant LMW 
Supernatants from induced cultures of E. coli HB2151 were blotted on Hybond membrane and scFv 
detected with reagents to the c-myc tag. 
(a) Supernatants derived from the 3
rd
 round of selection using library I 
(b) Supernatants derived from the 3
rd
 round of selection using library J  
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                              a                                                       b 
Figure 3. 52. Dot blot analysis of expression of soluble scFv against recombinant N-terminus and C-
terminus of Cwp66 
Supernatants from induced cultures of E. coli HB2151 were blotted on Hybond membrane and scFv 
detected with reagents to the c-myc tag. 
(a) Supernatants derived from the 3
rd
 round of selection against the N-terminus of Cwp 66 using library 
I+J 
(b) Supernatants derived from the 3
rd
 round of selection against the C-terminus of Cwp 66 using library I+J  
 
 
 
              
                                a                                                      b        
Figure 3. 53. Dot blot analysis of expression of soluble scFv against recombinant FliC and Sortase B 
Supernatants from induced cultures of E. coli HB2151 were blotted on Hybond membrane and scFv 
detected with reagents to the c-myc tag. 
(a) Supernatants derived from the 3
rd
 round of selection against FliC using library I+J 
(b) Supernatants derived from the 3
rd
 round of selection against Sortase B using library I+J  
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                                a                                                      b 
Figure 3. 54. Dot blot analysis of expression of soluble scFv against recombinant Cwp66 and extracted 
SlpA 
Supernatants from induced cultures of E. coli HB2151 were blotted on Hybond membrane and scFv 
detected with reagents to the c-myc tag. 
(a) Supernatants derived from the 3
rd
 round of selection against Cwp66 using library I+J 
(b) Supernatants derived from the 3
rd
 round of selection against SlpA using library I+J  
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                               a                                                       b 
 
Figure 3. 55. Monoclonal soluble scFv ELISA against recombinant CspA 
Recombinant soluble antibodies from 3
rd
 round of selection were detected in ELISA against purified 
recombinant CspA. After adding scFvs to the coated, blocked plate, antibody binding was detected with 
anti-c-myc and anti-rabbit-HRP reagents and substrate. 
(a) scFvs from 3
rd
 round of selection of library I against recombinant CspA 
(b) scFvs from 3
rd
 round of selection of library J against recombinant CspA  
 
 
 
 
 
                                 a                                                      b 
 
 
Figure 3. 56 Monoclonal soluble scFv ELISA against recombinant GroEL 
Recombinant soluble antibodies from 3
rd
 round of selection were detected in ELISA against purified 
recombinant GroEL. After adding scFvs to the coated, blocked plate, antibody binding was detected with 
anti-c-myc and anti-rabbit-HRP reagents and substrate. 
(a) scFvs from 3
rd
 round of selection of library I against recombinant  GroEL  
(b) scFvs from 3
rd
 round of selection of library J against recombinant  GroEL
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                                 a                                                            b 
 
Figure 3. 57. Monoclonal soluble scFv ELISA against recombinant FliC and Sortase B 
Recombinant soluble antibodies from 3
rd
 round of selection were detected in ELISA against purified 
recombinant FliC and Sortase B. After adding scFvs to the coated, blocked plate, antibody binding was 
detected with anti-c-myc and anti-rabbit-HRP reagents and substrate. 
(a) scFvs from 3
rd
 round of selection of libraries I+J against recombinant  FliC  
(b) scFvs from 3
rd
 round of selection of libraries I+J against recombinant Sortase B 
 
 
 
                                a                                                           b 
Figure 3. 58. Monoclonal soluble scFv ELISA against recombinant LMW 
Recombinant soluble antibodies from 3
rd
 round of selection were detected in ELISA against purified 
recombinant LMW. After adding scFvs to coated, blocked plate, antibody binding was detected with anti-
c-myc and anti-rabbit-HRP reagents and substrate.  
(a) scFvs from 3
rd
 round of selection of library I against recombinant LMW 
(b) scFvs from 3
rd
 round of selection of library J against recombinant LMW 
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Figure 3. 59. Monoclonal soluble scFv ELISA against recombinant N-terminus Cwp66 
Recombinant soluble antibodies from 3
rd
 round of selection  were detected in ELISA against purified 
recombinant N-terminus Cwp66. After adding scFvs to coated, blocked plate, antibody binding was 
detected with anti-c-myc and anti-rabbit-HRP reagents and substrate. 
 
 
 
 
                             a                                                        b 
Figure 3. 60. Monoclonal soluble scFv ELISA against recombinant FliD 
Recombinant soluble antibodies from 3
rd
 round of selection were detected in ELISA against purified 
recombinant FliD. After adding scFvs to coated, blocked plate, antibody binding was detected with anti-c-
myc and anti-rabbit-HRP reagents and substrate.  
(a) scFvs from 3
rd
 round of selection of library I against recombinant FliD 
(b) scFvs from 3
rd
 round of selection of library J against recombinant FliD 
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                             a                                                        b 
Figure 3. 61. Monoclonal soluble scFv ELISA against recombinant Cwp66 and the C-terminal region of the 
protein  
Recombinant soluble antibodies from 3
rd
 round of selection were detected in ELISA against purified 
recombinant C-terminus Cwp66 and Cwp66. After adding scFvs to coated, blocked plate, antibody binding 
was detected with anti-c-myc and anti-rabbit-HRP reagents and substrate.  
(a) scFvs from 3
rd
 round of selection of libraries I+J against recombinant Cwp66 
(b) scFvs from 3
rd
 round of selection of library J against recombinant C-terminus Cwp66  
 
 
 
 
 
Figure 3. 62. Monoclonal soluble scFv ELISA against extracted SlpA 
Recombinant soluble antibodies from 3
rd
 round of selection were detected in ELISA against purified 
extracted SlpA. After adding scFvs to coated, blocked plate, antibody binding was detected with anti-c-
myc and anti-rabbit-HRP reagents and substrate.  
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3.3.5 Characterisation of selected clones 
3.3.5.1  Sequence analysis of selected scFvs 
In total, 672 clones were picked against recombinant target proteins and 
tested by phage ELISA, monoclonal phage ELISA and other immunoassays. Based 
on the monoclonal screening described earlier and Western blot analysis 
(subsequent sections), 32 scFv clones were chosen which possessed high binding 
ability to their targets. To reveal their amino acid sequences – in particular the 
sequences of the CDRs – plasmid DNA was prepared from all 32 HB2151 clones for 
sequencing with primers LMB3 and gIII (Table 3.17). Sequencing with these 
primers determined the full sequence of the scFv reading frame including VH, 
linker and VL. All sequences were checked for the restriction sites present in the 
pIT2 vector (Figure 3.65) and aligned to VBASE sequences using DNAPLOT database 
(http://www.vbase2.org/vbase2.php) to predict their amino acid sequences. 
Predicted amino acid sequences were aligned with amino acid sequences of the 
single framework sequences of the Tomlinson libraries (VH: V3-23/DP-47 and VL: 
O12/DPK9) to reveal the CDRs .  
         The Tomlinson libraries are based on single human VH and VL frameworks 
with invariable CDR1 and diversity at defined points in CDR2 and CDR3. 
Specifically, the scFv heavy chain domain is based on the V3-23/DP-47 sequence 
and diversified in CDR2 (residues H50, H52, H52a, H53, H55, H56, and H58) and 
CDR3 (residues H95, H96, H97 and H98). In the light chain, the O12/O2/DPK9 
sequence is diversified in CDR2 (residues L50 and L53) and CDR3 (L91 L92, L93, L94, 
L96). 
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Table 3.18 shows the basic amino acid sequences of heavy and light chains 
of each scFv, connected into a scFv by a linker sequence. The diversified amino 
acid sequences of the sequenced clones for both heavy and light chains were 
extracted (Tables 3.19 [heavy chains] and 3.20 [light chains]). 
       In limited instances, clones were identical in sequence but the more common 
finding was that scFvs against particular target proteins shared general properties 
in CDRs 2 and 3. For example, the three antibodies against CspA were all unique in 
sequence through the VH and VL domains but the heavy chain CDR2 sequences all 
possess two or more hydroxylated residues (N2A9, one threonine, one serine; 
N2E7, five threonines; N2G12, one threonine, two serines), and in CDR3, 2 of the 4 
diversified residues were lysine or arginine. Taking scFvs against the N-terminus of 
Cwp66, clones N3A1 and N3H2 were closely related in sequence whereas the third 
sequenced clone (N3F4) was quite different. N3A1 and N3H2 shared an xGYSSAx 
sequence in CDR2 in the heavy chain, VH CDR3 sequences were identical and the 
light chain sequences were identical throughout.  
N11 clones were directed against the complete Cwp66 protein. Sequences 
were identical in VH at the diversified amino acids except just one (H50 of N11F4). 
In the sequence of VH for the N11 clones there are hydroxylated amino acids at 
one side of CDR2  (one threonine and one serine) and hydrophobic amino acid 
(isoleucine) at the middle and end of this region. The nature of CDR3 residues  of 
VH of these clones are mostly  hydrophobic. In VL sequences of the N11 clones, 
two are identical (C1 and F4) with a mix of hydrophobic and hydroxylated amino 
acids at CDR3. Clone N11A5 is notably for the presence of tryptophan in the CDR3 
of the VL domain; no other VL sequence possessed this feature and there was only 
one example amongst the VH sequences (N5E10; a scFv against GroEL). scFvs 
against the N-terminus of Cwp66 were similar but non-identical, a feature that also 
applied to anti-FliD scFvs (N8 clones).  
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      scFvs against SlpA were isolated by selection specifically against the LMW 
component and by panning against cell surface extracts. The six clones against 
LMW could be subdivided: LA6 and LD4 were identical and LG1 and LH1 formed a 
second identical pair; LF10 and LG7 were unique.  Although there were similarities 
amongst the anti-SlpA scFvs, the sequences were all unique.  
     The scFvs against FliC (N6 designation) are dissimilar in the CDRs of both the 
heavy and light chains, but an identical motif NYT (asparagine, tyrosine, threonine)  
can be seen in CDR2 of the VH for all antibodies. Just one clone against GroEL was 
analysed (N5E10). This generally carried charged residues at diversified points in 
CDR3 of VH and VL and uniformly hydrophobic residues at diversified points in 
CDR2 of VL. CDRs  of of the three anti-Sortase B scFvs (N10 clones) were very 
similar or identical.  
 
3.3.5.2 Restriction analysis of selected clones 
      The Tomlinson libraries are based upon the pIT2 vector (Figure 3.65 ) in which a 
scFv is separated from gIII of the M13 phage by a histidine purification tag, the c-
myc epitope and an amber stop codon. Four restriction sites (NcoI, XhoI, SalI and 
NotI) mark the boundaries of the VH and VL coding sequences. Digestion at these 
sites can be used to analyse whether individual clones carry a full length scFv or a 
truncated sequence. Restriction analysis was applied to verify whether the 
selected scFvs were indeed full length in sequence.  
       Fourteen selected clones in E. coli HB2151 were cultured for plasmid 
preparation. Purified plasmids were digested using three combinations of 
restriction enzymes. To check for the presence of a full length scFv, plasmids were 
digested with NcoI and NotI; Figure 3.66 illustrates the presence of these sites at 
the termini of the scFv insert. In the second and third digests, plasmids were 
treated with combinations of restriction enzymes to assess for the presence of VH 
and VL components. NcoI and XhoI were used to check for VH and digestion with 
SalI and NotI verified the presence of VL.  Figure 3.67 shows that digestion of 
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plasmids with NcoI and NotI excised a DNA fragment of the same size from all 
clones. The size of the fragment was consistent with the presence of a full-length 
scFv insert in all clones. This was substantiated by analysis for the presence of VH 
and VL components (Figure 3.68 upper and lower sections respectively).     
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Table 3. 17. Forward (LMB3) and reverse (gIII) primers used in sequencing of final selected clones. 
PRIMERS SEQUENCE FROM 5' TO 3' 
LMB3 CAGGAAACAGCTATGAC 
gIII CCCTCATAGTTAGCGTAACG 
Lin Seq new CGACCCGCCACCGCCCGCTG 
DPK9 FR1 seq CATCTGTAGGAGACAGAGTC 
pHEN seq CTATGCGGCCCCATTCA 
PelB ATGAAATACCTATTGCCTACGGCAGC 
 
 
 
 
 
 
 
Table 3. 18.  Basic sequence of heavy and light chains of scFv which were diversified in the creation of the 
Tomlinson libraries.  
 
 AMINO ACID SEQUENCE 
Heavy chain 
V3-23/DP-47 
 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGK
GLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLR
AEDTAVYYCAK 
 
Light chain 
O12/DPK9 
 
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAP
KLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQ
QSYSTPP 
 
Linker GGGGSGGGGSGGGG 
 
The highlighted sequences show CDR1 of both chains which are constant in all antibodies. The third row 
is the Gly-Ser linker sequence that connects VH and VL domains.     
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 ------------------------------------------------FR1------------------------------------------------- 
GAG GTG CAG CTG TTG GAG TCT GGG GGA GGC TTG GTA CAG CCT GGG 
 
-------------------------------------------------------------------              CDR1 
 GGG TCC CTG AGA CTC TCC TGT GCA GCC TCT        GGA TTC ACC TTT AGC 
                                                
                                              ---------------------------FR2---------------------------------- 
AGC   …..  …..  TAT GCC ATG AGC TGG GTC CGC CAG GCT CCA GGG AAG  
 
----------------------------------------                                     CDR2 
GGG CTG GAG TGG GTC TCA    TAT ATT AGT GAT …. ….  TCT GGT ACT 
                                               
                                        ------------------------------------------------------------------- 
GAT ACA TCT TAC GCAGAC TCC GTG AAG GGC CGGT TTC ACC ATC TCC 
 
-------------------------------------------------FR3------------------------------------------- 
 AGA GAC AAT TCC AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC  
 
----------------------------------------------------------------------------------------- 
CTG AGA GCC GAG GAC ACG GCC GTA TAT TAC TGT GCG AAA           TGT GCG 
                                                                                
                              CDR3                                  -----------------------FR4-------------------- 
 AAA ACT TAT GCT GGT TTT GAC TAC TGG GGC CAG GGA ACC CTG GTC  
 
------------ 
ACC GTC    
 
Figure 3. 63. Complete heavy chain nucleic acid sequence with framework regions (blue) and CDRs (red) 
highlighted 
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-------------------------------------------------FR1------------------------------------------------- 
GAC ATC CAG ATG ACC CAG TCT CCA TCC TCC CTG TCT GCA TCT GTA  
 
---------------------------------------------------------------------------              CDR1 
GGA GAC AGA GTC ACC ATC ACT TGC CGG GCA AGT         CAG AGC ATT AGC  
 
                                                 -----------------------------FR2---------------------------- 
…. …. …. ….. …. AGC TAT TTA AAT TGG TAT CAG CAG AAA CCA GGG  
 
----------------------------------------------------                               CDR2 
AAA GCC CCT AAG CTC CTG ATC TAT     AAT GCA TCC TCT TTG CAA AGT  
 
---------------------------------------------------FR3--------------------------------------------- 
GGG GTC CCA TCA AGG TTC AGT GGC AGT GGA TCT GGG ACA GAT TTC  
 
----------------------------------------------------------------------------------------------------- 
ACT CTC ACC ATC AGC AGT CTG CAA CCT GAA GAT TTT GCA ACT TAC  
 
------------                                                 CDR3                                                  ------ 
TAC TGT  CAA CAGTAT TGT CAA CAG TAT TCT TAT GGT CCT AGT ACG  
 
-----------------FR4----------------------------------------------------- 
TTC GGC CAA GGG ACC AAG GTG GAA ATC AAA CGG 
 
 
Figure 3. 64. Light chain nucleotide sequence with framework regions (blue) and CDRs (red) highlighted
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Table 3. 19.  Diversified amino acids in CDR2 and CDR3 in heavy chains of sequenced clones. Target 
specificities: N2, CspA; N3, N-terminus of Cwp66; N5, GroEL; N6, FliC; N8, FliD; N9, C-terminus of Cwp66; 
N10, SortaseB; N11,  Cwp66, L, LMW; slp, SlpA 
 
 
CLONES H50 H52 H52A H53 H55 H56 H58 H95 H96 H97 H98 
N2A9 T E K Q E S D R K P P 
N2E7 T T T P A T T T R R M 
N2G12 S S R T K G F L S K R 
N3A1 A G Y S S A R N A Y T 
N3F4 T S R L T N L N G A L 
N3H2 S G Y S S A I N A Y T 
------- ---- --- --- --- --- --- --- --- --- --- --- 
N9A11 G N Y D Y T S Y S T S 
N9B9 G T A N Y T S T G S N 
N9C9 R I P N Y T E S G H T 
------- ---- --- --- --- --- --- --- --- --- --- --- 
N11A5 T S R L T N L N G A L 
N11C1 T S R L T N L N G A L 
N11F4 S S R L T N L N G A L 
------- ---- --- --- --- --- --- --- --- --- --- --- 
N5E10 H T K E T G W R R H H 
------- ---- --- --- --- --- --- --- --- --- --- --- 
N6A4 G N S N Y T S Y G S N 
N6B5 G T A N Y T S S S T S 
N6C9 R I P N T T E S G H T 
------- ---- --- --- --- --- --- --- --- --- --- --- 
N8B4 S T S T D Y G T S S N 
N8F6 S A Y G D Y S S A Y N 
------- ---- --- --- --- --- --- --- --- --- --- --- 
N10B8 T T S L D F S P A A T 
N10D10 S T S L D F S P A A T 
N10D11 S T S L D F Q P S A T 
 
 
 
 
 
 
 
 
 
 
            CDR2                                                     CDR3 
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Table 3.19 continued 
 
 
 
 
 
 
 
 
CLCCCCL 
CLONES 
ONESONE 
H50 H52 H52A H53 H55 H56 H58 H95 H96 H97 H98 
LA6 S S G T Y S A G D S F 
LD4 
S S G T Y S A G D S F 
LF10 
S Y A ? T R K H P L I 
LG1 T G T Y S S A N A A A 
LG7 G S T H S R Q N G T L 
LH1 T G T Y S S A N A A A 
-------- ---- --- --- --- --- --- --- --- --- --- --- 
slpA9 G S T H S R Q N G T L 
slpA10 T S T A K G H N Y P A 
slpE10 L N A A T R L S M R A 
 
 
 
 
 
 
 
 
 
 
                   CDR2                                                              CDR3 
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Table 3. 20.  Diversified amino acids in CDR2 and CDR3 in light chains of sequenced clones. Target 
specificities: N2, CspA; N3, N-terminus of Cwp66; N5, GroEL; N6, FliC; N8, FliD; N9, C-terminus of Cwp66; 
N10, SortaseB; N11,  Cwp66, L, LMW; slp, SlpA 
 
CLONES L50 L53 L91 L92 L93 L94 L96 
N2A9 R H R M R A L 
N2E7 H R G T T L M 
N2G12 A S Q H R A H 
------- --- --- --- --- --- ---- --- 
N3A1 A Y S D N S A 
N3F4 A L S S V S P 
N3H2 A Y S D N S A 
------- --- --- --- --- --- --- --- 
N9A11 H G T A D S S 
N9B9 N S D G N S D 
N9C9 N I N S D A F 
------- --- --- --- --- --- --- --- 
N11A5 G S A W A L N 
N11C1 A L S S V S P 
N11F4 A L S S V S P 
------- --- --- --- --- --- --- --- 
N5E10 G Y F S R K S 
------- --- --- --- --- --- --- --- 
N6A4 D N S N S Y S 
N6B5 N Y G N N N S 
N6C9 Q N P V S A P 
-------- --- --- --- --- --- --- --- 
N8B4 G S D S N T A 
N8F6 S A A S N T G 
-------- --- --- --- --- --- --- --- 
N10B8 A S T T S T D 
N10D10 A S N L S T D 
N10D11 A S N T S T D 
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Table 3.20 continued 
 
 
 
 
 
 
 
 
CLONES L50 L53 L91 L92 L93 L94 L96 
LA6 S T A S S S T 
LD4 S T A S S S T 
LF10 M M K K A T A 
LG1 A S Y A Y Y T 
LG7 Q E A Q S N Q 
LH1 A S Y A Y Y T 
-------- --- --- --- --- --- --- --- 
slpA9 Q E A Q S N Q 
slpA10 P N H A T T P 
slpE10 K R G/E M S G T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CDR2                                             CDR3 
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Figure 3. 65. Vector map of phagemid pIT2 
ScFv is cloned between pelBleader and gIII protein of phage M13.  
 
 
 
 
Figure 3. 66. Sequence region of restriction sites on phagmid pIT2. 
VH sequence is inserted between NcoI and XhoI sites and VL lies between SalI and NotI. Each scFv 
includes a his tag and c-myc-tag before the TAG stop codon. The full length scFv can be excised by 
digestion with NcoI and NotI  sites while  
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Figure 3. 67. Restriction analysis for the presence of full-length scFv inserts in clones from the Tomlinson 
library. 
Plasmid DNA from each clone was digested with NcoI and NotI. Release of a full-length scFv insert is 
expected to result in a fragment of 717 bp.  
From the left: M, 1kb DNA ladder (Promega); Lane 1, N8B4; lane 2, N8B5; lane 3, N8A6; lane 4, N6B5; lane 
5, N6F1; lane 6, LF10; lane 7, LH1; lane 8, LG7; lane 9, LG1; lane 10, LA6; lane11, LD4; lane 12, slpA10; lane 
13, slpE10; lane 14, slpA9; M, 1kb plus marker (Invitrogen).  
Clones designated N6 were isolated by panning against FliD, N8 are directed against FliC, L indicates 
binding to LMW, and clones designated  slp were isolated against slpA. 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             M       1       2        3       4        5       6       7        8        9     10      11     12      13    14     M 
 
                                                                                                                                                                                      850bp 
                  750bp                                                                                                                                                         650BP 
                                                                                                
                                                                                                                                  
                    
                  250bp 
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Figure 3. 68. Restriction analysis of selected clones from Tomlinson library. 
Upper gel: Plasmid of each clone was digested with NcoI and XhoI . The expected appearing fragment is 
340 bp. Lower gel: digestion with SalI and NotI with expecting a 325 bp fragment size.From left: 1kb puls 
marker (Invitrogen); Lane 1, N8B4; lane 2, N8B5; lane 3, N8A6; lane 4, N6B5; lane 5, N6F1; lane 6, LF10; 
lane 7, LH1; lane 8, LG7; lane 9, LG1; lane 10, LA6; lane11, LD4; lane 12, slpA10; lane13, slpE10; lane 14, 
slpA9; 1kb DNA ladder (Promega). N6=fliD, N8=fliC, L=LMW AND slp=slpA. 
    
 
 
 
 
 
 
 
 
 
 M      1      2      3     4      5      6     7      8     9     10    11   12    13    14    M 
                                                                                                                                                                        500bp 
400bp                                                                                                                                                
300bp                                                                                                                                                              250bp 
                                                                                                                                                                      500bp 
400bp                                                                                                                                                
300bp                                                                                                                                                          250bp 
 Chapter 4                                        Discussion                                                                  199  
        
 
 
3.3.6 Antibody purification 
       Recombinant antibodies from the Tomlinson libraries are expressed as 
monovalent scFv proteins with histidine and c-myc tags at carboxy-termini (Figure 
3.66). The histidine tag can be used to purify the soluble fragments through nickel 
affinity chromatography and as detailed earlier, immunodetection of the presence 
of the protein is possible using reagents directed towards the c-myc component.     
         A large culture (200-500 ml) of each E. coli HB2151 clone carrying a specific 
scFv was induced with IPTG. Supernatants from overnight cultures were 
concentrated with 80% ammonium sulphate or ultrafiltration concentrators with a 
10 kDa cut-off in order to reduce the volume of sample to be processed. 
Concentrated fractions or dialysed samples from ammonium sulphate 
precipitation were passed through an equilibrated nickel chelating column 
allowing the scFv protein to bind. To elute the attached proteins, 200mM 
imidazole was pumped through the column and at least 5 fractions were collected. 
Fractions were initially checked via dot blotting to assess for the presence of 
protein with the c-myc tag. Those fractions that showed positive signals were 
pooled.  
Figures 3.69 and 3.70 show dot blots of fractions from purification of scFvs 
against FliC, FliD, LMW and SlpA. Based on the blot analysis, and the green 
colorimetric signal, scFv was recovered from each purification in a variable number 
of fractions.  Pooled fractions from each purification were sampled and analysed 
by SDS-PAGE. Figures 3.71 and 3.72 show the presence of a band of 30kDa, the 
expected molecular weight for a scFv protein. The concentration of the scFvs and 
their purity were variable. For example, the anti-FliD scFv N6C9 (lane 4 in Figure 
3.71) was detectable but recovered at low concentration when compared to other 
anti-FliC and anti-FliD antibodies shown in Figure 3.71. scFv LA6 (lane 4, Figure 
3.72) was also recovered at low concentration. The scFvs against FliC (lanes 5 to 9, 
Figure 3.71) were generally recovered with good purity, accepting that in lane 9 
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(scFv N8B4) trace impurities are evident but the overall concentration of scFv 
appears higher than in other samples. In contrast, anti-FliD antibodies were 
typically recovered with contaminating proteins of variable molecular weight (eg 
N6B5 [lane 1, Figure 3.71] versus N6F1 [lane 3 in the same Figure]) and for N6A5 
(lane 2), the contaminant was present at roughly equal concentration to the scFv. 
Although greater consistency of purity was achieved for scFvs against LMW and 
SlpA (Figure 3.72), the antibodies were recovered at a range of concentrations (eg 
LA6 [lane 4] was present at very low concentration whereas LG7 [lane 2] was more 
abundant). Irrespective of outcome, pooled fractions were concentrated using an 
ultrafiltration concencentrator with a 10 kDa cut-off and stored at -20˚C pending 
further analysis. 
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Figure 3. 69. Dot blot analysis from purification of anti FliC (N6) and anti FliD (N8) scFvs. Spotted 
samples on the Hyband C membrane were from different fractions of purification scFv through 
the Ni-chromatography. The presence of antibodies were detected with anti-c-myc reagent.  
The green signal was developed by adding anti-rabbit-HRP and TMB.  
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Figure 3. 70. Dot blot analysis from purification of anti LMW and anti SlpA scFvs. Spotted samples on 
the Hyband C membrane were from different fractions of purification scFv through the Ni-
chromatography. Presence of antibodies was detected with anti-c-myc reagent after blocking with 
2%MPBS. The green signal was developed by adding anti-rabbit-HRP and TMB.  
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Figure 3. 71. SDS-PAGE analysis of purified scFvs  against recombinant FliC and FliD.  
Columns were loaded with sample after adjusting pH and buffer conditions and washed with binding 
buffer initially without imidazole and then with buffer containing a low concentration of imidazole(40 
mM). The scFv protein was eluted with 200 imidazole in binding buffer. 
From the left: Marker (SeeBlue Plus2 pre-stained molecular weight markers (Invitrogen); lane 1, N6B5; 
lane 2, N6A6; lane 3, N6F1; lane 4, N6C9; lane  5, N8A6; lane  6, N8B5; lane 7, N8F6; lane 8, N8B4. 
scFvs designated N6 are directed against FliD, N8 indicates anti-FliC antiobodies. 
 
 
 
Figure 3. 72. SDS-PAGE analysis of pooled purified fractions of  scFvs  against recombinant LMW  and 
extracted SlpA. Columns were loaded with sample after adjusting pH and buffer conditions and washed 
with binding buffer initially without imidazole and then with buffer containing a low concentration of 
imidazole (40 mM). The scFv protein was eluted with 200 mM imidazole in binding buffer.From left: 
Marker (SeeBlue Plus2 Pre-Stained molecular weight markers( invitrogen), lane 1, LF10; lane 2, LG7; lane 
3, LD4; lane 4, LA6; lane 5, LG1; lane 6, LH1; lane 7,  slpE10; lane  8, slpA10; lane 9,slpa9. scFvs designated 
L are directed against LMW, slp indicates anti-slpA antiobodies. 
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3.3.7 Western blot analysis of selected scFvs against targets 
3.3.7.1 Immunoblot analysis with recombinant target proteins 
          Polyacrylamide gel electrophoresis and Western blotting were carried out to 
determine the specificity of the purified recombinant antibodies and to assess if 
they would recognise the clostridial target proteins after denaturation in SDS. 
Recombinant target proteins were run on SDS gels and then blotted to Hybond 
membrane which was the divided and individual strips were probed with scFvs 
against the target. The binding of scFvs was detected with anti c-myc antibody and 
anti rabbit-HRP as the developing reagent. In preliminary experiments, a mixture 
of three scFvs directed against a particular target was used in Western blot to 
reduce the number of blots required to screen all scFvs. Having established in 
these experiments that the scFvs would work on Western blots, single scFvs were 
then used.  Figures 3.73 – 3.80 show the results of these experiments.  
 
      The first general finding that is apparent through all Figures is that the scFvs 
were capable of recognising the recombinant clostridial proteins despite their 
treatment with SDS sample buffer and heating in preparation for SDS-PAGE. As 
regards the properties of groups of scFvs, signal strength in the blots was generally 
high with the exception of reactions against FliC (Figure 3.77). This was unlikely to 
be due to limitations of target on the blot since the FliC protein was successfully 
expressed and purified (Figure 3.29, lane 18). In many cases, cross-reaction or non-
specific binding to other proteins on the blots was minimal but in Figure 3.76, 
some differences can be observed between anti-FliD scFvs N6A4 and N6B5 (left 
and central panels; little binding to other proteins on the blot), and N6C9 which 
appears to bind to other species (right panel). In contrast, the anti-Cwp66 
antibodies N11A5, N11C1 and N11F4 appear more consistent in their binding to a 
contaminating protein of about 64 kDa (Figure 3.80).   
 
 
 
Chapter 3 Results 
 
205 
3.3.7.2 Immunoblot analysis with native C. difficile proteins 
With the exception of the anti-SlpA antibodies, all scFvs isolated from the 
Tomlinson libraries used recombinant clostridial proteins as targets and hence 
their ability to recognise the native proteins from C. difficile remained unknown to 
this point in the project. To address this issue, extracts from overnight cultures of 
C. difficile were prepared, run in SDS-PAGE and transferred to membranes so that 
the recognition of native proteins could be assessed via Western blotting. As an 
alternative approach for scFs directed against components of the clostridial 
surface layer, native electrophoresis was also carried out to determine if the 
behaviour of these antibodies changed when SDS was omitted from the 
electrophoretic separation. 
      Figure 3.81 shows the recognition by a range of scFvs of SlpA extracted from 
the surface of C. difficile 630. Note that scFvs with the “L” designation were 
originally isolated by panning with recombinant LMW protein whereas those with 
the “Slp” were extracted from the Tomlinson libraries using clostridial extracts. 
Reference to the middle row in Figure 3.81 illustrates that the dominant 
components of the bacterial extracts are two proteins, one of them under 50 kDa 
and one of a lower molecular weight (around 36 kDa). In the middle row, it can be 
seen that scFv LG1 (left panel) binds to the heavier of these proteins, whereas LF10 
(middle panel) and LG7 (right panel) recognise the lower molecular weight 
component. For LF10 and LG7, faint signal can be observed towards the 50 kDa 
molecular weight marker confirming this pattern. Other scFvs isolated by panning 
on the LMW protein (LD4, LH1, LA6; top row of the Figure) were consistent in their 
recognition of the higher molecular weight protein. Two scFvs isolated from 
panning on SlpA extracts (SlpA9 and SlpE10) recognised the lighter species (bottom 
row of the Figure) whilst a third bound to the 50 kDa form.  In summary, all the 
anti-SlpA scFvs recognised native target protein from C. difficile 630 in 
conventional Western blotting but whereas LA6, LD4, LG1, LH1 and SlpA10 could 
bind to the high molecular weight component, LF10, LG7, SlpA9 and SlpE10 
recognised the smaller protein.  
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Since the sequences of SlpA proteins possess conserved and variable 
regions, all nine scFvs against SlpA were tested in Western blotting using extracts 
from C. difficile 630 and two other strains, R20291 and M120 (Figure 3.82). None 
of the scFvs were able to bind to SlpA from C. difficile R20291 (central lane in each 
panel) but all showed the capacity to bind to SlpA components from strains 630 
and M120 and the characteristics described earlier – the ability to recognise high 
and low molecular weight components of SlpA – was also evident. Recombinant 
antibodies LF10, LG7, SlpA9 and SlpE10 could all bind to the low molecular weight 
protein from 630 and M120. The remaining scFvs, (LA6, LD4, LG1, LH1 and SlpA10) 
recognised the high molecular weight component of SlpA from strain 630 but also 
the smaller protein from M120.  
      Thus, the binding of scFvs to SlpA from C. difficile 630 was consistent with data 
presented earlier (Figure 3.81) but in contrast, all scFvs bound to the low 
molecular weight component of SlpA from strain M120. In some cases, this 
recognition resulted in strong signals on Western blots (scFvs LD4 and LF10; Figure 
3.82, top row central and right hand panels respectively, note the right lane in 
each case) whereas other scFvs reacted less strongly with material from M120 
versus 630 (LG1; middle row, left hand panel). In some instances, some recognition 
of the higher molecular weight protein in SlpA from C. difficile M120 was also 
evident (LG7 [middle row, central panel], SlpA9 [bottom row, left panel], SlpA10 
[bottom row, right panel]) but signal strength was weak in these cases. 
Further analysis was pursued by separating proteins by native 
electrophoresis and Western blotting. Using this approach the separation of high 
and low molecular weigh constitutents of the SlpA of C. difficile 630 was less 
apparent and the ability of scFvs LF10 and LG7 to react with the lower molecular 
weight component of SlpA described earlier was lost (Figure 3.83 top row, right 
panel; middle row, central panel). Other scFvs shown to be reactive with this 
protein (SlpA9, SlpE10; Figure 3.83 lower row left and right panels respectively) 
retained some reactivity with a low molecular weight constitutent but binding to 
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the main complex appeared dominant. Also, scFv LH1, shown in previous 
experiments to recognise the higher molecular weight protein from SlpA, showed 
some reaction with a lighter species (Figure 3.82 middle row right panel) so non-
specific binding might underlie the result. Native electrophoresis again showed 
that none of the panel of scFvs were able to bind to extracts from C. difficile 
R20291. Interaction with a protein from M120 of comparable molecular weight to 
the smaller protein from SlpA was retained. This was evident for all scFvs tested 
(Figure 3.83). 
The scFvs which were isolated against recombinant FliC and FliD were also 
tested against native forms of the proteins using crude flagellar extracts from C. 
difficile and Western blotting. For the scFvs against FliD , no signal was detected in 
Western blotting. Given the strong reaction of scFvs N6A4, N6B5 and N6C9 with 
recombinant FliD (Figure 3.76) , the result with bacterial extracts most probably 
arose because of the low amounts of FliD in the flagellar preparations. In contrast 
with Figure 3.77, Figure 3.83 shows the scFvs against recombinant Flic could bind 
to native proteins with molecular weights between about 28 and 38 kDa that were 
present in the flagellar extracts from C. difficile 630. All three scFvs had an ability 
to bind to these proteins; the complexity of the pattern of signals was unexpected 
and reaction with a protein so close to the 38 kDa molecular weight makers was 
unexpected since FliC from C. difficile 630 is known to have a molecular weight of 
around 33 kDa owing to glycolsylation of the protein (predicted molecular weight 
of the translation product is 30.7 kDa). The heaviest band in the profile was 
notable for its similarity of size to the LMW component of SlpA. Binding to a 
protein in flagellar extracts from strain R20291 was weaker but still detectable. 
Given the crude nature of the surface and flagellar extracts, the extent of 
cross-contamination and potential cross-reaction was explored using Western 
blotting with an anti-FliD scFv (N8B5) and LG7 which was isolated against a 
recombinant preparation of the LMW component of SlpA. Data is shown in Figure 
3.85. Panels 1 and 2 carry flagellar extracts of C. difficile 630 and the blots were 
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probed with N8B5 and LG7 respectively. The target in panels 3 and 4 were surface 
extracts; again, these were probed with N8B5 (panel 3) and LG7 (panel 4). The 
alignment of molecular weight makers in the Figure is imperfect but it appears 
from comparison of panels 1 and 2 that N8B5 is reactive with a component of the 
flagellar extract of similar molecular weight to the contaminating LMW component 
of SlpA present in these extracts. Cross reaction between N8B5 and LMW seems 
unlikely from the patterns of reaction shown in panels 3 and 4.    
Figure 3.86 presents an analysis of the properties of recombinant antibodies 
against CspA. The lysates of three strains (630, M120 and R20291) were used as 
targets from the blots. The Western blots showed that binding was only evident 
from extracts of M120 and in each case, antibody attachment appeared to take 
place to LMW of SlpA of M120 or a protein of similar molecular weight. The 
predicted molecular weight of native CspA is 7 kDa. In Figure 3.87 illustrates the 
reaction of scFvs against GroEL with proteins in extracts from the same strains of 
C. difficile. A signal at 60 kDa suggests specific reaction with GroEL in extracts from 
all strains (left panel) with scFv antibody N5E10. Other weak signals were 
developed around 50 kDa in 630 extracts for all three scFvs but the strongest 
signals are  at 36 kDa, against suggestive of a reaction with the LMW component of 
SlpA from strain   M120. Therefore based on Figure 3.87, three independent scFvs 
against GroEL appear able to bind to LMW of SlpA from M120. In Figure 3.88 the 
scFvs against recombinant SortaseB were tested in Western blots.  A band of 
around 27 kDa was expected in this experiment. As the Figure shows, the three 
anti-Sortase scFvs also bound strongly to the LMW from M120 strain, although 
weaker signals from a 50kDa protein can be also be seen.    
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Figure 3. 73. Western blot analysis of CspA probed with scFvs 
Recombinant CspA (24.96 kDa) was separated by SDS-PAGE and transferred to Hybond membrane that 
was then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate was used to detect 
the binding of scFv.  
In each panel, the left hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
standards (Invitrogen). The sizes of relevant molecular weight markers are indicated.  scFvs used for the 
analysis were as follows: 
Left panel:  N2A9; middle panel, N2E7; right panel N2G12. 
 
 
 
 
 
 
Figure 3. 74.Western blot analysis of N terminal of Cwp66 probed with scFvs 
Recombinant N-terminal of cwp66 (47.07 kDa) was separated by SDS-PAGE and transferred to Hybond 
membrane that was then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate 
was used to detect the binding of scFv.  
In each panel, the left hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
standards (Invitrogen). The sizes of relevant molecular weight markers are indicated.  scFvs used for the 
analysis were as follows: 
Left panel:  N3A1; middle panel, N3F4; right panel N3H12.
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Figure 3. 75.  Western blot analysis of  GroEL probed with scFvs 
Recombinant groEL (72.2 kDa) was separated by SDS-PAGE and transferred to Hybond membrane that 
was then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate was used to detect 
the binding of scFv.  
In each panel, the left hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
standards (Invitrogen). The sizes of relevant molecular weight markers are indicated.  scFvs used for the 
analysis were as follows: 
Left panel:  N5E10; right panel; N5E9. 
 
 
 
 
Figure 3. 76.  Western blot analysis of  FliD probed with scFvs 
Recombinant fliD (75.78 kDa) was separated by SDS-PAGE and transferred to Hybond membrane that 
was then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate was used to detect 
the binding of scFv.  
In each panel, the left  hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
standards (Invitrogen). The sizes of relevant molecular weight markers are indicated.  scFvs used for the 
analysis were as follows: 
Left panel:  N6A4; middle panel, N6B5; right panel N6C9. 
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Figure 3. 77. Western blot analysis of  FliC probed with scFvs 
Recombinant fliC (48.04 kDa) was separated by SDS-PAGE and transferred to Hybond membrane that was 
then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate was used to detect the 
binding of scFv.  
In each panel, the left  hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
standards (Invitrogen). The sizes of relevant molecular weight markers are indicated.  scFvs used for the 
analysis were as follows: 
Left panel:  N8F6; middle panel, N8B4; right panel N8A1. 
 
 
 
 
 
 
 
 
 
 Figure 3. 78.  Western blot analysis of  N-terminal of Cwp66 probed with scFvs 
Recombinant N-terminal of  cwp66 (53.94) was separated by SDS-PAGE and transferred to Hybond 
membrane that was then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate 
was used to detect the binding of scFv.  
In each panel, the left  hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
standards (Invitrogen). The sizes of relevant molecular weight markers are indicated.  scFvs used for the 
analysis were as follows: 
Left panel:  N3A1; middle panel, N3F4; right panel N3H2. 
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 Figure 3. 79. Western blot analysis of  Sortase B  probed with scFvs 
Recombinant sortase b (43.38 kDa) was separated by SDS-PAGE and transferred to Hybond membrane 
that was then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate was used to 
detect the binding of scFv.  
In each panel, the left  hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
standards (Invitrogen). The sizes of relevant molecular weight markers are indicated.  scFvs used for the 
analysis were as follows: 
Left panel:  N10D11; middle panel, N10D10; right panel N10B8. 
   
 
 
 
 
 
 
Figure 3. 80.  Western blot analysis of  Cwp66  probed with scFvs 
Recombinant cwp66 (83.31 kDa) was separated by SDS-PAGE and transferred to Hybond membrane that 
was then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate was used to detect 
the binding of scFv.  
In each panel, the left  hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
standards (Invitrogen). The sizes of relevant molecular weight markers are indicated.  scFvs used for the 
analysis were as follows: 
Left panel:  N11A5; middle panel, N11C1; right panel N11F4.
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Figure 3. 81. Western blot analysis of SlpA extracted from C. difficile 630 probed with scFvs 
Extracted SlpA from C. difficile 630 was separated by SDS-PAGE and transferred to Hybond membrane 
that was then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate was used to 
detect the binding of scFv.  
In each panel, the left hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
markers (Invitrogen). 
Upper row: left panel, LD4; middle panel, LH1; right panel, LA6.  
Middle row: left panel, LG1; middle panel, LF10; right panel, LG7.  
Bottom row: left panel, SlpA9; right panel, SlpE10.   
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Figure 3. 82.  Western blot analysis of SlpA extracted from C. difficile 630, R20291 and M120 probed with 
scFvs 
Extracted SlpA from C. difficile 630, R20291 and M120 were separated by SDS-PAGE and transferred to 
Hybond membrane that were then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP 
conjugate was used to detect the binding of scFv.  
In each panel, the left hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
markers (Invitrogen). 
Upper row: left panel, LA6; middle panel, LD4; right panel, LF10.  
Middle row: left panel, LG1; middle panel, LG7; right panel, LH1.  
Bottom row: left panel, SlpA9; right panel, SlpE10.   
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Figure 3. 83. Western blot analysis of SlpA extracted from C. difficile 630, R20291 and M120 probed with 
scFvs 
Extracted SlpA from C. difficile 630, R20291 and M120 were separated by 8% native electrophoresis and 
transferred to Hybond membrane that were then probed with an individual scFv. Anti c-myc and an anti 
rabbit-HRP conjugate was used to detect the binding of scFv.  
In each panel, the left hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
markers (Invitrogen). 
Upper row: left panel, LA6; middle panel, LD4; right panel, LF10.  
Middle row: left panel, LG1; middle panel, LG7; right panel, LH1.  
Bottom row: left panel, SlpA9; middle panel, SlpA10; right panel, slpE10.   
 
 
 Chapter 4                                        Discussion                                                                  216  
        
 
 
 
Figure 3. 84. Western blot analysis of flagellum preparation from C. difficile 630 and  R20291 probed with 
scFvs. 
Flagellum preparation  from C. difficile 630 and  R20291  were separated by SDS electrophoresis and 
transferred to Hybond membrane that were then probed with an individual scFv. Anti c-myc and an anti 
rabbit-HRP conjugate was used to detect the binding of scFv.  
In each panel, the left hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
markers (Invitrogen). 
Left panel, N8A6; middle panel, N8B4; right panel, N8B5.  
  
 
 
 
 
 
 
 
Figure 3. 85.  Western blot analysis of  FliC and LMW extracted from C. difficile 630  probed with scFvs. 
Extracted fliC and SlpA from C. difficile 630 were separated by SDS-PAGE and transferred to Hybond 
membrane that were then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate 
was used to detect the binding of scFv.  
In each panel, the left hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
markers (Invitrogen).panel 1, N8A6; panel 2, LG7; panel 3, N8B5; panel 4, LG7.  
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Figure 3. 86. Western blot  analysis of  CspA from C.difficile, 630, M120 and R20291 probed  with scFvs. 
Bacterial lysate of three strains were  separated by SDS-PAGE and transferred to Hybond membrane that 
was then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate was used to detect 
the binding of scFv.  
In each panel, the left  hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
standards (Invitrogen). The sizes of relevant molecular weight markers are indicated.  scFvs used for the 
analysis were as follows: 
Left panel:  N2A9; middle panel, N2E7; right panel N2G12. 
 
 
 
 
 
 
 
Figure 3. 87. Western blot  analysis of  CspA from C.difficile, 630, M120 and R20291 probed  with scFvs. 
Shocked bacterial lysate (42 ˚C) of three strains were  separated by SDS-PAGE and transferred to Hybond 
membrane that was then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate 
was used to detect the binding of scFv.  
In each panel, the left  hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
standards (Invitrogen). The sizes of relevant molecular weight markers are indicated.  scFvs used for the 
analysis were as follows: 
Left panel:  N5E10; middle panel, N5A1; right panel N5E9. 
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Figure 3. 88. Western blot  analysis of  CspA from C.difficile, 630, M120 and R20291 probed  with scFvs. 
Bacterial lysate of three strains were  separated by SDS-PAGE and transferred to Hybond membrane that 
was then probed with an individual scFv. Anti c-myc and an anti rabbit-HRP conjugate was used to detect 
the binding of scFv.  
In each panel, the left  hand lane shows the migration of SeeBlue Plus2 pre-stained molecular weight 
standards (Invitrogen). The sizes of relevant molecular weight markers are indicated.  scFvs used for the 
analysis were as follows: 
Left panel:  N10B8; middle panel, N10D11; right panel N10D10.
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3.3.8 Analysis of the  effect of antibodies on bacterial  motility 
       To determine the biological effects of scFvs against FliC and FliD, bacterial 
motility tests were carried out in the presence of these antibodies. To each 
counted incoulum of overnight culture of C. difficile 630 (105  CFU per sample), 
scFv was added and after incubating for one hour in anaerobic cabinet, 10 µl of the 
mixture was stabbed into 0.2% BHI agar. LA6  was used as a control for a scFv 
which was not reactive against flagellar proteins. The stabs prepared without 
antibody or inocula mixed with LA6 showed good evidence of the bacterial 
motility. Of the nine scFvs against FliC and the nine anti-FliD scFvs, four anti-FliD 
antibodies and four anti-FliC scFvs could inhibit bacterial motility.  
      Based on the results shown in Table 3.21, in total five antibodies were chosen 
for the second part of the inhibition test. Figure 3.89 shows the effects of serial 
dilution of the different scFvs on motility of bacteria. Each row shows 3 tubes each 
stabbed with 105 CFU following incubation of the bacterial cells with undiluted 
scFv and 1/10 and 1/100 dilutions of the antibodies. No motility could be seen by 
at any of the three dilutions after 48 hours incubation. In the last row of the 
Figure, tubes show the diffuse pattern of growth observed with a culture of 
Clostridium difficile 630 (left), the same strain after incubation with the control 
scFv LG6, and a stab prepared with the non-motile strain M120. Based on 
comparisons, strong evidence was obtained that the scFvs against FliC and FliD 
could inhibit bacterial motility.   
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Table 3. 21. Comparing of the effect of different scFvs on mobility of C.difficile 630 
scFvs AGAINST 
FliD 
24H 48H 
scFvs AGAINST 
FliC 
24H 48H 
N6A4 SM SM N8A1 SM SM 
N6A6 SM SM N8A6 NM NM 
N6A8 SM SM N8B4 NM NM 
N6B5 NM NM N8B5 NM NM 
N6C9 NM NM N8F1 SM SM 
N6D4 NM NM N8F6 NM NM 
N6D12 SM SM N8H2 SM SM 
N6F1 NM NM N8H5 SM SM 
N6H11 SM SM N8H11 SM SM 
  *SM=some motility, NM=non motile 
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From left:  
C. difficile 630, LA6+bacteria and C. difficile  
M120 
 
Figure 3. 89. Effect of recombinant antibodies on the motility of C. difficile  
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3.3.9 Indirect immmunoflurecsence and electron microscopy 
         In the final phase of the analysis, the scFvs were tested in 
immunofluorescence microscopy and immuno gold electron microscopy to assess 
if the surface location and distribution of target proteins could be determined by 
imaging methods. Experimental approaches included the use of Protein A-FITC to 
detect directly the presence of scFv at the bacterial surface or the use of anti c-
myc and anti-rabbit conjugated reagents.  
      In immunofluorecsence, most of the antibodies were found to be reactive with 
C. difficile M120, again supporting the notion that the LMW for SlpA of this strain 
was able to bind scFvs in a non-specific manner. N8F6 and N6F1 were carried out 
in this test for using C. difficile strains 630 and R20291. In both strains the selected 
scFvs generated strong signals at the bacterial surface (Figure 3.89). Of those 
antibodies able to bind to the LMW component of SlpA, scFvs LF10 and SlpA9 were 
tested in immunofluorescence with strains 630 and M120 strains. Both antibodies 
showed binding to the surface of bacterial cells (Figure 3.90). In these experiments, 
slides were also prepared without adding antibody (negative control) and mouse 
anti SlpA (positive control).  
       The resolution of these methods was insufficient to assess patterns of protein 
distribution. To address this, the antibodies were tested in immuno gold electron 
microscopy. Two labelling methods were tested: in the first,  Protein A-gold was 
used in an attempt to detect the presence of scFv on sections; in the second, anti 
c-myc and anti rabbit-gold conjugates were used step-wise with the same 
objective. The first approach did not show any signs of gold particles on the grids 
while the second was more successful. In preparation for electron microscopy, 
bacteria were cultured in agar based medium and in liquid culture in an attempt to 
assess whether these conditions impacted upon the synthesis and assembly of 
proteins at the bacterial surface. Figures 3.91 and 3.92 show the results of 
attempts to label flagella and surface protein, respectively. The quality of the 
sections is good and while gold particles are clearly evident, their distribution does 
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not show evidence of the specific labelling of flagella (Figure 3.91) or high 
concentration of target proteins at the bacterial surface (Figure 3.92) as was 
evident in immunofluorescence. 
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A: N8F6-strain630                              B: N6F1-strain 630 
 
C: N8F6-strain R20291                       D: N6F1-strain R20291                               
 
 
Figure 3. 90. Detection of  flagellum of two strains (630 and R20291) in indirect immunofluorescence test. 
N6=fliC and N8=fliD. The overnight bacterial bodies were attached on the slide using cytospin. The 
regents were step by step added with interval PBS washing.     
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A: LF10-strain 630                               B: slpA9-strain 630 
 
 
A: LF10-strain M120                            B: slpa9-strain M120 
 
 
Figure 3. 91. Detection of surface layer protein on the surface of 630 and M120 strains in indirect 
immunofluorescence.  Both checked antibodies were against LMW.  The overnight bacterial bodies were 
attached on the slide using cytospin. The regents were step by step added with interval PBS washing 
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A: N8F6 
 
B:N6F1 
 
 
Figure 3. 92. Immunogold labelling of C. difficile 630 with recombinant antibodies against flagellum. 
Bacterial bodies were fixed and added on the grids from a plate agar based medium. The prepared  grids 
were incubated with scFvs, anti c-myc and anti rabbit-gold respectively before examining in TEM.A) 
N6=fliC and B)N8=fliD    
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A: LF10 
 
B: slpA9 
 
 
Figure 3. 93. Immunogold lablling of C. difficile 630 with recombinant antibodies against surface layer 
protein. Bacterial bodies were fixed and added on the grids from a liquid medium. The prepared  grids 
were incubated with scFvs, anti c-myc and anti rabbit-gold respectively before examining in TEM. A)LF10 
and B)slpA9   
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4.1 Surface proteins in Gram positive bacteria 
     The surface of each microbial pathogen forms the frontier for encounter with 
the host and it is therefore inevitable that bacterial proteins in this location 
possess a variety of functions of significance to interaction with the host. The 
nature of these surface proteins and their activities can be exploited for 
identification and characterisation of the pathogen, the detection of the 
pathogen’s presence in the host, the development of antimicrobials and vaccines. 
Given the importance of their location, the functions of bacterial surface proteins 
are diverse, ranging between factors required for growth and cell division, to 
adherence, colonisation and the formation of biofilms, to lytic enzymes required 
for dissemination in the host, and toxins.  
    There are different types of systems in Gram positive bacteria to deliver these 
proteins to the surface.  Proteins can be targeted to the cytoplasmic membrane 
through possession of an amino terminal signal peptide, a defining feature of one 
transport pathway. Most surface proteins are transferred in an unfolded state 
from the cytoplasmic side of the membrane to the outer side via this process, 
known as the General Secretory Pathway, or Sec-dependent pathway because of 
the contribution of proteins (SecY, E, G, F, F and A) that assemble into channel and 
ATP-driven motor complexes. In contrast, the TAT (twine argentine) pathway is 
involved in the transport of proteins across the membrane in a folded state. Other 
protein transportation systems have also been described such as ATP- binding 
transporters employed in the export of bacteriocins or holin- like proteins (Scott 
and Barnett, 2006).  
     If proteins that are transported via these systems are destined for attachment 
at the bacterial surface, covalent and non-covalent attachment may take place. In 
covalent attachment, a transpeptidase termed a “sortase” may attach the protein 
to peptidoglycan, exploiting conserved carboxy-terminal features. The enzyme was 
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originally identified in Staphylococcus aureus (Mazmanian et al., 1999) but  
enzymes with similar activities have been discovered in a variety of Gram positive 
bacteria such as  Listeria monocytogenes (Bierne et al., 2002), Bacillus anthracis 
(Gaspar et al., 2005) and streptococcal species (Barnett and Scott, 2002, Bolken et 
al., 2001). Generally the protein substrate carries a carboxy-terminal anchoring 
domain consisting of an LPXTG motif that can be recognised by sortase which then 
carries out transpeptidation at the theronine residue. Other forms of surface 
attachment can take place by transglycoslyation and transpeptidation. Another 
feature of the action of sortase A is in the polymerisation of pilli as observed in 
Streptococcus agalactiae (Lauer et al., 2005). Reports have shown that sortases 
other than sortase A exist with different substrate sequences such as NPQTN for 
sortase B (Mazmanian et al., 2002) in S. aureus and QVPTGV for sortase C2 from S. 
pyogenes (Barnett et al., 2004) .    
      Non-covalent interactions can also bind proteins to the surface of Gram 
positive bacteria. Binding to teichoic or lipoteichoic acid is one such process in 
which repeats at the carboxy-terminus of the surface protein can mediate 
attachment to the cell wall. PspA and LytA are two examples of choline binding 
proteins from S. pneumoniae that attach in this way (Briles et al., 1998, Holtje and 
Tomasz, 1975). In other examples, glycine-tryptophan rich (GW repeats) as found 
in InlB from L. monocytogenes mediate binding to lipoteichoic acid (Gaillard et al., 
1991). The other group of highly abundant proteins that attach non-covalently to 
the surface are the surface layer proteins. In these examples,  the amino-terminus 
of the proteins form a domain that is involved in non-covalent attachment 
(Etienne-Toumelin et al., 1995). The LysM motif is a further example of a discrete 
protein domain which is responsible for non-covalent binding of proteins on the 
surface of Gram positive bacteria.  The major autolysin (AcmA) of Lactococcus 
lactis is one example of a protein that contains this domain, essential for 
attachment to the surface (Steen et al., 2003). 
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4.2 Surface proteins of C. difficile 
     The large glucosyltransferase toxins of C. difficile and the ribosyltransferase 
binary toxin produced by some strains are known to play important roles in the 
pathogenesis of infection. However, the surface proteins of vegetative cells have 
also attracted attention in attempts to clarify their roles and their functions in the 
pathogenic process.  
      Proteomic studies have used different methods to extract proteins from the 
bacterial surface and have documented a wide range of around 49 components. 
Although many have proved to be paralogs of SlpA , the main component of the 
surface layer, others have been related to the flagellum, proteins with enzymic 
activities, transporters, and proteins elicited by heat or cold (Wright et al., 2005). 
These surface proteins are likely to contribute many different functions to the 
biology of C. difficile but amongst them, a group of 29 have been classified as a 
family through the possession of a putative cell wall binding domain. In addition to 
members of this family, other proteins are also considered very likely to be 
components of the bacterial surface. A sortase has been identified along with 
seven putative sortase substrates; one of these is CD0384, a collagen binding 
protein, and another is CD3246 (http://nihserver.mbi.ucla.edu/Sortase ;(Fagan et 
al.). Other proteins have been known or suspected components of the surface of C. 
difficile for some time. Examples include Cwp66 (Waligora et al., 2001), Cwp2 and 
CwpV (Emerson et al., 2009), Cwp84 (Chapeton Montes et al.), Fbp68 (Hennequin 
et al., 2003), GroEL (Hennequin et al., 2001b) and the proteins that comprise the 
flagellum (Pechine et al., 2005b, Pechine et al., 2005a).  
    The extraction of these proteins from the bacterial surface so that their 
properties and contribution to the biology of C. difficile might be studied is difficult 
if not impossible. Therefore a number of known and putative surface proteins 
were chosen for study according using data from the C. difficile 630 genome 
project, the coding sequences were cloned and the target proteins were expressed 
in E. coli using a LIC vector system from Novagen. The underlying aim of this part of 
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the project was to gain access to purified recombinant proteins which could be 
used for the isolation of antibodies by phage display. The target sequences 
excluding signal sequences were amplified and ligated into the pET-32 EK/LIC 
vector. The cloned sequences were confirmed by sequencing into the inserts from 
either terminus using primers that annealed to vector-encoded sequences. Fusion 
of a His-tag to each recombinant target enabled the expressed proteins to be 
purified from cell lysates by affinity chromatography. Whilst the molecular weight 
of the purified proteins and their reaction with antibodies against a fused 
detection tag were indicative of their likely identity, mass spectrometry was used 
for confirmation.  Other groups have also followed this approach in attempting to 
characterise the properties of proteins from the surface of C. difficile and other 
virulence factors.    
     Codon usage in C. difficile can present difficulties went attempting to express 
native clostridial sequences in bacterial systems such as E. coli. That said, a recent 
study reports the expression and purification of recombinant Cwp19 for structural 
investigation and showed that the E. coli  expression vector pET28a could be used 
successfully. The recombinant Cwp19 carried a His-tag for purification by affinity 
chromatography.  The study showed successful purification and crystalisation of 
Cwp19, a putative glycosyl hydrolase with amino-terminal domains likely to be 
responsible for attachment to the clostridial cell wall (Kirby et al.)  
    GroEL from C. difficile has also been successfully expressed in E. coli by cloning 
into vector pGEX-6p-1 to prepare a recombinant fusion to glutathione S-
tranferase. This recombinant protein was purified through a glutathione-
Sepharose-4B column for the preparation of antibodies. These were used to 
identify the location GroEL in the clostridial cell and to document its release under 
heat shock (Hennequin et al., 2001b) project objectives similar to those posed in 
this study. The peptidoglycan hydrolase (Acd) was also cloned and expressed in E. 
coli using a further expression system, the pQE-32 vector. Although the expressed 
protein was purified by a  nickel chelation chromatography under denaturing 
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condition (8M urea) (Dhalluin et al., 2005) later functional studies showed that its 
ability to hydrolyse the bonds between N-acetylglucosamine and N-acetylmuramic 
acid in peptidoglycan was unimpaired, thereby confirming Acd’s activity as an N-
acetylglucosaminidase. Amongst those cell surface proteins thought to make a 
direct contribution to the virulence of C. difficile, a 68 kDa fibronectin binding 
protein, highly conserved between clostridial isolates, has been expressed in E.coli 
as a glutathione S-transferase fusion protein using again the pGEX-6p-1 vector. 
Mirroring the work of their earlier studies with GroEL, Hennequin and colleagues 
expressed the fusion protein in E. coli, purified it through a glutathione Sepharose 
4B column and raised specific anti-Fbp68 antibodies.  
     Using these reagents, the authors were able to show that this protein is 
localised on the surface and plays a role as a bridge between bacteria and the host 
cell. A competition  inhibition assay with anti-Fbp68 antibodies revealed that the 
target protein can bind soluble and immobilised fibronectin  (Hennequin et al., 
2003). Again, the study described in this thesis shares a common strategy – 
purification of recombinant target protein for the isolation of specific antibodies – 
with this published work. Base on a further study,   fibronectin binding protein is 
regarded as one the adhesion factors of this pathogen, a factor that is stabilised by 
the presence of manganese (Lin et al.). A recently released report tackles this issue 
directly by construction of a mutant thorough Clostron technology. In vitro tests 
revealed that mutant bacteria deficient in the production of Fbp68 could adhere to 
cultured epithelial cells at a higher rate than wild type C. difficile. In contrast, 
studies of caecal colonisation and intestinal implantation  showed a slower rate of 
colonisation for the mutant versus wild type (Barketi-Klai et al.). Proteins may have 
different roles in adherance and colonisation at the same time which should be 
considered.  One obvious feature of the surface composition of C. difficile is the 
presence of the flagellum. In many bacterial pathogens, motility plays an essential 
role in virulence and in some cases, flagella are thought to serve as adhesins. As an 
example, deletion of flgE of Vibrio vulnificus revealed decreasing mobility and 
adhesion of this pathogen to host cells (Lee et al., 2004). Another case is 
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Pseudomonas aeruginosa where motility by flagella is a preliminary step for 
infection of the respiratory tract and stimulation of immune system through 
mucosal epithelial cells. Due to this pivotal role in pathogenesis, flagella of this 
bacteria are considered as a important factors in vaccine development (Prince, 
2006). 
     In C. difficile, the contribution of flagella has been investigated and it is known 
that the flagellae are immunogenic in human patients. In one study, flagella were 
isolated from overnight culture on a solid medium and showed a positive signal in 
immunoblots using rabbit antiserum (Delmee et al., 1990). Other investigators 
have used molecular methods to prepare parts of the flagellum by recombinant 
methods. FliD was cloned into an expression vector (pGEX-6p-1), producing a GST-
FliD fusion protein on induction. The protein appeared able to mediate  adherence 
to mucus or cell receptors (Tasteyre et al., 2001b). In another study, FliC was also 
prepared via the same expression vector. The resulting protein possessed a 
molecular weight of 39 kDa protein but the size of the FliC proteins differed 
between strains according the length and sequence of the fliC gene (Tasteyre et 
al., 2000a). In the same study, antibodies raised against FliC were used to localise 
flagella on the bacterial surface using immunogold methods, a parallel with the 
aims of this project. 
       Other unexpected findings have emerged from work on Cwp84, a cysteine 
protease. The gene lies just downstream of cwp66 gene and both are paralogs of 
slpA, carrying cell wall–binding PF04122 motif (Sebaihia et al., 2006). Based on its 
gene sequence, the mass of the Cwp84 protein is 87.3 kDA and it is thought to 
carry a peptidase domain at its amino-terminus and three cell wall binding 
domains at the other end (Fagan et al.). Perhaps because of its proteolytic activity, 
expression and purification of a recombinant GST-Cwp84 protein has not been 
successful, a problem shared with other cysteine proteases (Wandersman, 1989). 
Like cysteine proteases such as Spe  from S. pyogenes (Doran et al., 1999, Musser 
et al., 1991), Cwp84 is very conserved between different strains and its activity can 
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be detected in the early exponential phase. This finding strengthened the idea that 
Cwp84 might play an important role in the maturation of other cell wall proteins 
(Savariau-Lacomme et al., 2003) as already shown for SpeB in S. pyogenes (Berge 
and Bjorck, 1995). The inability to purify GST-Cwp84 was overcome by expressing 
cwp84 in pET-28a and purifying the recombinant enzyme using the attached His-
tag. Automaturation, a mechanism that is seen for several cysteine proteases, was 
confirmed under reducing conditions resulting in a protein of 61 kDA. 
       This automaturation was previously reported for other bacterial proteases 
(Doran et al., 1999). Proteolytic activity against host proteins located in the 
extracellular environment – molecules such as fibronectin, laminin and vitronectin 
– was demonstrated in vitro and could be neutralised with antibodies against 
Cwp84 or chemical inhibitors and investigators proposed that the action of the 
protease on host tissue might facilitate the actions of toxins produced by C. difficile 
(Janoir et al., 2007). Given the important contributions proposed for Cwp84 in cell 
wall assembly and pathogenesis, gene knockout results were unexpected: 
mutation of cwp84 prevented the maturation of SlpA creating a change in colony 
morphology that was evident when compared with wild type. Mutants grew more 
slowly than wild type in liquid medium. However, experiments in animal models 
showed that there was no difference in virulence between mutants and wild type 
(Kirby et al., 2009). The putative protease CD1751, another enzyme likely to be 
associated with the bacterial surface and possessing similarity with Cwp84, had no 
effect on processing of SlpA and genome analysis of the virulent strain R20291 
revealed a deletion of the gene. 
       To understand the localisation of Cwp84, another study prepared different 
mutant forms of this protein by expression in pET28a. Investigation revealed that 
the fully processed form of Cwp84, a protein cleaved at Lys 91 and lacking 
proteolytic activity, could associate with the bacterial cell wall (Chapeton Montes 
et al.). Other recent data has suggested contribution from another cysteine 
protease (Cwp13) in the sequential processing of Cwp84  processing (de la Riva et 
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al.). Immunisation of experimental animals with Cwp84 appears to reduce 
intestinal colonisation and the severity of infection but fails to provide complete 
protection (Pechine et al., 2011). Understanding of the role of Cwp84 in the 
biology of C. difficile and its virulence is incomplete. 
    The most abundant protein on the surface of C. difficile is SlpA. This undergoes 
post translational processing from a single gene product to create a low molecular 
weight (LMW) amino-terminal protein and a high molecular weight (HMW) 
product derived from the remainder of the initial translation product (Calabi et al., 
2001). This surface protein has been isolated by chemical extraction methods or by 
expression as a recombinant product, allowing investigators to study 
characteristics such as sequence variability between strains (Calabi and 
Fairweather, 2002), the role of SlpA in binding C. difficile to the gastrointestinal 
tissue of the host (Calabi et al., 2002) or the interaction between LMW and HMW 
components in formation of the cell envelope (Fagan et al., 2009). 
     One of the first reports on the properties of SlpA used EDTA extraction 
combined with gel filtration and ion exchange chromatography to purify the LMW 
protein. A 36 kDa protein was obtained that lacked protease activity but reacted 
with the sera from patients infected with C. difficile  (Cerquetti et al., 1992b). In 
another approach to extraction, 8M urea generated a crude preparation (Cerquetti 
et al., 2000a) that could be purified by anion exchange chromatography (O'Brien et 
al., 2005). Other investigators have used prolonged exposure to 5M guanidine 
hydrochloride to extract SlpA from bacterial pellets. This was dialysed before 
further investigation  (McCoubrey and Poxton, 2001, Sanchez-Hurtado and Poxton, 
2008). Extraction with 0.2M glycine has also been explored, extracts being 
neutralised with 2M Tris before further analysis (Calabi et al., 2001, Qazi et al., 
2009, Drudy et al., 2004). In a comparison of a number of different approaches 
with two-dimensional gel analysis, Wright et al. found glycine extraction to be 
more efficient in recovering SlpA (Wright et al., 2005) and given the adoption of 
this approach by the Imperial College group in studies of SlpA and other surface 
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proteins from C. difficile, it was used in the present study. There are some reports 
of the use of molecular methods to prepare SlpA as a recombinant protein and 
sequencing of the gene from different strains in typing scheme or studies of strain 
variation (Eidhin et al., 2006, Karjalainen et al., 2002). pET28 has been used as an 
expression vector for the production of LMW and HMW components of SlpA  
allowing purification of the recombinant products (Calabi et al., 2001, Calabi et al., 
2002). The LMW was prepared as a GST-LMW fusion protein via  insertion of 
amplified  sequence into pGEX-6P-1 and purification through glutathione-
Sepahrose 4B (Brun et al., 2008).        Given these details,  surface proteins were 
considered as the targets for selection of recombinant antibody from an antibody 
phage display library.  
 
4.3 Recombinant antibodies and their interaction with 
different surface proteins 
       Phage display libraries have been used increasingly in a vast range of biological 
fields. Antibodies selected from these libraries can be applicable in therapy or 
diagnostics (Van Bockstaele et al., 2009, Wesolowski et al., 2009) or to better 
understand the nature of basic biological processes or disease.  
       In virology there are  many reports of the use of scFv antibodies across a 
variety of fields particularly in the isolation and development of antibodies with 
antiviral activity (Parren and Burton, 2001). In one example, antibodies against HIV 
were selected from a phage display library that was constructed from patient with 
lupus. These experiments isolated  binders against residues 421-436 of gp120 
showing that patient samples can be a valuable source of neutralising antibodies 
against HIV (Karle et al., 2004). The approach can use used for a range of hosts – 
for example, antibodies against foot and mouth disease virus were isolated from 
the bovine repertoire (Kim et al., 2004) – and adapted for use with conventional 
rodent monoclonal antibodies (ShengFeng et al., 2003). 
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  In bacteriology, phage display technology has also been used to enormous 
effect in selecting antibodies from synthetic libraries or libraries constructed from 
immunised or infected animals. In many cases, antibodies can be isolated that 
possess biological activity against the target molecule. The alpha toxin from 
Clostridium perfringens was used as target for a library that was made from a 
hybridoma cell line producing monoclonal antibody. Experiments successfully 
isolated a scFv that could be expressed as a recombinant protein with neutralising 
activity against the phospholipase activity of alpha toxin (Zhao and Xu, 2001). 
     Pertussis toxin was another target used to generate specific recombinant 
antibodies with neutralising activity. The selected antibodies against this toxin had 
the capability to recognise and also neutralise pertussis toxin in assays using CHO 
cells. The source of the scFvs in this study was a library produced from the 
peripheral blood a patient infected with Bordetella pertussis (Williamson and 
Matthews, 1999). It has also been reported that phage display using an immune 
library yielded scFv against a range of targets from Mycobacterium tuberculosis  
but managed to avoid isolating binders to the immunodominant 65 kDa antigen. 
This finding demonstrated the potential of phage display technologies to generate 
diverse populations of reactive binders that are of value in documenting the 
immune response to infection and vaccination (Cummings et al., 1998).  
     Further advantages are shown through work with a hybridoma clone able to 
produce high affinity monoclonal antibody for the detection of Staphylococcal 
Enterotoxin B.   In this example, the hybridoma cells had  lost the ability to secrete 
antibody as a consequence of repeated culture. A phage display library was 
constructed by transferring the immunoglobulin genes into a phagemid vector. 
Results showed that the anti-toxin reagent could be rescued and could be used 
successfully in assays with a high rate of success (Singh et al.).  
With regard to Gram positive pathogens, investigators have reported the 
isolation of two scFvs recognising the protective antigen of anthrax using a library 
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made from immunised chimpanzees. Antibodies showed the ability to neutralise 
the cytotoxicity of lethal toxin from Bacillus anthracis. Further analysis showed 
that these two antibodies bound to two conformational epitopes at the carboxy-
terminus of protective antigen (Chen et al., 2006). In another study, a recombinant 
antibody against Bacillus anthracis spores was characterised. The antibody showed 
no cross reactivity with spores from related species of Bacillius and with high 
affinity, they can be used for the detection of anthracis spores in immunoassays 
(Mechaly et al., 2008).  
     In other studies, immunised and non-immunised and libraries were used for 
isolation of antibodies against botulinum neurotoxin type A. Epitope mapping for 
scFvs selected from the immunised library showed differences between antibodies 
derived from each library and significantly, neutralising antibodies that were 
isolated from the immunised library were not found amongst the many anti-toxin 
scFvs from the non-immune library. In addition,  this report revealed that mixing of 
individual scFvs recognising different epitopes, improved the potency in 
neutralisation assays when compared to the biological activity of the individual 
binders (Amersdorfer et al., 2002).  
      A recent study reports the use of tandemly linked scFvs (chelating recombinant 
antibodies) as an effective approach in increasing the affinity of binders to non-
overlapping epitopes on protein targets. In other studies using virulence factors 
from Gram positive bacteria,  scFvs were isolated against different parts of tetanus 
toxin and it was shown that some were able to neutralise toxin activity by 
interference with ganglioside binding. Interestingly, scFvs with neutralisation 
activity could be identified that did not bind this suggests that scFvs able to inhibit 
the biological activity of bacterial virulence factors my be able to work through 
interference with conformational change in the target (Scott et al.). 
From all of the above examples, it is apparent that phage display offers 
researchers convenient access to powerful reagents for analysis of bacterial 
Chapter 4 Discussion 
 
239 
virulence. This is the first report of the selection of recombinant antibodies against 
a range of surface proteins from C. difficile. As explained already, several targets in 
this location are known to contribute to the pathogenic process. The project 
therefore aimed to express a range of targets – some of known location and 
function, others more uncertain – in E. coli and purify the recombinant proteins for 
selection of scFv antibodies from the semi-synthetic Tomlinson phage display 
libraries. Although there are reports of the isolation of antibodies against some of 
these targets from C. difficile so that the location and function of the clostridial 
proteins can be understood better, this the first report of the application of 
antibody phage display in this context.  
The Tomlinson I and J libraries differ in the manner of their diversification. 
Diversity in library I was carried by incorporation of DVT codons   (D: A, G or T; V: 
A, C or G) at selected positions in in the scFv CDRs. The DVT approach provides 
nine possible nucleotide combinations without the possibility of including a stop 
codon. Hence, the capacity for diversification is modest but a strength is that stop 
codons are excluded. In contrast, library J was diversified by incorporation of the 
NNK triplet (N: any nucleotide; K: G or T) at the same locations in the scFv reading 
frame.  
     Whilst the capacity for diversity is greater – 32 possible combinations – one stop 
codon can be incorporated. Propagation of the library can deplete its diversity – 
some clones may replicate or infect the bacterial host with greater success than 
others – and based on experience, it would be wise to check the diversity of 
libraries like this before starting selection. Initial aliquots from the library failed to 
show evidence of successful selection resulting in wasted time.  Other aliquots of 
the library were checked in trial selections against BSA and once evidence was 
seen of positive selection, experiments began with the clostridial target proteins.   
    These reagents were used for selection on all purified target proteins . Over 
three rounds of selection, polyclonal phage ELISAs showed sharp increases in 
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absorbance after the second round and flattened at the third round. Phage 
recoveries were calculated and the results revealed enhanced yields towards the 
last round of selection, the extent of this rise varying between different targets. 
This could be interpreted to mean higher representation of specific binders round 
on round, elevation in the affinity of dominant clones for the target or as 
recoveries stabilise, equilibration of selective effects between specific and non-
specific interactions. Other studies from this laboratory have observed similar 
effects (Li et al., 2003). 
 While some phage display experiments increase the number of rounds of 
selection from 3 to 5, this does not necessarily increase the specificity or quality of 
the recovered antibodies. In this study, phage taken from the third round of 
selection were checked in ELISA for reaction with BSA and skimmed milk but 
reaction with these blocking reagents were not detected and a constant base line 
absorbance was measured with increasing numbers of phage in the assay. The 
clones chosen by monoclonal phage ELISA were expressed as soluble scFvs and 
retested. Positive results were obtained in all cases though the strength of ELISA 
signal was variable. Those soluble antibodies that gave strongest signals in ELISA 
were chosen for further study but again, they showed no reaction with BSA or 
skimmed milk.  
      Some reports note differences in frequency of positive reaction in ELISA with 
phage versus soluble antibodies. This might arise from at least two causes.   The 
first are avidity effects. M13 phage is a filamentous phage that can possess up to 
three copies of the scFv-pIII fusion protein at its surface. The presence of three 
copies of the fusion protein can create multivalent binding to target, a feature that 
gives rise to high avidity phage antibodies (de Wildt et al., 2002). This has been 
reported by investigators who have used the Tomlinson antibody libraries (Wu et 
al., 2007). Under these circumstances, the phage are able to bind to target more 
strongly than when monovalent scFv is expressed or drive non-specific interactions 
with the selecting surface rather than the target itself. There are different ways to 
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solve these problems such as changing the composition of the immunotubes 
between rounds of selection, alternating blocking solutions in cycles of panning, or 
increasing the detergent concentration in the washing steps after each round.  
    The second cause of differences between phage and soluble scFv ELISAs for a 
given clone can be the presence of TAG stop codons that are suppressed in E. coli 
TG1 during the production of phage, but which result in premature termination in 
E. coli HB2151 when soluble scFvs are expressed. The NNK diversification strategy 
used in construction of the Tomlinson J library will incorporate TAG with 
approximately 3% frequency at each diversified codon. The stability of scFv could 
also be a factor (Lorimer et al., 1996).  
     None of these issues proved to be complicating factors in the present study and 
in summary, phage display provided a fast, efficient and productive strategy for 
isolation of monoclonal antibodies against a range of proteins from C. difficile. It 
also allowed the screening and analysis of significant numbers of clones. From an 
initial panel of 672 soluble antibodies against a range of targets, 100 were picked 
on the basis of the strength of ELISA signal and from these, 32 were chosen to 
comprise the final panel of reagents. This process of screening used soluble scFvs 
against recombinant targets in dot blots and Western blots. The reactivity of the 
scFvs in these analyses suggests that the epitopes recognised on each target 
protein may be linear rather than conformational. DNA sequencing showed that 
for a given target, CDR sequences were frequently (but not always) unique. Of the 
scFvs isolated, only those against the putative sortase target carried identical 
sequence in all CDRs with repeating hydrophobic and hydrophilic amino acids, 
indicating reaction with a single epitope on the sortase and perhaps the 
emergence of a single, dominant clones through the selection process.  Identity 
was noted for 2 of the 3 scFvs against the full-length Cwp66 and interestingly, one 
of the scFvs against the amino-terminal region of Cwp66 possessed the same CDR 
sequences. No such similarity was noted for scFvs against full-length Cwp66 and 
the carboxy-terminal region of the protein.  Hence, specific selection was easily 
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achieved but it was also clear that single clones failed to dominate the selection 
process. 
   The properties of selected scFvs were assessed through a number of 
experimental approaches using the targets from bacteria. One approach was to 
extract the target from bacterial cells and to assess if the scFvs could recognise the 
protein in Western blots. Analysis of selected scFvs against SlpA in this way 
revealed that the antibodies could bind to extracts of the C. difficile strains 630 and 
M120 when extracts were treated under denaturing and non-denaturing 
conditions but that the scFvs failed to bind to extracts from strain R20291. Firstly, 
this suggests that the epitopes for this panel of antibodies are probably linear and 
hence treatment with SDS does not disrupt the sites of interaction.  There are no 
predictive methods for identification of linear or conformational epitopes and it 
should be recalled that targets in the context of this project are not “antigens” in 
the usual immunological sense: the libraries simply contain a wide range of CDR 
sequences and their composition has not been influenced by exposure to foreign 
materials unlike the context in vivo.  For example, a panel of antibodies against 
severe acute respiratory syndrome (SARS) revealed both linear and conformational 
epitopes in the viral S protein (Chou et al., 2005) and the similar effects can be 
seen in antigenic site A of the haemaggluntinin of influenza virus (Ohkura et al.). 
   Secondly, the results suggest that the epitopes recognised by these 
antibodies may be shared between the SlpA molecules of 630 and M120; as 
explained below, this observation needs careful consideration. That aside, it is 
clear that the epitopes recognised by the anti-SlpA scFvs are not shared between 
630 and R20291 . Protein alignment between the SlpA sequences of 630 and 
R20291 has revealed that the cleavage site between the LMW and HMW 
components of SlpA are the same but to either side, there are differences in 
sequence.  
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      The extent of this variation is higher in the LMW than HMW. Conservation of 
the sequences around the SlpA cleavage site has been reported for other strains of 
C. difficile (Calabi et al., 2001) and 630 is substantially similar to R20291 at sites 
thought to mediate interaction between LMW and HMW. The likelihood is 
therefore high that the binding sites for anti-SlpA scFvs tested in these 
experiments lie elsewhere. Potentially, the location of epitopes could be refined by 
surveying a broad range of strains of C. difficile and through exchange of 
sequences between reactive and non-reactive SlpA proteins. The ability to express 
slpA in E. coli makes these experiments easy to conduct and the availability of anti-
SlpA antibodies that are strain specific might assist in monitoring the spread of 
strains of C. difficile and the emergence of new strains in the hospital environment.   
    The scFvs developed in the project may also contribute to a better 
understanding of the structure and function of SlpA. A conservation of sequence 
has been noted in the animo and carboxy-termini of LMW amongst different 
strains suggesting that together, these sequences form a distinct region – domain 
1 – that is internal to the surface layer complex. A separate region of LMW is 
thought to be external – domain 2 – and shows extensive strain to strain variability  
(Fagan et al., 2009). If this model is correct, it would seem unlikely that scFvs 
against sequences against domain 1  would have been isolated since the panning 
process used SlpA that was in native form. Others have reported that the HMW 
component of SlpA from C. difficile may have a role in binding the bacteria to host 
proteins like collagen I and that bacterial adhesion can be inhibited with a specific 
antiserum (Calabi et al., 2002). Given the ease with which anti-SlpA scFvs were 
isolated in this project, one future direction would be to seek anti-HMW 
antibodies and test if they possess similar properties. 
Antibody levels, including levels of IgM, against this surface protein are thought to 
be an important factor in preventing relapse and strain specific responses are also 
considered important (Drudy et al., 2004). The IgG responses of patients against 
SlpA  (Pantosti et al., 1989b) and the contribution of these responses to the 
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adaptive immune response have suggested that multicomponent vaccines against 
C. difficile might have value for patients at risk (Ausiello et al., 2006), such vaccines 
perhaps including a mixture of toxin A components and the low molecular part of 
SlpA since this appears to enhance the immunogenicity of co-administered 
antigens (Brun et al., 2008). These studies and others illustrate the importance of a 
more detailed understanding of the structure, function and biological activity of 
SlpA.   
       Results obtained with extracts from C. difficile M120 need careful 
consideration: nearly all of the scFvs used to probe Western blots appeared to be 
able to bind to a protein of a size consistent with the LMW of SlpA from the M120 
strain. This applied to scFvs directed against GroEL, Sortase B, FliC and CspA. 
Notably, anti-CspA scFvs recognised the recombinant clostridial protein on 
Western blots but failed to bind to proteins in extracts from C. difficile strain 630 
or R20291. This might be for a variety of reasons – for example, CspA might not be 
present in bacterial lysates at a concentration sufficient to allow detection – but 
reaction with a 36 kDa protein from M120 was striking. Given the number of scFvs 
that appear to react with this protein, tentatively, LMW from SlpA of M120, the 
most likely explanation is that it is able to bind scFvs not through interaction with 
residues in the CDRS of the antibodies, but through other parts of the scFvs. 
      There appear to be no reports of proteins from C. difficile with the general 
ability to bind immunoglobulin although this aspect of the pathogenic process is 
seen in many other pathogens. Isolated reports suggest that, in contrast, toxin A 
may be able to bind host antibodies through its ability to interact with 
carbohydrates(Cooke and Borriello, 1998) and this may extend to other proteins 
associated with immunoglobulins (Dallas and Rolfe, 1998). From the host 
perspective, interaction between GALT and the intestinal microflora  has profound 
effects on development of the immune system and some VH sequences are known 
to possess ligand binding sites for endogenous B cell superantigens (Rhee et al., 
2005) or superantigens such as Protein A that are derived from bacteria (Rhee et 
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al., 2004). Recent studies with Bacillus subtilis and other species (Severson et al., 
2010) have shown that spore proteins including ExsK are able to interact with 
immunoglobulins from some animals, and that scFvs generated from certain VH 
variants retain the ability to interact with these immunoglobulin binding proteins 
(Severson et al.).  
      The concept that some LMW proteins from C. difficile may possess the ability to 
bind host antibodies through superantigen-like activity may alter current views of 
the immunogenic properties of the LMW (Spigaglia et al.). Currently, it is 
recognised that many components of the clostridial cell wall are immunogenic and 
that sera from patients are reactive with native or recombinant forms of these 
proteins. For example, the sera from different patients have been tested in 
Western blot following two dimensional electrophoresis, with additional mass 
analysis to identify those spots that were reactive (Wright et al., 2008). In all, 42 
proteins were reactive in this way, of which 11 were cell wall or membrane 
associated. However, across the panel of patient sera only 3 reacted with Cwp84, 
and 4 reacted with FliC. The immunodominance of SlpA emerged from the finding 
that all sera were reactive with components of Slpa, mostly LMW (Wright et al., 
2008). 
As described earlier, antibodies against bacterial virulence factors sometime 
possess the capacity to block the biological activity of these proteins. For some of 
the clostridial targets used in this study, function remains uncertain (eg CspA is 
thought to be a protein produced in response to cold shock but its role in the 
biology of C. difficile  is unknown). For others it is difficult or impossible to assay 
the biological activity of the clostridial target (eg in vitro assays of sortase activity 
exist (Aulabaugh et al., 2007) but they require specialist equipment and expertise 
beyond the range possible in this project). 
      However, it was possible to assess whether the panel of scFvs against FliC and 
FliD were able to inhibit bacterial motility, using a scFv against LMW, a target 
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known to be at the surface of C. difficile as a control. In contrast to other scFvs 
tested in Western blotting, the scFvs against FliD did not generate a signal in blots 
when they were used as probes for flagellar extracts from strains 630 and R20291. 
This might have arisen because of the low quanitities of FliD in the extracts. It is 
unlikely that the epitopes recognised by these scFvs are conformational as the 
antibodies recognised recombinant FliD after SDS PAGE and blotting. Antibodies 
against FliC reacted strongly in blots prepared with flagellar extracts from 630 but 
weak reaction was evident with material from R20291. 
    Protein alignment for FliC and FliD sequences from the two strains showed a 
high degree of identity for both proteins with greater variation in the central 
region of each protein. This alignment and the results from blotting suggest that 
the binding site for the anti-FliC scFvs may lie in the diverse central region.  Others 
have reported sequence variation in this part of FliC among a wider range of 
different strains of C. difficile (Tasteyre et al., 2000b). The authors reported that 
FliC from six strains reacted with a polyclonal anti-FliC antibody (Tasteyre et al., 
2000a), noting that the predicted molecular weight from sequencing of the gene 
was different to the molecular weight of FliC from bacterial extracts.  More recent 
bioinformatics analysis of different strains has shown that the protein undergoes 
glycosylation, the differences in glycan biosynthesis genes further impacting upon 
the masses observed for FliC from different strains (Twine et al., 2009). In the cited 
experiments, bacterial motility was assessed by visualisation of growth and spread 
in soft agar. Aside from motility, FliC and FliD are thought to contribute to bacterial 
adherence to intestinal mucous in vitro and to the mouse intestine in vivo 
(Tasteyre et al., 2001a). Interestingly, bacterial mutants with complete loss of 
these proteins were more virulence and were enhanced over wild type in their 
ability to colonise the hamster intestine (Dingle et al.). 
     In the present study, the biological activity of anti-flagellar scFvs was assessed 
by binding antibodies to C. difficile 630 and examining bacterial motility in a 
simple, soft agar assay. Experiments showed that some but not all anti-FliC and 
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anti-FliD scFvs possessed the capacity to inhibit bacterial motility. Sequence data 
was only available for two scFvs against FliC and both were able to neutralise 
flagellar activity. Of the three anti-FliD scFvs that were sequenced, none carried 
identical CDR sequences in the heavy or light chain domains but there were some 
similarities between clones N6A4 and N6B5. While the former antibody only 
achieved partial inhibition of bacterial motility, the latter was more effective. It is 
therefore unclear whether the binding of scFvs to particular regions of the flagellar 
proteins is the key determinant in their biological activity, whether the affinity of 
the interaction explains partial from complete effect, or whether other factors are 
at work. The mode of action is similarly uncertain.  
     Some studies describe the immunisation with flagella or their constitutent 
proteins and effects on motility (for example, Faezi et al., 2011) but the use of 
native, multivalent antibodies might lead to aggregation of flagella at the bacterial 
surface or agglutination. There are very few published studies on the impact of 
recombinant antibodies on flagellar activity. In one report, scFvs were generated 
against the H7 flagella of E. coli O157 (Kanitpun et al., 2004). Properties included 
the ability to act in competition with polyclonal antibodies and thereby to 
inhibition bacterial agglutination. The authors propose the scFv might be of value 
in a capture assay for E. coli O157. In another study, scFvs were generated from 
conventional monoclonal antibodies against an immunodominant surface protein 
from the plant pathogen Spiroplasma citri (Malembic et al., 2002). The scFvs were 
able to inhibit bacterial growth and motility but as their target, spiralin, appears 
non-essential for motility (Duret et al., 2003), there are significant differences with 
the current study.    
Whilst the role of flagella in pathogenesis has yet to be resolved, it is clear that 
these features of the cell are immunogenic  as antibodies from patients infected 
with C. difficile are frequently reactive with FliC and FliD (Pechine et al., 2005a). 
When rates vary for FliC, this is most likely due to the variability of sequence of 
those parts of the protein that are surface exposed. Other studies have 
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documented the recognition of clostridial surface proteins by sera from patients. 
The surface exposure of other proteins such as Cwp66 (Waligora et al., 2001) also 
gives rise to high rates of seropositive reaction and many patients develop 
antibody against surface exposed domain of the protein ( 13 out of 17 samples) in 
contrast to recognition of the amino-terminal regions (2 out of 17 sera).  Cwp84 is 
also recognised commonly during infection (Pechine et al., 2005b). 
     These observations have prompted investigators to consider whether proteins 
at the bacterial surface might contribute to a vaccine against C. difficile infection. 
In experiments with mice, immunization with FliD via different routes showed the 
best IgG responses were achieve by combined intravenous and subcutaneous 
delivery whereas the rectal route was the best mucosal immunization route. This 
provoked better IgA responses than intranasal delivery.  These studies showed 
that the lowest rates of colonisation with C. difficile were achieved by rectal 
immunization with cell wall extracts and a cholera toxin adjuvant, but that a 
mixture of FliD and Cwp84 came close in effectiveness (Pechine et al., 2007).  
      Subsequent studies have confirmed the significance of host responses against 
Cwp84 but noted that immunization with this protein only has partial effect on 
colonisation and protection (Pechine et al., 2011). Vaccination of experimental 
animals with SlpA has similarly incomplete protective activity (Eidhin et al., 2008). 
In contrast, the stimulation of neutralising antibodies against the protein toxins of 
C. difficile is seen as a very promising way to prevent or treat infection and 
neutralising IgG and sIgA are thought to have a critical role in regulating the 
severity of infection (Hussack and Tanha). Different vaccines have been under 
development for the stimulation of anti-toxin antibodies (Giannasca and Warny, 
2004a) but the use of natural or recombinant antibodies as passive 
immunotherapeutics is also under development , building on early observations 
that protection could be transferred  through milk from vaccinated  adult hamsters 
to their offspring (Kim and Rolfe, 1989). One example from the literature describes 
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the selection of recombinant antibodies against toxin B of C.difficile (Deng et al., 
2003) using a hyperimmunised scFv library as source for selection.  
      In many different bacteria,  GroEL is recognised as a chaperone involved in 
ensuring the proper folding of proteins (Zeilstra-Ryalls et al., 1991). The over-
expression of GroEL has also assisted in generating high yields of recombinant 
proteins in heterologous expression systems (Arbabi-Ghahroudi et al., 2005) and in 
the production of recombinant antibodies, co-expression of antibody and  
chaperones has been found to improve the functional production of antibodies by 
2.4-fold  (Maeng et al.). With this in mind, the up-regulation of GroEL and other 
clostridial proteins in response to heat might be expected; its appearance at the 
surface and its proposed role in adherence may seem surprising (Hennequin et al., 
2001) but a body of evidence  indicates GroEL serves these functions in other 
species (reviewed in Hennequin et al., 2001).  
    Consistent with its function, alignment of GroEL protein sequences from C. 
difficile 630 and R20291 and BLAST analysis showed high degrees of similarity 
between strains and the presence of conserved domains. In this study, the scFvs 
isolated against GroEL appeared to recognise the native protein, a protein of 60 
kDa, in Western blots using extracts from three bacterial strains (630, M120 and 
R20291), after heat-shock of cultures. Although scFv N5E10 reacted with a protein 
of 60 kDa from all three bacterial strains reaction with a protein likely to be the 
LMW of M120 was also evident. This observation was also made with other scFvs 
against the putative sortase and CspA as discussed earlier. While heat shock 
seemed to elicit production of GroEL in C. difficile, allowing detection with the 
scFvs, antibodies against Cwp66 and CspA were unable to detect the presence of 
their native targets in bacterial extracts. It may be that the quantities present were 
insufficient for detection or that as the expression these proteins required 
specified conditions like temperature that were not met by culture conditions. 
Protein alignment and BLAST analysis showed quite similar sequences for the 
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putative sortase in strains 630 and R20291 and high similarity with  the sortase 
from Turicibacter  sanguinis (Cuiv et al.). 
   At the outset of the project, it was hoped that scFvs against the known and 
putative surface proteins of C. difficile could be used in immunofluorescence and 
electron microscopy to establish the location and distribution of the targets, and 
allow a simple screen for conditions that might regulate their expression. Although 
purified scFvs against FliC, FliD, LMW and HMW seemed able to bind to their 
targets in immunofluorescence experiments, a degree of caution needs to be 
exercised given that for strain M120, binding of scFvs through target-independent 
processes was evident in blotting. Other studies with antisera against the LMW of 
SlpA convincing contrast between immune and non-immune sera (Cerquetti et al., 
1992a) and immunofluorescence microscopy has also assisted the characterisation 
of the fibronectin binding protein from C. difficile (Hennequin et al., 2003). 
     As a system, immunostaining with scFvs has the potential to assist in validation 
of drug targets and the development of new therapeutics(Laforce-Nesbitt et al., 
2008) Poungpair et al., 2009), aspects that are important for infection with C. 
difficile but also more widely, particularly for pathogens transmitted in the hospital 
environment. 
    Recombinant antibodies against SlpA , FliC and FliD were also studied in electron 
microscopy using Protein A-gold but results were disappointing when compared to 
other studies.  In most reports of C. difficile that use these methods, polyclonal 
antisera were used, raised against  native or recombinant protein targets. The 
success of this approach is illustrated in studies of the presence of  flagellae  on 
strains of C. difficile. The binding of antibodies was visualised using colloidal gold 
particles as in the present investigation but with better outcome (Tasteyre et al., 
2000a). Similarly, the presence of CwpV at the surface of C. difficile and its phase 
variation was confirmed via these methods (Emerson et al., 2009) and GroEL was 
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detected by both immunoelectron microscopy and indirect immunofluorescence 
(Hennequin et al., 2001b).  
       Further, the exposure of amino and carboxy-terminal domains of Cwp66 at the 
bacterial surface was assessed using antisera raised against different regions of 
Cwp66 and immunogold techniques (Waligora et al., 2001). Again, had time 
allowed technical problems to be defined and overcome, the availability of scFvs 
against defined parts of Cwp66 would have allowed surface location and exposure 
to be determined. In future investigations, one option worth exploring is the 
recloning of scFv sequences to fuse a metal binding domain at the carboxy-
terminus. This would allow sensitive but direct detection of binding of the scFv to 
its target (Malecki et al., 2002).   
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4.4 Conclusion 
   Overall, this project has validated the strategy of generating recombinant 
antibodies against selected targets from a bacterial pathogen using genomic data 
as the starting point and accomplishing the aims set via heterologous expression of 
the chosen targets and isolation of specific scFv antibodies from a synthetically 
diversified library by phage display. The work has confirmed the Tomlinson 
humanised antibody libraries as an excellent source from which to select scFv 
binders against C. difficile targets. The scFvs generally carried unique CDR 
sequences suggesting binding sites for each target were different. All antibodies 
were checked for recognition of the recombinant target proteins and in many 
cases, the scFvs were able to bind the native proteins in extracts from C .difficile. In 
only one area was it possible to assess whether scFvs possessed the ability to block 
the action of the native protein but the study confirmed that ant-FliC and anti-FliD 
scFvs were able inhibit the motility of C. difficile.  
     The strategy was totally dependent on the ability to express and purifiy 
clostridial target proteins in a heterologous host, E. coli and while all eleven target 
sequences were recovered from the genome of C. difficile 630 by PCR and cloned 
into an expression vector, three (Cwp84, FbpA, Acd) could not be expressed. For 
the remaining eight plus purified LMW protein from SlpA, phage display 
successfully yielded specific scFv antibodies. For LMW, FliC that are known to be 
variable between strains of C. difficile, scFvs appeared to recognise strain-specific  
epitopes.  
     This was fortuitous as the phage display strategy was not steered towards this 
outcome. For some targets (eg CspA, sortase B), scFvs were reactive with the 
recombinant form of the protein but not with clostridial extracts. This might reflect 
abundance of the targets in the bacterial extracts. The study identified scFv-
binding activity in extracts of C. difficile M120 and this is putatively attributed to 
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the LMW component of SlpA in this strain Subject to the some limitations, the 
project showed that phage display can be used as a rapid method to generate 
specific reagents against a wide range of proteins from an important bacterial 
pathogen. These reagents have potential in diagnostics, in advancing 
understanding of the disease process, and in developing new therapeutics.  
     Immunofluorescence microscopy was used with scFvs against FliC and FliD and 
Protein A-FITC. Given the nature of the bacterial target, it was expected that this 
would generate a pattern of discrete labelling on the surface of the clostridial cells. 
Instead, uniform staining was observed over the entire surface of the cells. This 
was suggestive of non-specific staining. To have a definite pattern for those 
recombinant antibodies as a detached green signal from the body of bacteria this 
revealed a whole green exposure for all body.    
      This aspect of the project would have benefited from better choice of controls. 
For example, the scFv could have been omitted to assess if the FITC Protein-A 
conjugate was binding directly to the bacterial surface. Alternatively, recombinant 
antibodies could have been used in the staining protocol that were against targets 
not found on the surface of C.difficile, for instance anti-BSA, anti-ubiquitin or scFvs 
against surface proteins from other pathogens. These variations to the method 
could have helped clarify if in the pattern of immunoflourescence that was 
observed with anti-FliC and anti-FliD scFvs was specific.  
        The other approach to checking the immunofluorescence result would have 
been to use as target a knockout strain of C. difficile that was unable to synthesise 
flagellar subunits or assemble them into intact surface structures. For instance, 
inactivation of the glycosyltransferase gene present at the flagellar locus is known 
to lead to a failure to produce flagellae (Twine et al., 2009). Alternatively, naturally 
non-flagellated strains of C. difficile like M120 would make good controls though 
evidence collected here suggests that this particular strain may be able to capture 
scFvs through other processes. Overall, the immunofluorescence experiments 
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reported here show a staining pattern suggestive of uniform binding to the 
bacterial surface. Use of good controls could assess the reliability and 
reproducibility of the data reported.   
       It was unfortunate that limitations of time prevented a systematic 
investigation of why the binding of scFvs to the surface of C. difficile could not be 
detected in electron microscopy. With more time, investigation could have been 
carried out to assess whether sample preparation was a factor, specifically if 
fixation of the samples altered the clostridial targets in such a way that scFvs were 
unable to bind. Alternatively, the problem may have arisen in the interaction 
between scFvs and the Protein A-gold. Recent work has reported the direct 
conjugation of scFvs with gold nanoparticles. This interaction has been engineered 
by the introduction of cysteine or histidine residues into the scFv linker region and 
then coupling the protein with gold nanoparticles (Liu et al., 2009). In other work, 
metal binding domains have been fused to scFvs. This approach has been shown to 
create specific labelling with clear backgrounds and has been regarded by some 
researchers as more effective than conjugation with gold (Malecki et al., 2002). 
        While these aspects of the project left some issues unresolved, the ability of 
scFvs to inhibit bacterial motility offered a more satisfactory outcome. Results 
could have been enhanced with a more quantitative approach to the 
measurement of bacterial motility although this is complicated by the need to 
maintain the organisms under anaerobic conditions. Further enhancement could 
have come from a greater range of controls (eg non-motile strains created by gene 
knockouts) and the use of a wider range of motile C. difficile strains. Potentially, 
this could have been used to map the epitopes recognised by anti-FliC and anti-
FliD scFvs. 
      Again, with more time other scFvs could have been tested for the capacity to 
block the function of their respective targets. In vitro assays exist for GroEL 
activity. For example, it was reported the interaction of oxidized GroEL with 
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unfolded proteins can be monitored at low temperature. Oxidized GroEL then can 
efficiently bind to non native substrates at low temperature with out ability of 
ATPase activity that can be reserved at higher temperature leading to  release of 
native substrates (Melkani et al.) and in the absence of GroES, GroEL carries out 
potassium-dependant hydrolysis of ATP (Todd et al., 1993). These activities could 
be assayed in the absence and presence of anti-GroEL scFvs and, as controls, scFvs 
against other targets.   
               Other possibilities exist for future work. For example, Cwp66 has an ability 
to bind to cultured mammalian cells like Hep-2 or to gastrointestinal tissue. By 
inducing expression of Cwp66 through stress and checking its presence at the 
bacterial surface, there is potential here to assess the effect of all the selected 
recombinant antibodies on bacterial adherence in vitro. Given that scFvs were 
isolated against both the amino and carboxy terminal regions of Cwp66, these 
experiments could also clarify those regions of the protein that are responsible for 
its adherent activity.  
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5 Appendices 
5.1 Brazier’s CCEY agar 
Brazier’s powder (Oxoid)                                48.0 g to 1 litre deionised water  
The solution was autoclaved at 121 ˚C for 15 minutes. After cooling down to 47˚C, 
10 ml of cycloserine/cefoxitin(X093, LAB M) and 40 ml egg yolk emulsion (X073, 
LAB M) were added as supplement. 
5.2 BHI liquid medium 
BHI powder (Oxoid)                                                                  12.0 g  
The powder was dissolved in 1 litre deionised water and  autoclaved at 121˚C for 
15 minutes. 
5.3 Agarose solution in TEA buffer 
Agarose (invitrogene, Cat No. 15510-027)                          1g 
TEA buffer ( Tris-EDTA-Acetate, Amresco)                            4 ml of 25X  
After adding the volume of buffer to 100 ml,  agarose was dissolved in it and 
autoclaved at 121˚C for 15 minutes. After cooling it down, 3 µl of SYBR safe 
(invitrogen) was added and poured to a gel casting tray.  
5.4 2xYT medium 
Tryptone                                                                                  16g 
Yeast extract                                                                           10g 
Nacl                                                                                             5g 
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Above materials dissolved to 1 litre deionised water. The broth was autoclaved at 
121˚C for 15 minutes. To prepare an agar base of this medium, 15g agar can be 
added to all above material, then the same conditions used to autoclaved.  
5.5 Antibiotic solutions 
Stock solutions of ampicillin (1g/ml) and kanamycin (0.5g/ml) were prepared in 
distilled water. Solutions were filtered by passing them through a filter with  0.2µm 
pore  size and stored at -20˚C. 
 
5.6 Western blot solutions 
5.6.1  Electroblotting buffer 
Tris base                                                                                  7.2 g 
Glycine                                                                                    33.4 g 
Dissolve the above in 2L distilled water, add 600 ml methanol and make up to 3L 
with distilled water. 
5.6.2 Ponceau S solution 
Ponceau S                                                                                0.5 g 
Glacial acetic acid 1 ml. Make up to 100 ml with distilled water. 
5.6.3 Blocking buffer 
Marvel skimmed milk (2% w/v)                                              4 g 
Dissolved in 200ml PBS
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